
CITATION REPORT List of articles citing



DOI: 10.1111/j.2044-8341.1959.tb00467.x The British Journal of Medical Psychology, 1959, 32, 50-5.

Source: https://exaly.com/paper-pdf/7335337/citation-report.pdf

Version: 2024-04-17

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2240	High-grade gliomas. 156-169		
2239	Evaluation of a new tranquillizerbenzquinamide (P2647) by a sequential method. 1963 , 109, 539-43		5
2238	THE EYSENCK PERSONALITY INVENTORY: SOME CONSIDERATIONS. 1965 , 111, 755-9		40
2237	MANIFEST ANXIETY: UNIFACTORIAL OR MULTIFACTORIAL COMPOSITION?. 1965, 20, 773-80		65
2236	PHYSIOLOGICAL AND CLINICAL EFFECTS OF AMYLOBARBITONE SODIUM THERAPY IN PATIENTS WITH ANXIETY STATES. 1965 , 28, 78-87		5
2235	Factors predisposing to a placebo response in new out-patients with anxiety states. 1966 , 112, 557-67		20
2234	Specificity in somatic responses to anxiety. 1967 , 24, 1183-90		17
2233	A Sequential Trial of Adumbram (OXAZEPAM). 1967 , 1, 211-213		О
2232	The assessment of changes in anxiety in a drug trial: a comparison of methods. 1968 , 114, 863-9		33
2231	Observer Error in Medicine: Observer Error in Psychiatry. 1968 , 61, 453-454		1
2230	A clinical investigation of phobias. 1968 , 114, 673-97		82
2229	Specificity in verbal and physiological indicants of anxiety. 1969 , 29, 663-75		6
2228	A controlled trial of benzoctamine (Ba-30803) in neurotic anxiety. 1970 , 10, 342-8		1
2227	Habituation to a loud sound as a function of manifest anxiety. 1970 , 75, 189-94		17
2226	Correlation of subjective side effects with plasma concentrations of nortriptyline. 1970 , 4, 18-21		162
2225	A rating instrument for anxiety disorders. 1971 , 12, 371-9		2268
2224	A comparative trial of lorazepam and diazepam. 1971 , 119, 599-600		27

2223 Affective disturbance in hypothyroidism. 1971 , 119, 279-80	11
2222 Evaluation of a new tranquillizerWY 4036in the treatment of anxiety. 1971 , 119, 597-8	24
2221 A rating scale for anxiety states. 1971 , 221, 7-17	13
2220 Anxiety and the persisting novelty of input from the autonomic nervous system. 1971 , 2, 321-333	9
Assessment of low dosage haloperidol in anxiety states. 1971 , 119, 169-70	16
2218 Specificity in somatic indicants of anxiety in psychoneurotic patients. 1971 , 33, 147-62	5
2217 Lorazepam and diazepam in severe neurotic illness. 1972 , 1, 74-7	9
2216 Methodology of research in psychosomatic medicine. 1972 , 4, 285-7	3
2215 Clorazepate dipotassium in anxiety: a clinical trial with diazepam and placebo controls. 1972 , 12, 286-90	1
2214 Placebo-controlled evaluation of phenaglycodol in anxious, depressed outpatients. 1972 , 12, 280-5	
A pilot study of the short-term antianxiety effects of molindone HCl. 1972 , 12, 472-6	
2212 2. Improvement criteria in drug trials with neurotic patients. 1972 , 2, 73-80	63
2211 Effect of shape of medication in treatment of anxiety states. 1972 , 120, 507-9	26
A comparison of oxypertine and diazepam in anxiety neurosis seen in hospital out-patients. 1972 , 121, 507-8	2
2209 Stereotactic limbic leucotomy: a preliminary report on forty patients. 1973 , 123, 141-8	73
The differentiation of anxiety and depressive disorders: a psychopharmacological approach. 1973 , 14, 362-6	8
A controlled double-blind comparison of lorazepam and diazepam in anxiety neurosis. 1973 , 1, 199-202	4
2206 A double-blind controlled trial of lorazepam and diazepam in the treatment of anxiety. 1973 , 1, 265-8	14

2205	Clinical pharmacological studies on lorazepam. 1973 , 1, 262-4	6
2204	A comparison of lorazepam and diazepam in general practice. 1973 , 1, 269-71	12
2203	Comparison of lorazepam and diazepam in anxiety neurosis. 1973 , 1, 192-8	4
2202	Clinical experience with lorazepam in the treatment of neurotic patients. 1973 , 1, 291-5	10
2201	Stereotactic limbic leucotomya follow-up study of thirty patients. 1973 , 49, 865-82	34
2200	Clinical assessment of lorazepam in neurotic out-patients in Thailand. 1973 , 1, 591-5	1
2199	A self-rating scale of distress. 1973 , 3, 88-100	263
2198	Symptomatic volunteers: another patient dimension for clinical trials. 1973 , 13, 89-98	7
2197	Ratings of psychic and somatic anxiety indicants. Interrater reliability and relations to personality variables. 1973 , 49, 353-68	35
2196	A double blind trial for the clinical management of psychogenic headache. 1973 , 122, 181-3	46
2195	A Psychological and Physiological Evaluation of the Effects of Intravenous Clomipramine (Anafranil). 1973 , 1, 308-316	5
2194	Comparison of thioridazine and diazepam in the control of nonpsychotic symptoms associated with senility: double-blind study. 1973 , 21, 546-51	37
2193	Symptomatic relief with flupentixol (Fluanxol) of the anxious-algetic-depressive syndrome complex in neurotic states. A double-blind, placebo-controlled study. 1973 , 49, 15-27	20
2192	Clorazepate dipotassium: a new benzodiazepine antianxiety agent. 1973 , 13, 114-8	2
2191	Oxypertine (Integrin) in the Treatment of Morbid Anxiety. Report of a New Low Dosage Schedule. 1973 , 1, 573-579	
2190	Haloperidol versus diazepam: a double-blind crossover clinical trial. 1973 , 1, 586-8	5
2189	A controlled clinical trial of a new antianxiety agent lorazepam (Ativan). 1974 , 2, 660-1	2
2188	Clinical comparison of anxiolytic drug therapy. 1974 , 4, 381-7	31

2187	Response to propranolol and diazepam in somatic and psychic anxiety. 1974 , 2, 14-6	137
2186	An interactionist approach to the study of anxiety An analysis of an S-R inventory applied to an adolescent sample. 1974 , 15, 4-14	25
2185	The residual effects of N-desmethyldiazepam in patients. 1974 , 38, 81-90	40
2184	A comparative trial of lorazepam and doxepin in the treatment of anxiety. 1974 , 2, 240-3	4
2183	Assessment of lorazepam in severe neurotic states. 1974 , 2, 444-8	
2182	An evaluation of clinical response to piperazine oestrone sulphate ('Harmogen') in menopause patients. 1974 , 2, 417-23	25
2181	A double-blind controlled study of loxapine succinate in the treatment of anxiety neuroses. 1974 , 14, 464-9	5
2180	The rating of clinical anxiety. 1974 , 50, 112-37	14
2179	The short-term antianxiety effects of propranolol HCL. 1974 , 14, 301-4	29
2178	Sedative effects on physiological and psychological measures in anxious patients. 1974 , 4, 374-80	40
2177	The treatment of mixed anxiety and depression with loxapine: a controlled comparative study. 1974 , 14, 455-63	8
2176	Personality differences in patients with depressive illness and anxiety neurosis. 1974 , 50, 183-91	42
2175	A study of refractory cases of depressive illnesses and their response to combined antidepressant treatment. 1974 , 124, 265-72	67
2174	The effect of social class on psychiatric psychological evaluations in patients with pulmonary tuberculosis. 1975 , 51, 249-56	1
2173	Recent advances in the behavioural measurement of obsessional illness. Difficulties common to these and other measures. 1975 , 20, 33-40	29
2172	Metronome conditioned relaxation and urinary retention. 1975 , 20, 139-41	8
2171	N-desmethyldiazepam and amylobarbitone sodium as hypnotics in anxious patients. Plasma levels, clinical efficacy and residual effects. 1975 , 41, 81-5	35
2170	A practical classification of morbid anxiety. 1975 , 20, 283-4	

2169	Therapy of anxiety in patients with rheumatic disease: crossover double-blind study comparing lorazepam with placebo. 1975 , 16, 120-3	1
2168	Anxiety and EEG alpha activity in neurotic patients. 1975 , 52, 116-31	20
2167	The evaluation of Bellergal Tablets compared to librium and placebo in the treatment of symptoms of anxiety tension states associated with functional gastrointestinal disorders. 1976 , 17, 202-9	2
2166	A double blind cross over trial of gonadotrophin releasing hormone (LHRH) in sexually impotent men. 1976 , 5, 601-7	36
2165	A double-blind comparison of sulpiride with chlordiazepoxide in neurosis. 1976 , 30, 153-64	5
2164	The assessment of drugs in obsessional states. 1976 , 3, 91-5	10
2163	Double Blind Study on the Effect of Etrogen on Sleep, Anxiety and Depression in Perimenopausal Women: Preliminary Results. 1976 , 69, 829-830	6
2162	Double-blind placebo-controlled efficacy study of ketazolam (U-28,774). 1976 , 4, 50-4	11
2161	A brief anxiety rating scale in evaluating anxiolytics. 1976 , 16, 99-105	9
2160	Ripazepam (CI-683): double-blind comparison with placebo in anxious patients. 1976 , 16, 377-83	6
2159	Stereotactic limbic leucotomya follow-up at 16 months. 1976 , 128, 226-40	115
2158	A pilot study of the short-term psychotropic effects of GPA 2640. 1976 , 16, 194-7	3
2157	Evidence of stress as a function of experimentally altered appraisal of stimulus aversiveness and coping adequacy 1976 , 33, 632-646	23
2156	The Leeds scales for the self-assessment of anxiety and depression. 1976 , 128, 156-65	243
2155	A placebo controlled trial of diazepam and oxprenolol for anxiety. 1976 , 50, 177-9	32
2154	Worry and emotionality components of test anxiety in different sex and age groups of elementary school children. 1976 , 39, 1327-34	14
2153	A double-blind crossover controlled study of lorazepam (Wy 4036) and diazepam. 1976 , 3, 668-671	4
2152	Psychometric attributes of the Self-Rating Anxiety Scale. 1977 , 40, 303-6	51

2151	Hormones and sleep. 1977 , 4, 67-72	1
2150	A clinical trial of phenelzine in anxiety depressive and phobic neuroses. 1977 , 131, 486-92	85
2149	Effect of a new benzodiazepine derivate, clobazam, in anxious patients with gastrointestinal disorders. 1977 , 17, 441-6	7
2148	The private practice research group (PPRG): a working model from psychopharmacology for clinical research in family practice. 1977 , 17, 541-54	16
2147	A method for evaluating anxiolytic sedatives. 1977 , 17, 269-75	1
2146	Lithium in acute myeloid leukaemia. 1977 , 1, 1307	32
2145	Lorazepam in anxiety with GI disorders. 1977 , 18, 55-8	3
2144	Effects on EMG feedback, diazepam and their combination on chronic anxiety. 1977 , 21, 65-71	28
2143	Prazepam in anxiety: a controlled clinical trial. 1977 , 18, 239-49	15
2142	A double-blind study of prazepam versus placebo in single daily doses in the treatment of anxiety. 1977 , 18, 147-55	7
2141	GI illness: treatment of the anxiety component. 1977 , 18, 49-54	4
2140	A controlled comparative trial of clorazepate (Tranxene) and diazepam (Valium) for anxiety. 1977 , 2, 525-8	8
2139	Oxypertine and Medazepam in Patients Suffering from Anxiety Neurosis. Report of a Double Blind Study. 1977 , 5, 130-135	
2138	The Brief Outpatient Psychopathology Scale (BOPS). 1977 , 33, 677-88	4
2137	Halazepam and diazepam in neurotic anxiety: a double-blind study. 1977 , 52, 129-36	11
2136	Intensive design in evaluating anxiolytic agents. 1977 , 52, 79-85	12
2135	Comparative efficacy of cognitive therapy and pharmacotherapy in the treatment of depressed outpatients. 1977 , 1, 17-37	626
2134	Controlled double-blind trial of camazepam, a new benzodiazepine derivative, versus chlordiazepoxide. 1978 , 13, 335-7	

2133	Use of antianxiety agents in anxious outpatients. 1978 , 58, 1-17	95
2132	Assessment of psychiatric illness severity by family physicians. 1978 , 12, 45-47	2
2131	A study in the management of anxiety with lorazepam. 1978 , 18, 210-9	3
2130	Loxapine in neurotic anxiety: some modifiers of treatment response. 1978 , 6, 180-5	2
2129	A clinical scale for the self-assessment of irritability. 1978 , 132, 164-71	237
2128	Agoraphobia: a critical review of the concept. 1978 , 133, 314-9	105
2127	Clobazam versus diazepama double-blind study in anxiety neurosis. 1978 , 18, 358-64	17
2126	The effects of one-day treatment of anxiety with high doses of halazepam. 1978 , 18, 203-9	8
2125	A double-blind comparison of clobazam and diazepam in the treatment of anxiety neurosis. 1978 , 18, 353-7	7
2124	Multivariate statistical methods and problems of classification in psychiatry. 1978 , 133, 53-67	61
2123	A comparative study of haloperidol and diazepam in the treatment of anxiety. 1979 , 5, 759-65	6
2122	The effects of chlordiazepoxide on self-rated depression, anxiety, and well-being. 1979 , 64, 185-91	34
2121	Effects of testosterone undecanoate on sexual potency and the hypothalamic-pituitary-gonadal axis of impotent males. 1979 , 8, 471-9	54
2120	A comparison of the clinical and psychological effects of diazepam and amylobarbitone in anxious patients. 1979 , 7, 605-11	11
2119	Evaluation of the effects of clobazam, A 1,5 benzodiazepine, on mood and psychomotor performance in clinically anxious patients in general practice. 1979 , 7 Suppl 1, 113S-118S	29
2118	Clobazam versus diazepam: a double-blind study in anxiety neurosis [proceedings]. 1979 , 7 Suppl 1, 119S	3
2117	Construction of a new psychiatric rating instrument, the Comprehensive Psychopathological Rating Scale (CPRS). 1979 , 3, 405-12	43
2116	Psychological performance in anxious patients treated with diazepam. 1979 , 3, 361-8	5

2115	Symptomatic volunteers in multicenter drug trials. 1979 , 3, 521-33	58
2114	Anxiety associated with cardiovascular disorders: a study using lorazepam. 1979 , 20, 709-13	3
2113	A controlled comparative trial of mianserin and diazepam in the treatment of anxiety states in psychiatric out-patients. 1979 , 7, 285-9	22
2112	A three-month double-blind study of clobazam versus diazepam in out-patients suffering from neurotic disturbances. 1979 , 7, 404-10	4
2111	Neurotic illness and its response to anxiolytic and antidepressant treatment. 1980 , 10, 321-8	178
2110	Double-blind clinical assessment of alprazolam, a new benzodiazepine derivative, in the treatment of moderate to severe anxiety. 1980 , 20, 693-9	15
2109	Clinical and pharmacokinetic factors affecting response to phenelzine. 1980 , 136, 359-65	42
2108	Ketazolam compared to diazepam and placebo in the treatment of anxiety. 1980 , 8, 439-45	3
2107	Ketazolam and diazepam in anxiety: a controlled study. 1980 , 20, 581-9	9
2106	Somatic neurosis in Muslim women in India. 1980 , 15, 203-206	10
2105	Anxiolytic efficacy of alprazolam compared to diazepam and placebo. 1980 , 8, 139-43	23
2104	The arousal-performance relationship revisited. 1980 , 51, 77-90	78
2103	A comparison of frontalis EMG feedback training and progressive relaxation in the treatment of chronic anxiety. 1980 , 137, 279-84	53
2102	Anxiety reduction in hospitalized schizophrenics through thermal biofeedback and relaxation training. 1980 , 51, 475-82	18
2101	Prediction of response to treatment with phenelzine in neurotic patients. 1980 , 4, 303-8	2
2100	A re-examination of the clinical effects of imipramine and amitriptyline in depressive illness. 1980 , 2, 89-94	7
2099	Immunoglobulins, cognitive status and duration of illness in alzheimer's disease. 1980 , 1, 165-8	4
2098	Single daily dose treatment of anxiety with clobazam: a double-blind study versus normal multiple-dose treatment with diazepam. 1980 , 6, 593-7	4

2097 Effect of open heart surgery on intellectual performance. 1981 , 3, 181-97	31
2096 The Hamilton depression scale. Evaluation of objectivity using logistic models. 1981 , 63, 290-9	296
Rating of anxiety, depression and vulnerability. The development of a new rating scale (The Anxiety and Depression Scale). 1981 , 64, 301-13	6
2094 Diazepam, propranolol and their combination in the management of chronic anxiety. 1981 , 139, 417-21	42
2093 Rating scales. 1981 , 138, 512-4	63
Mentally ill foragers and beggars in a peasant society: Their social networks and psychopathology. 1981, 3, 295-309	
The relationships between clinical response, psychophysiological variables and plasma levels of amitriptyline and diazepam in neurotic outpatients. 1981 , 72, 233-40	21
2090 Stability of cross-situational patterns of behavior. 1981 , 15, 488-496	4
Changes in complex perception and memory after three different psychosurgical operations. 1981 , 19, 553-63	9
2088 The Measurement of Outcome in Social Care of the Elderly. 1981 , 10, 179-208	20
Part two: Lao folk diagnoses for mental disorder: Comparison with psychiatric diagnosis and assessment with psychiatric rating scales. 1981 , 5, 425-443	9
2086 Beteendeterapi vid figestneuros. En evaluerande Dersikt. 1982 , 11, 113-134	1
Successful treatment of anxiety with a single night-time dose of chlormezanone: double-blind comparison with diazepam. 1982 , 8, 33-8	
$_{2084}$ The Clinical Anxiety Scale: an instrument derived from the Hamilton Anxiety Scale. 1982 , 141, 518-23	193
Skin conductance habituation during acute episodes of schizophrenia: qualitative differences from anxious and depressed patients. 1982 , 12, 575-83	19
A multicentre placebo-controlled trial comparing the efficacy of mianserin and chlordiazepoxide in general practice patients with primary anxiety. 1982 , 66, 199-207	17
$_{2081}$ A controlled trial of diazepam withdrawal in chronically anxious outpatients. 1982 , 65, 171-9	29
2080 Multicenter controlled study of oxazepam in anxious elderly outpatients. 1982 , 23, 641-5	19

Extent of agreement between patient and physician ratings of emotional distress. 1982 , 23, 1135-8, 1143, 1146	, 14
2078 Biofeedback treatment of narcotic addiction: a double-blind study. 1982 , 9, 111-7	7
An analysis of the skin conductance orienting response in samples of American, British, and German schizophrenics. 1982 , 14, 155-211	179
2076 Two-dose comparison of chlormezanone in sleep disturbance due to anxiety. 1982 , 8, 22-7	
Studies in the relationship between depressive disorders and anxiety states. Part 1. Rating scales. 1982 , 4, 127-47	63
2074 Leeds scales and the GHQ in women who had recently lost a baby. 1982 , 141, 429-30	4
Treatment of chronic obsessive compulsive states with stereotactic anterior capsulotomy or cingulotomy. 1982 , 62, 1-23	48
2072 A self-help treatment program for anxiety state patients. 1982 , 13, 103-111	54
2071 The factor structure of self-reported physical stress reactions. 1982 , 7, 35-47	12
2070 Sleep laboratory study of the effects of midazolam in insomniac patients. 1982 , 21, 479-84	25
A double blind comparison of alprazolam, diazepam and placebo in the treatment of anxious out-patients. 1983 , 80, 308-10	16
2068 Effects of THIP on chronic anxiety. 1983 , 80, 338-41	43
Comparative efficacy and safety of bupropion and placebo in the treatment of depression. 1983 , 79, 343-7	15
2066 Suriclone: a new anxiolytic drug. 1983 , 7, 805-7	3
2065 The general adult inpatient psychiatric assessment scale (GAIPAS). 1983 , 10, 217-36	2
2064 The concept of clinical state in psychiatry: a review. 1983 , 24, 370-91	4
The effect of clobazam and lorazepam on the psychomotor performance of anxious patients. 1983 , 16, 95-9	10
2062 Bulimia nervosa: a placebo controlled double-blind therapeutic trial of mianserin. 1983 , 15 Suppl 2,	195S-202S 104

2061	The Hamilton Anxiety Scale. Evaluation of homogeneity and inter-observer reliability in patients with depressive disorders. 1983 , 5, 163-70	51
2060	Relationship between neurosis and personality disorder. 1983 , 142, 404-8	147
2059	Abstinence syndrome from therapeutic doses of oxazepam. 1983 , 28, 298-300	15
2058	Impulsiveness in obsessive-compulsive patients. 1983 , 143, 177-82	47
2057	A comparison of the efficacy and tolerability of clobazam and chlordiazepoxide in the treatment of acute withdrawal from alcohol in patients with primary alcoholism. 1983 , 11, 205-11	17
2056	Effect of the H2-receptor antagonist ranitidine on depression and anxiety in duodenal ulcer patients. 1984 , 60, 353-5	13
2055	The brief scale for anxiety: a subdivision of the comprehensive psychopathological rating scale. 1984 , 47, 970-5	206
2054	A long-acting benzodiazepine is more effective in divided doses. 1984 , 310, 526	2
2053	Psychological performance of anxious patients in tests used in anxiolytic drug trials. 1984 , 40, 1143-50	3
2052	Affective information processing and the assessment of anxiety. 1984 , 6, 369-95	64
2051	L-5HTP treatment in primary headaches: an attempt at clinical identification of responsive patients. 1984 , 4, 159-65	17
2050	Duration of benzodiazepine clinical activity: lack of direct relationship with plasma half-life. A comparison of single vs divided dosage schedules of prazepam. 1984 , 84, 293-8	10
2049	Vasoactive intestinal polypeptide decreased in cerebrospinal fluid (CSF) in atypical depression. Vasoactive intestinal polypeptide, cholecystokinin and gastrin in CSF in psychiatric disorders. 1984 , 7, 325-37	31
2048	Aging and right-left asymmetry in experimental pain measurement. 1984 , 19, 43-48	59
2047	A clinical trial of the beta blocker propranolol in premature ejaculation. 1984 , 28, 331-6	52
2046	Bupropion hydrochloride. 1984 , 18, 957-64	13
2045	Mood changes in bulimia nervosa. 1984 , 145, 512-6	27
2044	Trihexyphenidyl dependence. 1984 , 69, 538-42	21

2043	Cognitive-behavioral and psychodynamic group psychotherapy in treatment of geriatric depression 1984 , 52, 180-189	163
2042	"Cognitive-behavioral therapy in geriatric depression": Reply to Riskind, Beck, and Steer 1985 , 53, 946-947	4
2041	Controlled study of withdrawal symptoms and rebound anxiety after six week course of diazepam for generalised anxiety. 1985 , 290, 1246-8	60
2040	ACTH 4-9 analogue (Org 2766) in depressed elderly patients. I. Effect on depressed mood. 1985 , 72, 341-8	9
2039	Mianserin is better tolerated and more effective in depression than a nomifensine-clobazam combination: a double-blind study. 1985 , 320, 75-80	7
2038	Comparison of buspirone and diazepam in generalized anxiety disorder. 1985 , 5, 290-6	66
2037	Withdrawal of trihexyphenidyl. 1985 , 71, 297-303	20
2036	An evaluation of alprazolam in the treatment of reactive or neurotic (secondary) depression. 1985 , 146, 515-9	24
2035	Randomized comparison of atenolol and placebo in the treatment of anxiety: a double-blind study. 1985 , 28 Suppl, 109-10	6
2034	Studies on the suanzaorentang in the treatment of anxiety. 1985 , 85, 486-7	9
2033	Initial study of methylclonazepam in generalized anxiety disorder. Evidence for greater power in the cross-over design. 1985 , 87, 130-5	13
2032	Locus of control in chronic anxiety disorders. 1985 , 72, 529-35	28
2031	Irritability: definition, assessment and associated factors. 1985 , 147, 127-36	163
2030	Chronic pain and depression. II. Symptoms of anxiety in chronic low back pain patients and their relationship to subtypes of depression. 1985 , 22, 289-294	77
2029	A multi-centre, double-blind parallel trial of bromazepam ('Lexotan') and lorazepam to compare the acute benefit-risk ratio in the treatment of patients with anxiety. 1985 , 9, 505-10	2
2028	Rating scales for depression and anxiety: a current perspective. 1985 , 19 Suppl 1, 17S-20S	76
2027	A double-blind comparison of alprazolam, diazepam and placebo in the treatment of anxious out-patients. 1985 , 19 Suppl 1, 37S-43S	9
2026	What does the dexamethasone suppression test identify?. 1985 , 20, 957-64	25

2025 Meditation and anxiety reduction: A literature review. 1985 , 5, 91-102	40
2024 Tritiated imipramine binding to platelets is decreased in patients with agoraphobia. 1985 , 16, 1-9	60
2023 Abnormal escape from dexamethasone suppression in agoraphobia with panic attacks. 1985 , 15, 301-11	40
2022 Somatic response to stress, physical symptoms and health service use. 1986 , 24, 569-76	5
The utility of the Anxiety Disorders Interview Schedule (ADIS) in the diagnosis of post-traumatic stress disorder (PTSD) in Vietnam veterans. 1986 , 24, 577-80	28
2020 Review of the side-effect profile of buspirone. 1986 , 80, 17-21	79
2019 Neuroendocrine effects of buspirone in patients with generalized anxiety disorder. 1986 , 80, 36-40	27
2018 Somatic symptoms of anxiety: comparison of self-report and physiological measures. 1986 , 21, 301-10	51
2017 Platelet MAO-B activity in anxiety and depression. 1986 , 21, 847-9	26
2016 Preliminary study of carbamazepine in post-traumatic stress disorder. 1986 , 27, 849-54	157
Effect of experimental and pathological weight loss upon the hypothalamo-pituitary-adrenal axis. 1986 , 11, 295-305	60
2014 Suriclon og Diazepam i behandlingen af angst En prliminaer rapport. 1986, 40, 445-449	
Weight loss causes neuroendocrine disturbances: experimental study in healthy starving subjects. 1986 , 17, 61-72	111
2012 Reduction in hypochondriasis with treatment of panic disorder. 1986 , 149, 631-5	141
2011 Antianxiety properties of lormetazepam. A double-blind crossover trial versus diazepam. 1986 , 14, 311-5	1
Test of the conditioning model of neurosis: Differential aversive conditioning of angry and neutral facial expressions in anxiety disorder patients 1986 , 95, 208-213	82
Comparison of self-rated and observer-rated scales in DSM-III borderline personality disorder. 1986 , 31, 708-13	5
2008 References. 1986 , 73, 36-37	

2007	Bromazepam and lorazepam in generalized anxiety: a placebo-controlled study with measurement of drug plasma concentrations. 1986 , 74, 451-8	20
2006	Psychosocial benefits of a cancer support group. 1986 , 57, 183-9	250
2005	Differentiation of depressive disorders from generalized anxiety by the Beck Depression Inventory. 1986 , 42, 475-8	57
2004	Effects of mianserin in neuroleptic-induced parkinsonism. 1986 , 88, 109-11	13
2003	Suanzaorentang in cardiac patients with anxiety. 1986 , 30, 481-4	3
2002	The Montgomery-Asberg Depression Scale: reliability and validity. 1986 , 73, 544-8	146
2001	Some aspects of sexuality and vaginal symptoms during menopause and their relation to anxiety and depression. <i>The British Journal of Medical Psychology</i> , 1986 , 59 (Pt 2), 173-80	59
2000	Concordance between clinicians' and patients' ratings of anxiety and depression as mediated by private self-consciousness. 1986 , 50, 93-106	17
1999	Alprazolam compared to amitriptyline in the treatment of major depression. 1987 , 75, 656-63	22
1998	DSM-III og psykosomatik: Psykofarmakologiske perspektiver. 1987 , 41, 459-462	
1998 1997	DSM-III og psykosomatik: Psykofarmakologiske perspektiver. 1987 , 41, 459-462 The effects of relaxation training with cognitive or nondirective therapy and the role of relaxation-induced anxiety in the treatment of generalized anxiety 1987 , 55, 883-888	107
	The effects of relaxation training with cognitive or nondirective therapy and the role of	107
1997	The effects of relaxation training with cognitive or nondirective therapy and the role of relaxation-induced anxiety in the treatment of generalized anxiety 1987 , 55, 883-888 The effect of tricyclic antidepressants on stress-induced heart rate changes in panic disorder	
1997 1996	The effects of relaxation training with cognitive or nondirective therapy and the role of relaxation-induced anxiety in the treatment of generalized anxiety 1987 , 55, 883-888 The effect of tricyclic antidepressants on stress-induced heart rate changes in panic disorder patients. 1987 , 76, 324-7 CSF-amine metabolites in depression, dementia and in controls. 1987 , 75, 619-28	2
1997 1996 1995	The effects of relaxation training with cognitive or nondirective therapy and the role of relaxation-induced anxiety in the treatment of generalized anxiety 1987 , 55, 883-888 The effect of tricyclic antidepressants on stress-induced heart rate changes in panic disorder patients. 1987 , 76, 324-7 CSF-amine metabolites in depression, dementia and in controls. 1987 , 75, 619-28	33
1997 1996 1995	The effects of relaxation training with cognitive or nondirective therapy and the role of relaxation-induced anxiety in the treatment of generalized anxiety 1987, 55, 883-888 The effect of tricyclic antidepressants on stress-induced heart rate changes in panic disorder patients. 1987, 76, 324-7 CSF-amine metabolites in depression, dementia and in controls. 1987, 75, 619-28 Lactate infusions: the role of baseline anxiety. 1987, 21, 169-79	33 38
1997 1996 1995 1994	The effects of relaxation training with cognitive or nondirective therapy and the role of relaxation-induced anxiety in the treatment of generalized anxiety 1987, 55, 883-888 The effect of tricyclic antidepressants on stress-induced heart rate changes in panic disorder patients. 1987, 76, 324-7 CSF-amine metabolites in depression, dementia and in controls. 1987, 75, 619-28 Lactate infusions: the role of baseline anxiety. 1987, 21, 169-79 Beta-adrenoceptors on lymphocytes of patients with major depressive disorder. 1987, 20, 239-48	2 33 38 35
1997 1996 1995 1994 1993	The effects of relaxation training with cognitive or nondirective therapy and the role of relaxation-induced anxiety in the treatment of generalized anxiety 1987, 55, 883-888 The effect of tricyclic antidepressants on stress-induced heart rate changes in panic disorder patients. 1987, 76, 324-7 CSF-amine metabolites in depression, dementia and in controls. 1987, 75, 619-28 Lactate infusions: the role of baseline anxiety. 1987, 21, 169-79 Beta-adrenoceptors on lymphocytes of patients with major depressive disorder. 1987, 20, 239-48 Psychiatric morbidity and platelet monoamine oxidase activity in cancer patients. 1987, 22, 111-6 Noradrenergic function and hypothalamic-pituitary-adrenal axis activity in primary unipolar major	2 33 38 35 5

1989	Peripheral benzodiazepine binding sites on platelet membranes are increased during diazepam treatment of anxious patients. 1987 , 138, 289-92	82
1988	Assessing the efficacy of antianxiety agents. 1987 , 82, 1-6	3
1987	Plasma MHPG levels in lactate and isoproterenol anxiety states. 1987 , 22, 1127-36	22
1986	Platelet [3H]imipramine binding in generalized anxiety disorder, panic disorder, and agoraphobia with panic attacks. 1987 , 22, 59-66	34
1985	Electrodermal psychophysiology of anxiety disorder: orienting response and spontaneous fluctuations. 1987 , 22, 653-6	14
1984	5-HT and 5-HIAA in cerebrospinal fluid in depression. 1987 , 12, 13-22	51
1983	Anxiety management for persistent generalised anxiety. 1987 , 151, 535-42	111
1982	Personality in chronic post-traumatic stress disorder:: A study of the eysenck inventory. 1987 , 1, 295-300	28
1981	Psychopharmacological treatment of panic disorder and related states: a placebo controlled study of alprazolam. 1987 , 11, 105-13	5
1980	Comparison of withdrawal of buspirone and diazepam: a placebo controlled study. 1987 , 11, 189-97	18
1979	The risk-benefit assessment of antidepressant drugs. 1987 , 2, 445-62	21
1978	Measurement of anxiety in children and adolescents using semistructured interviews. 1987 , 26, 541-5	30
1977	Assessing Affect in the Elderly. 1987, 3, 65-85	24
1976	A pilot study of phenelzine in the treatment of post-traumatic stress disorder. 1987 , 150, 252-5	46
1975	Us et abus des ⊡helles d∏aluation en psychopathologie. 1987 , 2, 379-386	4
1974	Impact of home monitoring for sudden infant death syndrome on family life. A controlled study. 1987 , 146, 159-61	14
1973	Suriclone and diazepam in the treatment of neurotic anxiety. A double-blind cross-over trial. 1987 , 93, 296-300	11
1972	Treadmill exercise test and ambulatory measures in panic attacks. 1987 , 60, 48J-52J	37

Comparisons of psychological and social factors in patients with chronic oro-facial pain and dental phobic disorders. 1987 , 32, 331-5	16
Multidimensional assessment of combat-related PTSD: Phenomenological, psychometric, and psychophysiological considerations. 1988 , 1, 373-394	27
1969 Neuroleptics in the treatment of dementia. 1988 , 3, 79-88	47
1968 Preliminary studies of clonidine in psychotic patients. 1988 , 71, 115-21	3
1967 Factor analysis of the cognitive-somatic anxiety questionnaire. 1988 , 10, 367-375	7
Levels of hopelessness in DSM-III disorders: A partial test of content specificity in depression. 1988 , 12, 459-469	70
1965 The physical and mental health of elderly in a Balinese village. 1988 , 3, 105-20	4
1964 Increased urinary tribulin output in generalised anxiety disorder. 1988 , 95, 378-80	35
The effects of long-term benzodiazepine treatment and graded withdrawal on psychometric performance. 1988 , 95, 135-8	10
1962 The psychosocial environment and the cellular immunity in the pregnant patient. 1988 , 4, 49-56	25
1961 The family systems of Munchausen syndrome by proxy. 1988 , 27, 423-37	25
1960 Applied Relaxation in the Treatment of Panic Disorder. 1988, 17, 111-124	4
1959 Anxiety induced by false heart rate feedback in patients with panic disorder. 1988 , 26, 1-11	134
1958 Applied relaxation vs progressive relaxation in the treatment of panic disorder. 1988 , 26, 13-22	128
Somatic response to stress, physical symptoms and health service use: the role of current stress. 1957 1988, 26, 481-7	9
Predicting response to anxiety management in patients with generalised anxiety disorders. 1988 , 26, 531-4	14
1955 Monoamine oxidase inhibitors in anxiety disorders. 1988 , 22 Suppl 1, 87-98	40
1954 The relationship of panic attacks to autonomically labile generalized anxiety. 1988 , 29, 91-7	2

1953	Dexamethasone suppression test and primary obsessional compulsive disorder. 1988 , 29, 498-502	8
1952	Correlates of DSM-III personality disorder in panic disorder and agoraphobia. 1988 , 29, 535-44	49
1951	Lactate- and isoproterenol-induced panic attacks in panic disorder patients and controls. 1988 , 23, 153-60	23
1950	Relationship of urinary free cortisol levels in patients with panic disorder to symptoms of depression and agoraphobia. 1988 , 24, 211-21	39
1949	Response to sodium lactate in panic disorder: relationship to presenting clinical variables. 1988 , 25, 253-9	7
1948	An inventory for measuring clinical anxiety: Psychometric properties 1988 , 56, 893-897	8122
1947	Response to lactate infusion in generalized anxiety disorder. 1988 , 24, 409-14	19
1946	HPA axis disturbance and treatment outcome in panic disorder. 1988 , 24, 762-6	20
1945	Sodium lactate infusions after treatment with tricyclic antidepressants: behavioral and physiological findings. 1988 , 24, 767-74	17
1944	Pharmacokinetic-pharmacodynamic modeling of CNS drug effects: an overview. 1988 , 38, 1-52	77
1943	Distress and attitudes in patients perceived as hypochondriacal by medical staff. 1988 , 10, 157-62	7
1942	Menstrual fluctuation in the symptoms of panic anxiety. 1988 , 15, 169-74	54
1941	An experimental antidepressant increases REM sleep. 1988 , 12, 899-907	4
1940	Controlled study on the anxiolytic activity of a newly-developed benzodiazepine, metaclazepam. 1988 , 11, 41-4	1
1939	A double-blind comparison of the anxiolytic activity of two benzodiazepines, metaclazepam and bromazepam, in anxiety neurosis. 1988 , 11, 45-7	
1938	Platelet serotonin uptake in panic disorder: comparison with normal controls and the effect of treatment. 1988 , 22, 390-5	10
1937	Detecting anxiety and depression in general medical settings. 1988 , 297, 897-9	687
1936	Public and private self-consciousness and social phobia. 1988 , 52, 626-39	100

1935	The natural history of tolerance to the benzodiazepines. 1988, 13, 1-55	16
1934	Imipramine binding in depressive patients diagnosed according to different criteria. 1988 , 78, 156-61	17
1933	Myotonic dystrophy of Steinert: are anxiety and depression necessarily concomitants?. 1988 , 33, 203-6	12
1932	Psychosomatic aspects of coronary artery bypass graft surgery. A prospective study of 101 male patients. 1988 , 340, 1-112	27
1931	The Drug Treatment of Anxiety and Depression. 1988 , 72, 815-830	14
1930	Tribulin in post-traumatic stress disorder. 1988 , 18, 833-6	13
1929	Treatment of nonphobic anxiety disorders: A comparison of nondirective, cognitive, and coping desensitization therapy 1988 , 56, 877-884	130
1928	The management of depression: a review of pharmacological and non-pharmacological treatments (for editorial comment, see page 362). 1989 , 151, 397-406	3
1927	Phobic disorders and anxiety states: how do they differ?. 1989 , 23, 81-8	11
1926	A Controlled Comparison of Cognitive B ehaviour Therapy, Diazepam and Placebo in the Management of Generalized Anxiety. 1989 , 17, 1-14	54
1925	Etizolam in the treatment of generalized anxiety disorder associated with depressive symptoms. 1989 , 11, 543-9	13
1924	A comparison of alprazolam with amitriptyline in the treatment of patients with neurotic or reactive depression. A report of a randomised, double blind study by a General Practitioner Working Party. 1989 , 158, 110-3	8
1923	Documentation of an instrument for assessment of subjective CNS-related symptoms during cardiovascular pharmacotherapy. 1989 , 3, 919-27	32
1922	Behavioral treatment of panic disorder. 1989 , 20, 261-282	483
1921	Case study evaluations of a bio-cognitive-behavioral approach for the treatment of borderline personality disorder. 1989 , 20, 477-489	20
1920	Cardiac response to relevant stimuli as an adjunct in diagnosing post-traumatic stress disorder: Replication and extension. 1989 , 20, 535-543	31
1919	Evaluation of a day hospital program for eating disorders. 1989 , 8, 523-532	21
1918	Clomipramine and mianserin in chronic idiopathic pain syndrome. A placebo controlled study. 1989 , 99, 1-7	83

1917	Neuroleptic-induced akathisia: a review. 1989 , 97, 1-11	103
1916	Mind-body patterns of symptom generation. 1989 , 28, 137-52	5
1915	Delusions of fatal contagion among refugee patients. 1989 , 30, 374-82	5
1914	Somatostatin and beta-endorphin levels in cerebrospinal fluid of nonmedicated and medicated patients with epileptic seizures. 1989 , 13, 9-15	18
1913	Treatment outcome evaluation methodology with anxiety disorders: Strengths and key issues. 1989 , 11, 121-132	9
1912	Pseudocholinesterase in obsessive-compulsive patients. 1989 , 27, 65-9	8
1911	Differential rates of urinary noradrenalin excretion in affective disorders: utility of a short time sampling procedure. 1989 , 30, 253-8	4
1910	Computed tomography in depression: association between ventricular size and psychopathology. 1989 , 29, 221-30	25
1909	Computerized tomography (CT) in affective disorders: relationship with psychopathology. 1989 , 29, 271-2	5
1908	Noradrenergic function in generalized anxiety disorder: effects of yohimbine in healthy subjects and patients with generalized anxiety disorder. 1989 , 27, 173-82	76
1907	The relationship of panic disorder and its treatment outcome to 24-hour urinary MHPG levels. 1989 , 30, 53-61	16
1906	Abnormal thyroid stimulating hormone, prolactin, and growth hormone responses to thyrotropin releasing hormone in abstinent alcoholic men with cerebral atrophy. 1989 , 28, 89-96	10
1905	Dehydroepiandrosterone-sulfate/cortisol ratio in panic disorder. 1989 , 28, 345-50	30
1904	Instructions to focus upon or distract from internal cues during exposure treatment of agoraphobic avoidance. 1989 , 27, 663-72	74
1903	DSM-III-R personality diagnoses in anxiety disorder patients. 1989 , 30, 251-8	27
1902	Examination stress, platelet peripheral benzodiazepine binding sites, and plasma hormone levels. 1989 , 44, 1077-82	37
1901	Regional cerebral blood flow in depression: associations with psychopathology. 1989 , 17, 211-8	57
1900	Response of panic disorder to fixed doses of alprazolam or imipramine. 1989 , 17, 261-70	45

A sequential double-blind controlled study of moclobemide and diazepam in patients with atypical depression. 1989 , 16, 181-7	18
1898 Relationship of client participation to psychotherapy. 1989 , 20, 155-62	31
1897 Free and conjugated plasma homovanillic acid in schizophrenic patients. 1989 , 26, 87-96	8
1896 Lactate-induced anxiety. 1989, 25, 669-70	4
The significance of HPA axis disturbance in panic disorder. 1989 , 25, 989-1002	46
1894 Postviral fatigue syndrome and the VP-1 antigen. 1989 , 2, 1160-1	11
Computerized brain tomography measures compared with spontaneous and suppressed plasma cortisol levels in major depression. 1989 , 14, 209-16	20
1892 Neurochemical and cognitive aspects of anxiety disorders. 1989 , 32, 391-402	3
1891 Somatization among refugees: an epidemiologic study. 1989 , 30, 34-43	59
Generalized anxiety symptoms in phobic disorders and anxiety states: A test of the worry hypothesis. 1989 , 3, 159-169	12
1889 Childhood separation anxiety and panic disorder: a comparative study. 1989 , 13, 665-71	20
[Does flumazenil, a benzodiazepine antagonist used during the anesthesia recovery period, have an anxiogenic effect?]. 1989 , 8, 306-10	1
1887 Stress and cognitive functioning in sport. 1989 , 7, 41-63	28
1886 Recognition of panic disorder. 1989 , 43, 511-513	
An Open Study Examining the Diagnosis of Anxiety and the Use of Buspirone in a Primary Care Environment. 1989 , 1, 3-10	3
1884 Denial: predictor of outcome following coronary bypass surgery. 1988 , 18, 57-66	29
Explorative single-blind study on the sedative and hypnotic effects of buspirone in anxiety patients. 1989 , 79, 129-35	16
Respiratory control: its contribution to the treatment of panic attacks. A controlled study. 1989 , 154, 232-6	38

1881	A factor analytical study of the Comprehensive Psychopathological Rating Scale among patients with anxiety and depressive disorders. 1989 , 80, 492-8	19
1880	Hyperventilation: is it a cause of panic attacks?. 1989 , 155, 805-9	49
1879	Cognitive aspects of panic attacks. Content, course and relationship to laboratory stressors. 1989 , 155, 86-91	29
1878	Cognitive mediation in general psychiatric outpatients: A test of the content-specificity hypothesis 1989 , 56, 958-964	122
1877	Psychosis proneness and clinical psychopathology: Examination of the correlates of schizotypy 1989 , 98, 3-8	77
1876	Decreased density of benzodiazepine receptors in lymphocytes of anxious patients: reversal after chronic diazepam treatment. 1990 , 82, 169-73	71
1875	Adinazolam sustained release formulation in the treatment of panic disorder: a pilot study. 1990 , 7, 124-128	4
1874	Beck Self-Concept Test 1990 , 2, 191-197	38
1873	Agoraphobia outcome measurement: A review and meta-analysis 1990 , 2, 317-325	28
1872	Psychometric posttraumatic stress disorder measurement techniques: A review 1990 , 2, 460-469	75
1871	Chronic benzodiazepine dependence. A comparative study of abrupt withdrawal under propranolol cover versus gradual withdrawal. 1990 , 156, 406-11	52
1870	The stress profile. 1990 , 156, 685-8	25
1869	Mind-body problems in family therapy: contrasting first- and second-order cybernetics approaches. 1990 , 29, 13-28	29
1868	Bromazepam in generalized anxiety. Randomized, multi-practice comparisons with both chlorprothixene and placebo. 1990 , 100, 383-6	16
1867	Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. 1990 , 102, 85-94	171
1866	Delineating generalized anxiety: A preliminary investigation. 1990 , 12, 345-358	1
1865	Clinical evaluation of alprazolam in patients with panic disorder: A double-blind comparison with imipramine. 1990 , 5, 159-163	10
1864	The Relationship Between Panic Disorder/Agoraphobia and Personality Disorders. 1990 , 13, 661-684	21

(1990-1990)

1863	, 9, 80-92	12
1862	The treatment of mixed affective disorders in general practice: a comparison of trazodone and dothiepin. 1990 , 12, 34-42	5
1861	Etizolam versus placebo in the treatment of panic disorder with agoraphobia: a double-blind study. 1990 , 12, 185-90	17
1860	Structured interview guides for the Hamilton Rating Scales. 1990 , 9, 48-63	12
1859	Cerebrospinal fluid monoamine metabolites and neuropeptides in patients with panic disorder. 1990 , 22, 237-9	8
1858	Long Term Efficacy and Clinical Safety of Tianeptine in Depressed Alcoholic Patients after Alcohol Withdrawal. 1990 , 2, 225-234	2
1857	Etizolam in the treatment of generalized anxiety disorder: a double-blind study versus placebo. 1990 , 12, 215-23	26
1856	Beta 2-adrenoceptor antagonism in anxiety. 1990 , 1, 75-7	5
1855	Sex differences in panic disorder with agoraphobia. 1990 , 4, 317-324	29
1854	Adinazolam sustained release formulation in the treatment of generalized anxiety disorder. 1990 , 4, 239-246	6
1853	A controlled comparison of cognitive- behaviour therapy, Diazepam, and placebo, alone and in combination, for the treatment of generalised anxiety disorder. 1990 , 4, 267-292	116
1852	Reduction of gastrointestinal symptoms following treatment for panic disorder. 1990 , 31, 75-9	48
1851	Plasmatic vasopressin neurophysin in depression: basic levels and relations with HPA axis. 1990 , 27, 1249-63	12
1850	Psychophysiological correlates of posttraumatic stress disorder in Vietnam veterans. 1990 , 27, 419-30	95
1849	Treatment effects of alprazolam and imipramine: physiological versus subjective changes in patients with generalized anxiety disorder. 1990 , 28, 849-61	26
1848	Effects of isoproterenol in panic disorder patients after antidepressant treatment. 1990 , 28, 203-14	11
1847	Platelet MAO activity in personality disorders and normal controls. 1990 , 33, 221-7	24
1846	Serum phosphate and anxiety in major depression. 1990 , 31, 217	1

1845	Imipramine binding in depressed patients with psychogenic pain. 1990 , 32, 29-34	1
1844	Cognitive specificity and positive-negative affectivity: Complementary or contradictory views on anxiety and depression?. 1990 , 99, 148-155	136
1843	Symptom and comorbidity patterns in World War II and Vietnam veterans with posttraumatic stress disorder. 1990 , 31, 162-70	109
1842	The nature of worry in generalized anxiety disorder: a predominance of thought activity. 1990 , 28, 153-8	445
1841	Cognitive and somatic anxiety. 1990 , 28, 75-81	32
1840	The Agoraphobia Scale: an evaluation of its reliability and validity. 1990 , 28, 323-9	34
1839	Development and validation of the Penn State Worry Questionnaire. 1990 , 28, 487-95	3268
1838	The role of anxiety and depression in the irritable bowel syndrome. 1990 , 28, 401-5	125
1837	Prospective study of psychiatric morbidity in HIV-seropositive women without AIDS. 1990 , 12, 30-5	51
1836	Generalized anxiety disorder: A review of clinical features and theoretical concepts. 1991 , 11, 419-440	143
1835	Imipramine an effective treatment for illness phobia. 1991 , 22, 43-8	40
1834	Platelet peripheral benzodiazepine receptors are decreased in Parkinson's disease. 1991 , 48, 1185-90	15
1833	Platelet peripheral benzodiazepine receptors in repeated stress. 1991 , 48, 341-6	28
1832	The changes of thyroid hormone during pharmacological treatment of panic disorder patients. 1991 , 15, 595-600	9
1831	A pilot study of buspirone in the treatment of social phobia. 1991 , 5, 87-98	54
1830	Relationship between the beck anxiety inventory and the Hamilton anxiety rating scale with anxious outpatients. 1991 , 5, 213-223	177
1829	Evaluation of the effects of diazepam and an experimental anti-anxiety drug on regional cerebral blood flow. 1991 , 40, 125-34	14
1828	Tripartite model of anxiety and depression: Psychometric evidence and taxonomic implications 1991, 100, 316-336	2957

(1991-1991)

1827	32, 120-9	12
1826	Anxiety in depressive disorders. 1991 , 32, 217-28	4
1825	Personality traits associated with panic disorder: change associated with treatment. 1991 , 32, 283-94	33
1824	Cerebrospinal fluid levels of monoamine metabolites in panic disorder. 1991 , 36, 243-51	30
1823	Reliability and validity of the Apathy Evaluation Scale. 1991 , 38, 143-62	1158
1822	Is there a relationship between MHPG and anxiety in depressed patients?. 1991 , 38, 187-95	3
1821	Behavioral, biochemical, and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder. 1991 , 36, 115-27	55
1820	Peripheral-type benzodiazepine receptors in anxiety disorders. 1991 , 84, 537-44	53
1819	The prognostic significance of HPA-axis disturbance in panic disorder: a three-year follow-up. 1991 , 29, 96-102	24
1818	CSF opioids in panic disorder. 1991 , 30, 512-4	10
1817	DSM-III-R state anxiety symptoms in anxiety disorder patients. 1991 , 30, 519-22	3
1816	Adinazolam-SR in the treatment of generalized anxiety disorder and panic disorder. 1991 , 5, 255-265	
1815	Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. 1991 , 30, 179-86	174
1814	The Rating and Self-rating of Anxiety. 1991 , 159, 15-22	19
1813	Clinical target syndromes in psychiatry: latent structure analysis versus factor analysis. 1991 , 6, 301-306	3
1812	Pilot study of milnacipran in panic disorder. 1991 , 6, 103-105	1
1811	The structure of phobias in panic disorder. 1991 , 159, 378-82	11
1810	Indole-3-pyruvic acid as a possible hypnotic agent in insomniac subjects. 1991 , 19, 403-9	8

1809	Meta-analyses of the efficacy and tolerability of the tricyclic antidepressant lofepramine. 1991 , 19, 183-201	83
1808	Psychological morbidity associated with local recurrence of breast cancer. 1991 , 21, 149-55	74
1807	Characteristics of panic disorder patients responding to placebo. 1991 , 365, 33-8	27
1806	5-HT2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin. 1991 , 83, 244-8	79
1805	Alprazolam, imipramine and placebo treatment of panic disorder: predicting therapeutic response. 1991 , 365, 46-52	16
1804	The prediction of treatment response in bulimia nervosa. A study of patient variables. 1991 , 159, 846-9	35
1803	Mania secondary to thyrotoxicosis. 1991 , 159, 712-3	22
1802	Symptoms of anxiety in inpatient alcoholics with and without DSM-III-R anxiety diagnoses. 1991 , 15, 102-5	31
1801	Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. 1991 , 365, 18-27	61
1800	Secondary depression in panic disorder: an indicator of severity with a weak effect on outcome in alprazolam and imipramine treatment. 1991 , 365, 39-45	22
1799	Moclobemide in depression: a randomized, multicentre trial against isocarboxazide and clomipramine emphasizing atypical depression. 1991 , 84, 564-70	47
1798	AIDS panic: effects of mass media publicity. 1991 , 84, 121-4	2
1797	Social phobia: Axis I and II correlates 1991 , 100, 102-106	94
1796	Comparison of behavior therapy and cognitive behavior therapy in the treatment of generalized anxiety disorder 1991 , 59, 167-175	259
1795	Psychometric prediction of PTSD among POW survivors 1991 , 3, 105-110	18
1794	Pharmacokinetics of alprazolam in geriatric patients with neurotic depression. 1991 , 68, 121-4	4
1793	Behavioral treatment of panic disorder: A two-year follow-up. 1991 , 22, 289-304	191
1792	The concurrent validity of items in the Quality-of-Life Index in a cohort of HIV-positive and HIV-negative gay men. 1991 , 12, 129S-141S	23

1791	Chronology of panic and avoidance, age of onset in panic disorder, and prediction of treatment response. A report from the Cross-National Collaborative Panic Study. 1991 , 240, 163-8	12
1790	Avoidance behaviour: a predictor of the efficacy of pharmacotherapy in panic disorder?. 1991 , 241, 151-8	20
1789	Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. 1991 , 105, 428-32	65
1788	Controlled comparison of the efficacy and safety of four doses of suriclone, diazepam, and placebo in generalized anxiety disorder. 1991 , 104, 439-43	31
1787	Differential emotional precipitation of migraine and tension-type headache attacks. 1991 , 11, 47-52	14
1786	A comparison of a 🛘 -adrenoceptor antagonist (ICI 118,551), diazepam and placebo in the treatment of acute anxiety. 1991 , 5, 155-9	3
1785	Flumazenil-precipitated withdrawal symptoms in chronic users of therapeutic doses of diazepam. 1991 , 5, 215-9	20
1784	Worry: A critical analysis of some theoretical approaches. 1991 , 4, 97-108	20
1783	Disorders of Emotion. 1991 , 2, 58-71	219
1782	Clinical and humoral effects of beta-blockade with ICI 118,551 in the general neurotic syndrome. 1991 , 5, 238-42	1
1781	The Bradford Somatic Inventory. A multi-ethnic inventory of somatic symptoms reported by anxious and depressed patients in Britain and the Indo-Pakistan subcontinent. 1991 , 158, 379-86	180
1780	The Hamilton scales and the Hopkins Symptom Checklist (SCL-90). A cross-national validity study in patients with panic disorders. 1992 , 160, 206-11	67
1779	A pilot study of the effects of flumazenil on symptoms persisting after benzodiazepine withdrawal. 1992 , 6, 357-63	25
1778	Physiological and Cognitive Provocation of Panic Attacks in Panic Disorder Patients. 1992 , 21, 191-208	1
1777	A prospective study of panic and anxiety in agoraphobia with panic disorder. 1992 , 160, 57-64	31
1776	Mllng af klinisk demens i relation til positive og negative symptomer ved skizofreni. 1992 , 46, 61-64	1
1775	An Exploratory Study of the Role of Psychotropic Medications in the Treatment of Sex Offenders. 1992 , 18, 75-88	37
1774	Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators. 1992 , 160, 191-202; discussion 202-5	164

1773	Cardiac vagal tone in generalised anxiety disorder. 1992 , 161, 831-5	43
1772	Relationship between facial expressiveness and sympathetic activation in emotion: A critical review, with emphasis on modeling underlying mechanisms and individual differences 1992 , 62, 110-128	101
1771	Response to hyperventilation and inhalation of 5.5% carbon dioxide-enriched air across the DSM-III R anxiety disorders 1992 , 101, 538-552	226
1770	Comparison of bulimics, obese binge eaters, social phobics, and individuals with panic disorder on comorbidity across DSM-III R anxiety disorders 1992 , 101, 675-681	110
1769	Distinguishing anxiety and depression: Reexamination of the reconstructed Hamilton scales 1992 , 4, 224-227	49
1768	Treatment of a Compulsive Paraphiliac With Buspirone. 1992 , 5, 239-246	
1767	Anosognosia in patients with cerebrovascular lesions. A study of causative factors. 1992 , 23, 1446-53	206
1766	The relationship between depression and anxiety: construction of a prototypical anxiety and depression scale. 1992 , 22, 597-606	8
1765	Bulimia nervosa: a 5-year follow-up study. 1992 , 22, 951-9	42
1764	Response to diazepam in sons of alcoholics. 1992 , 16, 1057-63	28
1763	Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. 1992 , 86, 273-82	121
1762	A placebo-controlled trial of buspirone in anxious inpatient alcoholics. 1992 , 16, 1007-13	127
1761	Effects of beta-blocking drugs in alcohol withdrawal: a double-blind comparative study with propranolol and diazepam. 1992 , 46, 419-24	24
1760	Buspirone vs Alprazolam: A Double-Blind Comparative Study of Their Efficacy, Adverse Effects and Withdrawal Symptoms. 1992 , 4, 316-321	6
1759	Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. 1992 , 161, 353-60	265
1758	The Galway Study of Panic Disorder. I: Clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial. 1992 , 25, 63-75	49
1757	Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. 1992 , 2, 21-9	98
1756	Platelet imipramine binding and plasma cortisol levels in Israeli civilians during the Gulf War. 1992 , 32, 170-8	4

1755	Immunity, major depression, and panic disorder comorbidity. 1992 , 31, 896-908	44
1754	Oxytocin in obsessive compulsive disorder. 1992 , 13, 1083-5	60
1753	The MSH/ACTH analog ORG 2766 in anxiety disorders. 1992 , 13, 109-12	10
1752	Fenfluramine stimulation of prolactin in obsessive-compulsive disorder. 1992 , 42, 81-92	22
1751	Peptide T Treatment of Cognitive Impairment in HIV-Positive Intravenous Drug Users. 1992 , 1, 332-338	2
1750	A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure. 1992 , 23, 175-82	46
1749	Prediction of outcome from cognitive-behavioral treatment of irritable bowel syndrome. 1992 , 30, 647-50	36
1748	Self report assessment of anxiety: a cross validation of the Lehrer Woolfolk Anxiety Symptom Questionnaire in three populations. 1992 , 30, 521-31	19
1747	Psychometric properties of the Penn State Worry Questionnaire in a clinical anxiety disorders sample. 1992 , 30, 33-7	599
1746	Crisis intervention response and long-term outcome: a pilot study. 1992 , 33, 388-96	8
1745	Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial. 1992 , 161, 665-70	51
1744	TRH TEST IN ALCOHOLICS: RELATIONSHIP OF THE ENDOCRINE RESULTS WITH NEURORADIOLOGICAL ANDNEUROPSYCHOLOGICAL FINDINGS. 1992 ,	
1743	Long-Term Use of Tianeptine in 380 Depressed Patients. 1992 , 160, 61-65	25
1742	Efficacy of Tianeptine in Comparative Trials versus Reference Antidepressants An Overview. 1992 , 160, 72-75	29
1741	Long-Term Administration of Tianeptine in Depressed Patients after Alcohol Withdrawal. 1992 , 160, 66-71	23
1740	Psychosocial, neuropsychological and neurological status in a sample of heart transplant recipients. 1992 , 1, 119-28	29
1739	Amitriptyline for PTSD in a torture survivor: A case study. 1992 , 5, 77-83	6
1738	DSM-III mental disorders in general medical sector: a follow-up and incidence study over a two-year period. 1992 , 27, 234-41	15

1737	Resuscitation training for cardiac patients and their relativesits effect on anxiety. 1992 , 24, 7-11	23
1736	Treatment of a compulsive paraphiliac with buspirone. 1992 , 5, 239-246	9
1735	Natural history of symptoms of depression and anxiety during inpatient treatment on general medicine wards. 1992 , 7, 287-93	35
1734	Mood and global functioning in borderline personality disorder: individual regression models for longitudinal measurements. 1992 , 26, 1-16	7
1733	Effects of alprazolam and imipramine on parasympathetic cardiac control in patients with generalized anxiety disorder. 1992 , 107, 535-40	33
1732	Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type. 1992 , 4, 191-205	44
1731	Behavioral treatment of generalized anxiety disorder. 1992 , 23, 551-570	180
1730	Clomipramine/bentazepam combination in the treatment of major depressive disorders. 1992 , 7, 115-122	5
1729	Amitriptyline for PTSD in a torture survivor: A case study. 1992 , 5, 77-83	1
1728	Cognitive-behavioral group psychotherapy of bulimia nervosa: importance of logistical variables. 1993 , 14, 277-87	56
1727	Human basal ganglia volume asymmetries on magnetic resonance images. 1993 , 11, 493-8	54
1726	The stress profile in China: A pilot study in patients with psychological disorders. 1993 , 9, 21-24	2
1725	Sleep patterns in anxiety and depression associated with stress. 1993 , 9, 127-129	11
1724	Neuropsychiatric disturbance in cancer patients with epidural spinal cord compression receiving high dose corticosteroids: A prospective comparison study. 1993 , 2, 233-245	17
1723	Discomfort with space and motion: A possible marker of vestibular dysfunction assessed by the situational characteristics questionnaire. 1993 , 15, 299-324	76
1722	Diagnostic and symptom distinguishability of generalized anxiety disorder and obsessive-compulsive disorder. 1993 , 24, 227-240	71
1721	An exploration of the relationship between expression of hostility and the anxiety disorders. 1993 , 27, 17-26	10
1720	Psychiatric morbidity in burning mouth syndrome. Psychiatric interview versus depression and anxiety scales. 1993 , 75, 308-11	60

1719	anxiety-depression 1993 , 61, 412-420	27
1718	MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study. 1993 , 112, 483-9	40
1717	Anxiety sensitivity: An examination of theoretical and methodological issues. 1993 , 15, 147-183	134
1716	Generalized anxiety disorder with early and late onset of anxiety symptoms. 1993 , 34, 291-8	70
1715	Primary depressives with secondary alcoholism compared with alcoholics and depressives. 1993 , 34, 83-6	14
1714	Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder 1993 , 61, 611-619	522
1713	Clomipramine, fluoxetine, and behavior therapy in the treatment of obsessive-compulsive disorder: a meta-analysis. 1993 , 24, 149-53	114
1712	Assessing reliable and clinically significant change in social phobia: validity of the social phobia and anxiety inventory. 1993 , 31, 331-7	43
1711	Applied relaxation, exposure in vivo and cognitive methods in the treatment of panic disorder with agoraphobia. 1993 , 31, 383-94	89
1710	A prospective study of psychiatric aspects of early HIV disease in women. 1993 , 15, 139-47	41
1709	Brotizolam versus triazolam for the treatment of insomnia in anxious patients. 1993 , 53, 9-17	
1708	Treatment of primary degenerative dementia and multi-infarct dementia with glycosaminoglycan polysulfate: A comparison of two diagnoses and two doses. 1993 , 54, 44-64	5
1707	Rapid relief of anxiety in cancer patients with both alprazolam and placebo. 1993 , 34, 324-32	19
1706	A multi-method test of the cognitive content-specificity hypothesis in young adolescents. 1993 , 7, 223-233	26
1705	The utility of the Beck anxiety inventory with inpatient adolescents. 1993 , 7, 95-106	32
1704	A screening test for subtle cognitive impairment early in the course of HIV infection. 1993 , 34, 424-31	4
1703	Anxiety disorders in the joint hypermobility syndrome. 1993 , 46, 59-68	81
1702	Valproate treatment of panic disorder and lactate-induced panic attacks. 1993 , 33, 542-6	71

1701	Serotonergic (5-HT2) mediation of anxiety-therapeutic effects of serazepine in generalized anxiety disorder. 1993 , 34, 41-4	23
1700	CSF corticotropin-releasing factor is not affected in panic disorder. 1993 , 33, 136-8	43
1699	Structure of the computer-assisted Beck Anxiety Inventory with psychiatric inpatients. 1993 , 60, 532-42	80
1698	Psychological treatment of generalised anxiety disorder. A review of the clinical significance of results in outcome studies since 1980. 1993 , 163, 19-26	54
1697	Apathy following cerebrovascular lesions. 1993 , 24, 1625-30	315
1696	Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. 1993 , 162, 776-87	349
1695	Types of self-reported anxiety in outpatients with DSM-III-R anxiety disorders1. 1993 , 6, 43-55	12
1694	Some clinical and psychometric characteristics of primary and secondary premature ejaculators. 1993 , 19, 276-88	62
1693	Somatization: A Transcultural Perspective. 1993 , 5, 231-242	24
1692	Emotions, defenses, coping mechanisms, and symptoms 1993 , 10, 237-260	9
1691	Subtypes of HIV-related neuropsychological functioning: A cluster analysis approach 1993 , 7, 62-72	13
1690	Cognitive therapy of anxiety disorders 1993 , 61, 248-260	219
1689	Development and validation of a computer-administered version of the Hamilton Rating Scale	16
	1993 , 5, 487-492	46
1688		8
1688 1687	1993, 5, 487-492 Changes in appetite and weight during the pharmacological treatment of patients with panic	·
	1993, 5, 487-492 Changes in appetite and weight during the pharmacological treatment of patients with panic disorder. 1993, 38, 19-22	8
1687	Changes in appetite and weight during the pharmacological treatment of patients with panic disorder. 1993, 38, 19-22 Treatment of obsessive-compulsive disorder by psychosurgery. 1993, 87, 197-207 The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a	8

1683	Anxiety and Depression in Parkinson Disease. 1993 , 6, 151-154	26
1682	Prediction: Nonsense or Hope?. 1993 , 163, 46-54	1
1681	Efficacy of tianeptine in the treatment of major depression and depressed bipolar disorders. Illustration of the interest of surveillance of a European multicentre double-blind study in progress: tianeptine versus placebo and imipramine. 1993 , 8, 111s-115s	
1680	Evaluation of safety and side effects in the process of anti-anxiety drug development *. 1993 , 8, 285-291	4
1679	Diagnostic Assessment. 1993 , 16, 431-441	14
1678	Panic disorder. An overlapping or independent entity?. 1994 , 164, 818-25	11
1677	Central & Peripheral Nervous System: 5-HT3 receptor antagonists. 1994 , 4, 669-680	5
1676	Treatment of panic disorder with alprazolam and imipramine: clinical relevance of DSM III dysthymia. 1994 , 9, 27-32	1
1675	Suicidal Behaviour Following Stroke Importance of Lesion Location. 1994 , 17, 1-8	
1674	Psychopathology and long-term adjustment after crises in refugees from East Germany. 1994 , 40, 165-76	11
1673	Anxiety symptoms in stable chronic schizophrenics. 1994 , 3, 257-262	21
1672	Sertraline in the treatment of patients with social phobia. 1994 , 1, 291-7	10
1671	Natural killer cell activity in patients with panic disorder. 1994 , 1, 192-5	8
1670	Social rhythm in anxiety disorder patients. 1994 , 1, 90-5	27
1669	Sertraline in social phobia. 1994 , 1, 196-8	16
1668	Lactate-induced anxiety after imipramine and diazepam treatment. 1994 , 1, 54-63	11
1667	Il Symptom Questionnaire come strumento di screening nei contesti sanitari di base. 1994 , 3, 31-37	1
1666	Common and specific dimensions of self-reported anxiety and depression: Implications for the cognitive and tripartite models 1994 , 103, 645-654	200

1665	The effects of electroconvulsive therapy and depression on confabulation, memory processing, and suggestibility. 1994 , 48, 443-451	19
1664	Psychosocial study on Hong Kong Chinese with gynecological cancer. 1994 , 15, 111-7	15
1663	Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. 1994 , 115, 128-34	195
1662	Prospective follow-up study lasting 2 years in patients with panic disorder with and without depressive disorders. 1994 , 244, 39-44	12
1661	Common psychiatric disorders in cancer patients. I. Adjustment disorders and depressive disorders. 1994 , 2, 223-32	35
1660	A trial of eltoprazine in the treatment of aggressive behaviours in two populations: Patients with epilepsy or Gilles de la Tourette's Syndrome. 1994 , 9, 253-258	3
1659	Overlap of buspirone with lorazepam, diazepam and bromazepam in patients with generalized anxiety disorder: Findings from a controlled, multicentre, double-blind study. 1994 , 9, 409-422	5
1658	Mapping of SPECT regional cerebral perfusion abnormalities in obsessive-compulsive disorder. 1994 , 1, 237-48	13
1657	Pilot efficacy trial of abt-200 in patients with major depressive disorder. 1994 , 2, 315-318	3
1656	Peripheral-type benzodiazepine receptors on human blood mononuclear cells are not regulated by ovarian steroids. 1994 , 19, 65-78	3
1655	Subsyndromal ("mixed") anxietydepression in primary care. 1994 , 9, 507-12	54
1654	Muscle tension in generalized anxiety disorder: elevated muscle tonus or agitated movement?. 1994 , 31, 189-95	58
1653	Clinical trials of treatments of premenstrual syndrome: entry criteria and scales for measuring treatment outcomes. 1994 , 101, 689-95	55
1652	Three years follow-up of panic disorder patients: a naturalistic study. 1994 , 35, 254-62	3
1651	Eye movement effects of diazepam in sons of alcoholic fathers and male control subjects. 1994 , 18, 324-32	35
1650	Family history of alcoholism in women with generalized anxiety disorder who have premenstrual syndrome: patient reports of premenstrual alcohol consumption and symptoms of anxiety. 1994 , 18, 664-70	30
1649	Behavioral assessment and treatment planning for alcohol, tobacco, and other drug problems: Current status with an emphasis on clinical applications. 1994 , 25, 533-580	69
1648	Behavioral assessment and treatment of panic disorder: Current status, future directions. 1994 , 25, 581-611	26

1647	Baseline and fear-potentiated startle in panic disorder patients. 1994 , 35, 431-9	173
1646	Enhanced stress responsivity of Tourette syndrome patients undergoing lumbar puncture. 1994 , 36, 35-43	78
1645	Studies of a neurochemical link between depression, anxiety, and stress from [3H]imipramine and [3H]paroxetine binding on human platelets. 1994 , 36, 281-91	65
1644	Predictors of response to alprazolam and placebo in patients with panic disorder. 1994 , 30, 5-13	24
1643	Temperament predicts clomipramine and desipramine response in major depression. 1994 , 30, 35-46	169
1642	Plasma interleukin-1 beta concentrations in panic disorder. 1994 , 54, 135-42	45
1641	Psychological and endocrine abnormalities in refugees from East Germany: Part I. Prolonged stress, psychopathology, and hypothalamic-pituitary-thyroid axis activity. 1994 , 51, 61-73	47
1640	Platelet serotonin measures in posttraumatic stress disorder. 1994 , 53, 99-101	14
1639	Hamilton Anxiety Rating Scale Interview guide: joint interview and test-retest methods for interrater reliability. 1994 , 53, 191-202	121
1638	Circadian pattern of motor activity in major depressed patients undergoing antidepressant therapy: relationship between actigraphic measures and clinical course. 1994 , 52, 85-98	79
1637	Anxiety and conduct disorders in early onset alcoholism. 1994 , 708, 181-6	16
1636	The Dementia Signs and Symptoms Scale: A New Scale for Comprehensive Assessment of Psychopathology in Alzheimer's Disease. 1994 , 2, 60-74	21
1635	Abnormal magnetic resonance imaging T2 relaxation time asymmetries in Tourette's syndrome. 1994 , 55, 205-221	29
1634	A multicomponent behavioral treatment for social phobia: social effectiveness therapy. 1994 , 32, 381-90	127
1633	Differentiating major depression and panic disorders by self-report and clinical rating scales: ROC analysis and information theory. 1994 , 32, 771-82	29
1632	Alexithymia: relationship to personality disorders. 1994 , 35, 239-43	79
1631	Personality disorder traits in generalized anxiety and panic disorder patients. 1994 , 35, 329-34	14
1630	Insomnia in relation to depression and anxiety: epidemiologic considerations. 1994 , 38 Suppl 1, 3-8	97

1629	Insomnia in anxiety: sleep EEG changes. 1994 , 38 Suppl 1, 93-104	33
1628	A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase. 1995 , 56, 319-26	26
1627	Pre-treatment predictors of treatment outcome in panic disorder and agoraphobia treated with alprazolam and exposure. 1994 , 30, 123-32	39
1626	A new scale for the evaluation of benzodiazepine withdrawal symptoms: Sessb. 1994 , 55, 275-289	2
1625	Safety and efficacy of bupropion and nortriptyline in outpatients with depression. 1994 , 55, 851-863	6
1624	A phase II multicenter dose-finding, efficacy and safety trial of ipsapirone in outpatients with generalized anxiety disorder. 1994 , 18, 447-63	19
1623	Cerebral atrophy and plasma cortisol levels in alcoholics after short or a long period of abstinence. 1994 , 18, 519-35	7
1622	Frequency and correlates of adjustment disorder related to cardiac surgery in older patients. 1994 , 35, 557-68	32
1621	Reliability and validity of the Hamilton Anxiety Rating Scale in an adolescent sample. 1994 , 33, 354-60	80
1620	Gender and the comparison of self and observer ratings of anxiety and depression in adolescents. 1994 , 33, 1284-8	27
1619	Cardiac awareness before and after cognitive-behavioral treatment for panic disorder. 1994 , 8, 341-350	18
1618	A fixed-dose study of adinazolam-SR tablets in generalized anxiety disorder. 1994 , 18, 979-93	5
1617	Mirtazapine, a Novel Antidepressant, in the Treatment of Anxiety Symptoms. 1994 , 8, 339-344	13
1616	Anxiety in elderly patients. A comparison of azapirones and benzodiazepines. 1994 , 5, 335-45	26
1615	Cognitive therapy, analytic psychotherapy and anxiety management training for generalised anxiety disorder. 1994 , 165, 315-23	147
1614	Symptoms of anxiety and risk of coronary heart disease. The Normative Aging Study. 1994 , 90, 2225-9	508
1613	The effect of citalopram in panic disorder and agoraphobia:A pilot study. 1994 , 48, 13-17	14
1612	Pilot study of a CCKB antagonist in patients with panic disorder: preliminary findings. 1994 , 1, 141-3	12

1611	Double-blind pilot trial of desipramine versus fluoxetine in panic patients. 1994 , 1, 287-90	16
1610	Negative and depressive symptoms in suicidal schizophrenics. 1994 , 89, 81-7	54
1609	Social phobia: A comparison of behavior therapy and atenolol 1994 , 62, 350-358	151
1608	Comparison of cognitive therapy and relaxation training for panic disorder 1994 , 62, 818-826	87
1607	Alprazolam and exposure for panic disorder with agoraphobia. Attribution of improvement to medication predicts subsequent relapse. 1994 , 164, 652-9	81
1606	Comparison of the efficacy, safety and withdrawal of alpidem and alprazolam in anxious patients. 1994 , 165, 94-100	7
1605	Ten-year follow-up of 50 patients with bulimia nervosa. 1994 , 164, 80-7	85
1604	Safety and side-effects of alprazolam. Controlled study in agoraphobia with panic disorder. 1994 , 165, 79-86	32
1603	Autorotation test abnormalities of the horizontal and vertical vestibulo-ocular reflexes in panic disorder. 1994 , 110, 259-69	24
1602	Therapeutic efficacy of specific serotonin reuptake inhibitors (SSRIs) in dysthymia. 1994 , 39, 21-6	29
1601	A blinded, controlled evaluation of anxiety and depressive symptoms in patients with fibromyalgia, as measured by standardized psychometric interview scales. 1994 , 89, 370-5	61
1600	Relationships between age and symptom severity among women seeking medical treatment for premenstrual symptoms. 1995 , 25, 309-15	47
1599	The HNRC 500neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. 1995 , 1, 231-51	512
1598	Effects of a safe person on induced distress following a biological challenge in panic disorder with agoraphobia 1995 , 104, 156-163	75
1597	Predicted versus unpredicted panic attacks: Acute versus general distress 1995 , 104, 214-223	48
1596	Depression research methodologies in the Journal of Personality and Social Psychology: a review and critique. 1995 , 68, 870-84; discussion 885-91	108
1595	Polysomnographische Untersuchung des Schlafes bei Patienten mit Panikstorung und Primfer Insomnie. 1995 , 5, 81-88	
1594	Section Review Central & Peripheral Nervous Systems: Mirtazapine - a novel antidepressant compound currently undergoing clinical evaluation. 1995 , 4, 945-954	2

1593	Stress and depressive symptoms prospectively predict immune change among HIV-seropositive men. HIV Neurobehavioral Research Center Group. 1995 , 58, 299-312	43
1592	Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. 1995 , 92, 351-8	95
1591	Selection and use of clinical rating instruments in child psychiatric nursing. 1995 , 8, 33-42; quiz 43-4	1
1590	Effects of cerebral electrical stimulation on alcoholism: a pilot study. 1995 , 19, 1004-10	5
1589	The prevalence and clinical correlates of apathy and irritability in Alzheimer's disease. 1995 , 2, 540-6	39
1588	Multivariate investigation of anxiety in a psychiatric population. 1995 , 51, 196-201	
1587	An age-matched comparison of subjects with binge eating disorder and bulimia nervosa. 1995 , 18, 135-43	54
1586	The development of a clinician-administered PTSD scale. 1995 , 8, 75-90	3861
1585	Ball experiments in 32 acute akinetic catatonic patients: deficits of internal initiation and generation of movements. 1995 , 10, 589-95	36
1584	A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. 1995 , 58, 444-52	134
1583	A multicentre double-blind placebo-controlled study investigating the anxiolytic efficacy of hydroxyzine in patients with generalized anxiety. 1995 , 10, 181-187	24
1582	What treatments do patients with panic disorder and agoraphobia get?. 1995 , 245, 165-71	17
1581	Catatonia: short-term response to lorazepam and dopaminergic metabolism. 1995 , 122, 182-6	54
1580	Clinical and differential diagnostic aspects of treatment-resistant depression. 1995 , 29, 43-50	54
1579	Three-year follow-up and clinical implications of a mindfulness meditation-based stress reduction intervention in the treatment of anxiety disorders. 1995 , 17, 192-200	610
1578	Double-blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients. 1995 , 3, 163-169	35
1577	Placebo-controlled study of ABT-200 versus fluoxetine in the treatment of major depressive disorder. 1995 , 3, 199-203	15
1576	Alexithymia, obesity, and binge eating disorder. 1995 , 17, 135-40	51

1575	Anxiety Disorders. 1995 , 4, 305-322	2
1574	Quality of life, sexual functioning and sex role identity after surgical orchidectomy in patients with prostatic cancer. 1995 , 29, 497-500	24
1573	Neuropsychological outcome from psychosurgery for obsessive-compulsive disorder. 1995 , 29, 293-8	36
1572	Buspirone treatment as an aid to benzodiazepine withdrawal. 1995 , 9, 331-5	4
1571	Behavioural aggression in panic disorder after 8 weeks' treatment with alprazolam. 1995 , 35, 117-23	52
1570	REM latency, dexamethasone suppression test, and thyroid releasing hormone stimulation test in posttraumatic stress disorder. 1995 , 19, 433-43	31
1569	Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam. 1995 , 19, 567-75	10
1568	Stressful life events and coping styles in relation to dysthymia and major depressive disorder: variations associated with alleviation of symptoms following pharmacotherapy. 1995 , 19, 637-53	52
1567	Test therapy in the treatment of generalized anxiety disorders with low dose fluspirilene. 1995 , 19, 1049-60	6
1566	Correlates of DMS-III personality disorder in Generalized Anxiety Disorder. 1995 , 9, 103-115	15
1565	Effects of alprazolam dose on the induction and habituation processes during behavioral panic induction treatment. 1995 , 9, 217-227	17
1564	A brief self-rating scale for PTSD after road vehicle accident. 1995 , 9, 503-514	32
1563	Alcoholism abolishes the growth hormone response to sumatriptan administration in man. 1995 , 44, 1577-80	8
1562	A self-report diagnostic measure of generalized anxiety disorder. 1995 , 26, 345-50	61
1561	The Beck Anxiety Inventory in a non-clinical sample. 1995 , 33, 477-85	252
1560	Two-year follow-up of social phobias treated with Social Effectiveness Therapy. 1995 , 33, 553-5	42
1559	Applied relaxation vs cognitive behavior therapy in the treatment of panic disorder. 1995 , 33, 145-58	116
1558	Factor structure of the Yale-Brown Obsessive-Compulsive Scale: a two dimensional measure. 1995 , 33, 865-9	76

1557	Suicide attempt history in depressed patients with and without a history of panic attacks. 1995 , 36, 25-30	17
1556	A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. 1995 , 37, 462-6	101
1555	Caffeine withdrawal increases lithium blood levels. 1995 , 37, 348-50	35
1554	Cerebrospinal fluid gamma-aminobutyric acid in patients with panic disorder. 1995 , 38, 737-41	17
1553	Monoamine oxidase A and B activities in heavy smokers. 1995 , 38, 756-61	119
1552	Psychiatric status after human fetal mesencephalic tissue transplantation in Parkinson's disease. 1995 , 38, 498-505	19
1551	Relationship of generalized anxiety symptoms to urinary 5-hydroxyindoleacetic acid and vanillylmandelic acid. 1995 , 57, 1-5	16
1550	T-lymphocyte concentrations of cholecystokinin-8 and beta-endorphin in eating disorders: II. Bulimia nervosa. 1995 , 59, 51-6	18
1549	Serum cholinesterase in obsessive-compulsive disorder. 1995 , 58, 265-8	5
1548	Mazindol treatment for cocaine dependence. 1995 , 39, 245-52	48
1547	Measuring quality of life in patients with depression or anxiety. 1995 , 8, 305-15	19
1546	Life events and panic disorder/agoraphobia. 1995 , 36, 118-22	14
1545	Descriptive validity and stability of diagnostic criteria for dysthymic disorder. 1995 , 36, 338-43	10
1544	A new approach to affective symptoms in relapsing-remitting multiple sclerosis. 1995 , 36, 390-5	42
1543	Phobic symptoms as predictors of nonresponse to drug therapy in panic disorder patients (a preliminary report). 1995 , 33, 31-8	16
1542	Platelet peripheral-type benzodiazepine receptor in major depression. 1995 , 33, 257-61	32
1541	Reliability and validity of the Japanese version of the Yale-Brown Obsessive-Compulsive Scale. 1995 , 49, 121-6	48
1540	Attaque de panique et syndrome d'hyperventilation. 1995 , 35, 614-620	

1539	CSF isatin is elevated in bulimia nervosa. 1995 , 37, 481-3	18
1538	Anxiety and Depression as Predictors of Recurrence in Geriatric Depression: A Preliminary Report. 1996 , 4, 252-257	15
1537	Anxiety disorders in children and adolescents: a review of the past 10 years. 1996 , 35, 1110-9	250
1536	A double-blind comparison of tianeptine, imipramine and placebo in the treatment of major depressive episodes. 1996 , 11, 254-9	24
1535	A randomized, double-blind study of alpidem vs placebo in the prevention and treatment of benzodiazepine withdrawal syndrome. 1996 , 11, 93-9	4
1534	Key considerations for long-term studies with anxiolytics. 1996 , 11, 144-8	2
1533	Association of levels of N-acetyl-beta-glucosaminidase with severity of psychiatric symptoms in panic disorder. 1996 , 60, 185-90	2
1532	Cerebrospinal fluid corticotropin-releasing factor concentrations in patients with anxiety disorders and normal comparison subjects. 1996 , 39, 703-7	69
1531	Elevated cerebrospinal fluid corticotropin-releasing factor in Tourette's syndrome: comparison to obsessive compulsive disorder and normal controls. 1996 , 39, 776-83	68
1530	Prospective study of FK506 side effects: anxiety or akathisia?. 1996 , 40, 407-11	18
1529	Cardiovascular, neuroendocrine, and monoaminergic responses to psychological stressors: possible differences between remitted panic disorder patients and healthy controls. 1996 , 40, 353-60	22
1528	m-Chlorophenylpiperazine challenge in borderline personality disorder: relationship of neuroendocrine response, behavioral response, and clinical measures. 1996 , 40, 508-13	27
1527	Depression in women treated with a gonadotropin-releasing hormone agonist. 1996 , 39, 378-82	16
1526	High-energy phosphate metabolism in the frontal lobes of patients with panic disorder detected by phase-encoded 31P-MRS. 1996 , 40, 785-93	28
1525	Cytokine production in obsessive-compulsive disorder. 1996 , 40, 908-12	35
1524	Impulsivity and neuroendocrine response to buspirone in bulimia nervosa. 1996 , 39, 371-4	17
1523	Quantitative electroencephalographic characteristics of crack cocaine dependence. 1996 , 40, 986-93	35
1522	A controlled trial of fluoxetine in crack cocaine dependence. 1996 , 41, 137-42	99

1521	The effect of anxiety and depression on completion/withdrawal status in patients admitted to substance abuse detoxification program. 1996 , 13, 61-6	27
1520	Anxiety Rating for Children [Revised: Reliability and validity. 1996 , 10, 97-114	25
1519	Culturally relevant factors in the behavioral treatment of social phobia: A case study. 1996 , 10, 201-209	19
1518	Fluvoxamine, placebo, and cognitive behaviour therapy used alone and in combination in the treatment of panic disorder and agoraphobia. 1996 , 10, 219-242	75
1517	Personality dimensions in panic disorder and generalized anxiety disorder. 1996 , 37, 75-9	87
1516	Primary dysthymia: a study of several psychosocial, endocrine and immune correlates. 1996 , 40, 73-84	40
1515	Effect of benzodiazepines on plasma levels of homovanillic acid in anxious patients and control subjects. 1996 , 65, 53-9	6
1514	Social skills training in a case of obsessive-compulsive disorder with schizotypal personality disorder. 1996 , 27, 189-94	15
1513	Characteristics of generalized anxiety disorder in older adults: a descriptive study. 1996 , 34, 225-34	104
1512	Trauma management therapy: a preliminary evaluation of a multicomponent behavioral treatment for chronic combat-related PTSD. 1996 , 34, 533-43	78
1511	Clinical features affecting treatment outcome in social phobia. 1996 , 34, 795-804	59
1510	Generalized anxiety and panic disorders: Response to Cox, Cohen, Direnfeld, and Swinson (1996). 1996 , 34, 955-957	22
1509	Reply to Steer and Beck: Panic disorder, generalized anxiety disorder, and quantitative versus qualitative differences in anxiety assessment. 1996 , 34, 959-961	10
1508	Psychopathology in 90 consecutive human immunodeficiency virus-seropositive and acquired immune deficiency syndrome patients with mostly intravenous drug use history. 1996 , 37, 267-72	15
1507	Number of symptoms, quantification, and qualification of depression. 1996 , 37, 307-15	38
1506	Effects of the 5-HT1A receptor agonist flesinoxan in panic disorder. 1996 , 127, 174-80	36
1505	Computer-administered clinical rating scales. 1996 , 127, 291-301	57
1504	Oesophageal motility disorders in patients with psychiatric disease. 1996 , 23, 1583-7	8

1503 Optimal management of anxiety in older patients. 1996, 9, 191-201 3 1502 Work induced stress. 1996, 64 (Pt 4), 153-7 Platelet alpha 2-adrenoreceptors, catecholamines, hemodynamic variables, and anxiety in panic 1501 10 patients and their asymptomatic relatives. 1996, 58, 289-301 1500 Possible selves in major depression. **1996**, 184, 739-45 Serum cholesterol levels in patients with generalized anxiety disorder (GAD) and with GAD and 1499 24 comorbid major depression. 1996, 41, 465-8 An open trial of brief supportive-expressive psychotherapy in the treatment of generalized anxiety 1498 58 disorder.. 1996, 33, 418-430 The impact of gender on alpha-methyl-para-tyrosine mediated changes in prolactin secretion and 1497 7 6-hydroxymelatonin sulfate excretion. **1996**, 21, 469-78 Is the relationship between anxious and depressive cognitions and symptoms linear or curvilinear?. 1496 15 **1996**, 20, 135-154 1495 Measurement of perceived control over anxiety-related events. 1996, 27, 279-293 220 Treatment of generalized anxiety in older adults: A preliminary comparison of cognitive-behavioral 1494 144 and supportive approaches. 1996, 27, 565-581 1493 The effect of fluoxetine on anxiety and depression symptoms in cancer patients. 1996, 94, 205-10 137 1492 What do anxiety scales measure?. **1996**, 93, 177-80 74 1491 A naturalistic 6-year follow-up study of patients with panic disorder. 1996, 93, 181-3 23 1490 Effect of diazepam on plasma gamma-aminobutyric acid in sons of alcoholic fathers. 1996, 20, 343-7 9 Polydrug use in adolescent drinkers with and without DSM-IV alcohol abuse and dependence. 1996, 1489 107 20, 1099-1108 Efficacy of a special Kava extract (Piper methysticum) in patients with states of anxiety, tension and $_{1488}$ excitedness of non-mental origin - A double-blind placebo-controlled study of four weeks 49 treatment. 1996, 3, 113-9 Rebound insomnia after abrupt discontinuation of hypnotic treatment: double-blind randomized 1487 25 comparison of zolpidem versus triazolam. 1996, 11, 225-233 Controlled Comparison of Tianeptine, Alprazolam and Mianserin in the Treatment of Adjustment 1486 26 Disorders with Anxiety and Depression. 1996, 11, 293-298

1485	Neurocognitive Effects of Zidovudine and 2?,3?-Dideoxyinosine During the Treatment of Asymptomatic and Symptomatic HIV-1 Seropositive Patients. Comparison with Non-Treated Patients. 1996 , 11, 415-420	2
1484	Caring for someone with Parkinson's disease: factors that contribute to distress. 1996 , 11, 263-268	51
1483	Posttraumatic stress disorder, depression, alcohol use disorders and quality of life in adolescents. 1996 , 2, 226-33	61
1482	Two domains of anosognosia in Alzheimer's disease. 1996 , 61, 485-90	101
1481	Alprazolam withdrawal symptoms in agoraphobia with panic disorder: observations from a controlled Anglo-Canadian study. 1996 , 10, 101-9	7
1480	Cognitive functioning in patients with chronic fatigue syndrome. 1996 , 18, 666-77	35
1479	Catatonia in depression: prevalence, clinical correlates, and validation of a scale. 1996 , 60, 326-32	75
1478	Validation of the Panic Outcomes Module. 1997 , 20, 81-95	3
1477	The effect of citalopram in panic disorder. 1997 , 170, 549-53	127
1476	Effects of trazodone on insomnia and anxiety in depressed patients: a clinical and sleep EEG study. 1997 , 1, 281-6	2
1475	Making treatment decisions with HIV infection: a pilot study of patient preferences. 1997 , 17, 307-14	15
1474	Buspirone, a serotonergic 5-HT1A agonist, is active in cerebellar ataxia. A new fact in favor of the serotonergic theory of ataxia. 1997 , 114, 589-99	15
1473	Pharmacotherapy of schizophrenia patients with comorbid substance abuse. 1997 , 23, 215-28	53
1472	Psychological effects of cardiac surgery: a review of the literature. 1997 , 117, 245-9	11
1471	Psychological sequelae of cancer diagnosis: a meta-analytical review of 58 studies after 1980. 1997 , 59, 280-93	382
1470	Prospective longitudinal study of depression and anosognosia in Alzheimer's disease. 1997 , 171, 47-52	129
1469	Assessment of a new self-rating scale for post-traumatic stress disorder. 1997 , 27, 153-60	764
1468	Psychological preparedness for trauma as a protective factor in survivors of torture. 1997 , 27, 1421-33	149

1467	Laterality in somatization. 1997 , 59, 236-40	30
1466	Persistence of defective serotonergic and GABAergic controls of growth hormone secretion in long-term abstinent alcoholics. 1997 , 32, 85-90	17
1465	Change in obsessive-compulsive and avoidant personality disorders following time-limited supportive-expressive therapy 1997 , 34, 133-143	8o
1464	Psychological theory testing versus psychometric nay-saying: Comment on Neuberg et al.'s (1997) critique of the Need for Closure Scale 1997 , 73, 1005-1016	101
1463	Psychometric evaluation of the Beck Anxiety Inventory with older medical patients 1997 , 9, 136-144	114
1462	Plasma noradrenaline response to electroconvulsive therapy in depressive illness. 1997 , 171, 182-6	28
1461	Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. 1997 , 171, 73-7	143
1460	Buspirone. 1997 , 7, 68-88	49
1459	Selective Serotonin Reuptake Inhibitors. 1997 , 7, 452-467	26
1458	Magnetic resonance imaging of children without sedation: preparation with simulation. 1997 , 36, 853-9	138
1457	Dual diagnosis in primary care. Detecting and treating both the addiction and mental illness. 1997 , 81, 1017-36	28
1456	Traumas and other adverse life events in adolescents with alcohol abuse and dependence. 1997 , 36, 1744-51	207
1455	Levels of anxiety, depression and denial in patients with myocardial infarction. 1997 , 12, 149-51	6
1454	Depression and anxiety as a single disorder: evidence from brain stem auditory evoked potentials. 1997 , 12, 395-8	1
1453	A short-term cognitive behavioural therapy for bulimia nervosa including brief hospitalisation. 1997 , 12, 405-11	2
1452	Measuring disability in subjects with anxiety disorders. 1997 , 12 Suppl 3, 249s-53s	5
1451	Post-Traumatic Stress Disorder. 1997 , 8, 293-322	14
1450	Practice parameters for the assessment and treatment of children and adolescents with anxiety disorders. American Academy of Child and Adolescent Psychiatry. 1997 , 36, 69S-84S	105

1449	Functional status in coronary artery disease: a one-year prospective study of the role of anxiety and depression. 1997 , 103, 348-56	128
1448	Psychometric properties and diagnostic utility of the Beck Anxiety Inventory and the State-Trait Anxiety Inventory with older adult psychiatric outpatients. 1997 , 11, 33-47	304
1447	The assessment of panic using self-report: a comprehensive survey of validated instruments. 1997 , 11, 89-111	24
1446	A comparison of focused and standard cognitive therapy for panic disorder. 1997 , 11, 329-45	21
1445	Application of the Stages of Change Scale in a clinical drug trial. 1997 , 11, 395-408	13
1444	How does interoceptive exposure for panic disorder work? An uncontrolled case study. 1997 , 11, 541-56	33
1443	Frontal CSF enlargement in panic disorder: a qualitative CT-scan study. 1997 , 76, 83-7	10
1442	Secondary alexithymia as a state reaction in panic disorder and social phobia. 1997 , 38, 166-70	83
1441	The short-term natural history of irritable bowel syndrome: a time-series analysis. 1997 , 35, 319-26	20
1440	Does concurrent drug intake affect the long-term outcome of group cognitive behaviour therapy in panic disorder with or without agoraphobia?. 1997 , 35, 851-7	23
1439	Psychiatric characteristics of consecutively evaluated outpatient renal transplant candidates and comparisons with consultation-liaison inpatients. 1997 , 38, 269-76	21
1438	Interoceptive exposure versus breathing retraining within cognitive-behavioural therapy for panic disorder with agoraphobia. 1997 , 36, 85-99	95
1437	Efficacy of tianeptine in major depressive disorders with or without melancholia. 1997 , 7 Suppl 3, S341-5	8
1436	Effect of alpha-methyl-para-tyrosine on response to cocaine challenge. 1997 , 42, 181-90	22
1435	Elevated levels of serum interleukin-1 beta in combat-related posttraumatic stress disorder. 1997 , 42, 345-8	171
1434	Phenomenological and pharmacological study of provoked obsessive/anxiety symptoms in obsessive-compulsive disorder: a preliminary study. 1997 , 42, 969-75	5
1433	Hypersensitivity to carbon dioxide as a disease-specific trait marker. 1997 , 41, 259-63	69
1432	Does muscle tension reflect arousal? Relationship between electromyographic and electroencephalographic recordings. 1997 , 71, 49-55	28

1431	Psychopathological and cognitive features in subclinical hypothyroidism. 1997 , 21, 925-35	121
1430	Corpus callosal morphology in treatment-naive pediatric obsessive compulsive disorder. 1997 , 21, 1269-83	77
1429	Efficacy and safety of two dosing regimens of buspirone in the treatment of outpatients with persistent anxiety. 1997 , 19, 498-506	22
1428	Effects of past history of major depression on smoking characteristics, monoamine oxidase-A and -B activities and withdrawal symptoms in dependent smokers. 1997 , 45, 31-7	32
1427	Test-retest reliability of the Personality Diagnostic Questionnaire: Revised. 1997 , 51, 369-72	13
1426	Measurement properties of quantitative urine benzoylecgonine in clinical trials research. 1997 , 92, 297-302	10
1425	A combination of plant extracts in the treatment of outpatients with adjustment disorder with anxious mood: controlled study versus placebo. 1997 , 11, 127-32	58
1424	Nocturnal panic 1997 , 4, 153-174	39
1423	Patient outcomes used by advanced practice psychiatric nurses to evaluate effectiveness of practice. 1997 , 11, 184-97	17
1422	Prenatal biopsychosocial risk assessment and low birthweight. 1997 , 44, 1107-14	14
1421	Cerebrospinal fluid and plasma beta-endorphin in combat veterans with post-traumatic stress disorder. 1997 , 22, 517-29	71
1420	Anxiety disorders in the elderly: The emerging role of behavior therapy. 1997 , 28, 83-100	42
1419	Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: A preliminary meta-analysis. 1997 , 28, 285-305	260
1418	Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS. Improvements in affective and somatic symptoms. 1997 , 19, 89-97	64
1417	Prevalence of anxiety disorders comorbidity in bipolar depression, unipolar depression and dysthymia. 1997 , 42, 145-53	182
1416	Evaluating the diagnostic specificity of the Munich Personality Test dimensions in major depression. 1997 , 43, 187-94	26
1415	Predicting factors for absenteeism in patients with major depressive disorders. 1997 , 13, 87-93	15
1414	Moclobemide in social phobia. 1997 , 247, 71-80	59

1413	Physiological, biochemical and subjective parameters in anxiety patients with panic disorder during stress exposure as compared with healthy controls. 1997 , 247, 264-74	29
1412	Effectiveness of group anxiety management with elderly clients of a community psychogeriatric team. 1997 , 12, 79-84	16
1411	Relationship of depression, anxiety, and obsessionality to state of illness in anorexia nervosa. 1997 , 21, 367-76	190
1410	Responses to civilian war experiences: predictors of psychological functioning and coping. 1998 , 11, 571-7	38
1409	Auricular Acupuncture as an Adjunctive Treatment for Cocaine Addiction: A Pilot Study. 1998 , 7, 164-170	21
1408	The Minnesota Substance Abuse Problems Scale. 1998 , 7, 24-34	4
1407	Symptom relief with amitriptyline in the irritable bowel syndrome. 1998 , 13, 738-41	74
1406	Cocaine decreases cortical cerebral blood flow but does not obscure regional activation in functional magnetic resonance imaging in human subjects. 1998 , 18, 724-34	108
1405	Emotional symptoms are secondary to the voice disorder in patients with spasmodic dysphonia. 1998 , 20, 255-9	26
1404	Medication side effects in anxious patients: negative placebo responses?. 1998 , 47, 183-90	26
1403	Assessment of suicide in schizophrenia: Development of the interview for suicide in schizophrenia. 1998 , 5, 139-169	9
1402	Tryptophan depletion during continuous CSF sampling in healthy human subjects. 1998 , 19, 26-35	226
1401	Persistent QEEG abnormality in crack cocaine users at 6 months of drug abstinence. 1998 , 19, 1-9	45
1400	Smoked cocaine self-administration in females and voucher incentives for abstinence. 1998 , 10, 143-62	3
1399	Comparative efficacy of treatments for post-traumatic stress disorder: a meta-analysis. 1998 , 5, 126-144	371
1398	Evaluation of the efficacy of metaclazepam and its effects on sleep, psychomotor performance and cognitive function in anxious patients. 1998 , 13, 247-254	1
1397	Stress associated with asbestosis: the trauma of waiting for death. 1998 , 7, 126-8	17
1396	A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. 1998 , 7, 291-300	108

1395	Assessment of locus of control in patients with anxiety and depressive disorders. 1998, 54, 509-15	28
1394	Depression in classic versus akinetic-rigid Parkinson's disease. 1998 , 13, 29-33	178
1393	Social status, alcohol consumption and affective disorders in non-institutionalized elderly. 1998 , 26, 111-116	
1392	The impact of diabetes mellitus on quality of life in elderly patients. 1998 , 26, 417-422	4
1391	Average daily nutrient intake and mood among obese women. 1998 , 18, 1103-1112	19
1390	Tianeptine therapy for depression in the elderly. 1998 , 22, 319-29	16
1389	The use of the Panic and Agoraphobia Scale in a clinical trial. 1998 , 77, 43-9	44
1388	Decreased heart-period variability in patients with panic disorder: a study of Holter ECG records. 1998 , 78, 89-99	87
1387	GABAergic function in detoxified heroin addicts: relationship to anxiety disorders. 1998, 77, 89-96	12
1386	Adrenergic receptors in premenstrual dysphoric disorder. II. Neutrophil beta2-adrenergic receptors: Gs protein coupling, phase of menstrual cycle and prediction of luteal phase symptom severity. 1998 , 79, 31-42	15
1385	Plasma norepinephrine response to a cold pressor test in subtypes of depressive illness. 1998 , 81, 39-50	20
1384	Is the efficacy of topical corticosteroid therapy for psoriasis vulgaris enhanced by concurrent moclobemide therapy? A double-blind, placebo-controlled study. 1998 , 38, 197-200	23
1383	Variations in psychosocial functioning associated with patterns of progression in cocaine-dependent men. 1998 , 23, 179-89	11
1382	Don't worry and beware of white bears: thought suppression in anxiety patients. 1998 , 12, 39-55	69
1381	Cognitions in generalized anxiety disorder and panic disorder patients. 1998 , 12, 567-77	37
1380	An open clinical trial of venlafaxine treatment of fibromyalgia. 1998 , 39, 14-7	134
1379	Pretreatment patient factors predicting attrition from a multicenter randomized controlled treatment study for panic disorder. 1998 , 39, 323-32	50
1378	The neurobiology of tryptophan depletion in depression: effects of intravenous tryptophan infusion. 1998 , 43, 339-47	47

1377	Platelet cytosolic calcium responses to serotonin in depressed patients and controls: relationship to symptomatology and medication. 1998 , 43, 327-34	34
1376	A.E. Bennett Research Award. Toward a neurodevelopmental model of of obsessivecompulsive disorder. 1998 , 43, 623-40	315
1375	Assessment of serotonergic function in major depression using d-fenfluramine: relation to clinical variables and antidepressant response. 1998 , 44, 555-61	39
1374	Adrenergic receptors in premenstrual dysphoric disorder: I. Platelet alpha 2 receptors: Gi protein coupling, phase of menstrual cycle, and prediction of luteal phase symptom severity. 1998 , 44, 600-9	19
1373	Case study: caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder. 1998 , 37, 663-7	68
1372	Sleep Deprivation in social phobia and generalized anxiety disorder. 1998 , 43, 840-2	21
1371	Psychiatric disorder in essential dyspepsia. 1998 , 2, 41-5	
1370	Serotonin 5-HT1a Receptor Agonists as Antidepressants. 1998 , 10, 343-353	24
1369	Stage of Change as a Predictor of Abstinence Among Alcohol-Dependent Subjects in Pharmacotherapy Trials. 1998 , 19, 81-91	18
1368	Discriminant validity of the SCL-90 dimensions of anxiety and depression. 1998 , 5, 197-201	44
1367	Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. 1998 , 173, 54-60	110
1366	Measures of anhedonia and hedonic responses to sucrose in depressive and schizophrenic patients in comparison with healthy subjects. 1998 , 13, 303-9	126
1365	Early predictors of two month response with mianserin and selective serotonin reuptake inhibitors and influence of definition of outcome on prediction. 1998 , 13, 138-42	6
1364	Differences and variability in plasma noradrenaline between depressive and anxiety disorders. 1998 , 12, 161-7	28
1363	Stressful reactions and panic attacks induced by flumazenil in chronic benzodiazepine users. 1998 , 12, 146-50	20
1362	Placebo-controlled trial of moclobemide in social phobia. 1998 , 172, 70-7	125
1361	Spectral electroencephalogram and clinical follow-up during alprazolam and imipramine treatment in panic disorder. 1998 , 52, 245-249	1
1360	Mood improvement in 'normal' volunteers. 1998 , 12, 246-51	31

1359 Anxiety and alcohol abuse in patients in treatment for depression. 1998 , 24, 453-63	8
1358 Two psychological treatments for hypochondriasis. A randomised controlled trial. 1998	8 , 173, 218-25 238
1357 Shared Symptoms of Panic Disorder in an Elderly Couple. 1998 , 6, 340-344	
1356 Psychopharmacological Treatment of Panic Disorder. 1998 , 8, 426-451	3
The rationale for developing and outcome batteries for routine use in service settings a psychotherapy outcome research implementing core. 1998 , 7, 35-47	and 140
1354 Reduced lymphocyte proliferation and interleukin-2 production in anxiety disorders. 19	998 , 60, 479-83 40
The effect of personality on withdrawal severity and taper outcome in benzodiazepine patients. 1998 , 28, 713-20	e dependent 41
1352 Aspects of dysphoria and symptoms of schizophrenia. 1998 , 28, 1433-41	44
Depressive symptom differences in hospitalized, medically ill, depressed psychiatric inpronomedical controls 1998 , 107, 38-48	patients and 58
Psychometric properties of the 42-item and 21-item versions of the Depression Anxiety Scales in clinical groups and a community sample 1998 , 10, 176-181	y Stress 2544
PSYCHOLOGIST, PATIENT, AND GENERAL PRACTITIONER RATINGS OF OUTCOME OF PHARMACOLOGICAL AND PSYCHOLOGICAL TREATMENTS FOR PANIC DISORDER AND AGORAPHOBIA IN PRIMARY CARE. 1998 , 26, 13-27) 10
$_{1348}$ Interaction of pharmacological and psychological treatments of anxiety. 1998 , 173, 42-	-48 31
The spectrum of generalised anxiety in clinical practice: the role of short-term, intermit treatment*. 1998 , 173, 49-54	ttent 18
1346 Psychoeducation for People Vulnerable to Schizophrenia. 1998 , 571-595	3
The Relationship of Two Aspects of Perfectionism with Symptoms in a Psychiatric Outp Population. 1998 , 17, 50-68	patient 24
1344 Affective Disorders. 1998 , 339-366	
1343 Abecarnil, a new beta-carboline, in the treatment of anxiety disorders. 1998 , 173, 55-63	3 18
1342 Management of Psychiatric Symptoms in Medically III Patients in the Homecare Setting	g. 1998 , 10, 315-326 2

Personality differences in the Munich Personality Test between patients with major depression and panic disorder. **1998**, 52, 403-6

1340	Fluvoxamine in the Treatment of Trichotillomania: An 8-Week, Open-Label Study. 1998 , 3, 64-71	5
1339	Anxiety Disorders. 1998 , 171-191	3
1338	Carbon dioxide induced panic attacks and short term clonazepam treatment. Preliminary study. 1999 , 57, 361-5	13
1337	Long term efficacy of paroxetine in major depression: A study with plasma levels. 1999 , 3, 115-9	7
1336	Sexual dysfunction in multiple sclerosis: a case-control study. I. Frequency and comparison of groups. 1999 , 5, 418-27	167
1335	Brief Cognitive Behaviour Therapy of Panic Disorder. 1999 , 28, 49-57	26
1334	Psychometric properties of the Liebowitz Social Anxiety Scale. 1999 , 29, 199-212	575
1333	A cognitive model of generalized anxiety disorder. 1999 , 23, 526-55	78
1332	Anxiety and Panic Disorders in Older Adults Sharon. 1999 , 11, 49-59	
1331	Amisulpride in medium-term treatment of dysthymia: a six-month, double-blind safety study versus amitriptyline. AMILONG investigators. 1999 , 13, 248-54	34
1330	Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo. 1999 , 29, 107-17	22
1329	A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression. 1999 , 13, 406-14	60
1328	Perceived quality of life in depression: Effect of clinical and demographic variables. 1999 , 3, 35-41	
1327	Decreased density of GABA-A receptors in the left sensorimotor cortex in akinetic catatonia: investigation of in vivo benzodiazepine receptor binding. 1999 , 67, 445-50	111
1326	Comorbidity of headache and depressive disorders. 1999 , 19, 211-7	163
1325	A beneficial effect on mood in partial epilepsy patients treated with gabapentin. 1999 , 40, 1129-34	58
1324	The equivalence of computerized and paper-and-pencil psychological instruments: implications for measures of negative affect. 1999 , 31, 315-21	37

1323 Divalproex in posttraumatic stress disorder: an open-label clinical trial. 1999 , 12, 395-401	80
The disclosure of information to cancer patients and its relationship to their mental state in a consultation-liaison psychiatry setting in Japan. 1999 , 21, 368-73	33
A neuroendocrine study of serotonin function in depressed stroke patients compared to non depressed stroke patients and healthy controls. 1999 , 52, 121-33	10
1320 Differential clinical features of early-onset panic disorder. 1999 , 54, 109-17	20
Delineating psychopathologic clusters within dysthymia: a study of 512 out-patients without made depression. 1999 , 56, 17-25	ajor 42
Adrenergic receptor function in panic disorder. II. Neutrophil beta 2 receptors: Gs protein couple effects of imipramine treatment and relationship to treatment outcome. 1999 , 33, 309-22	ing, 22
1317 Attempted suicide: repetition and survivalfindings of a follow-up study. 1999 , 100, 205-11	110
Thyrotropin stimulating hormone response to thyrotropin releasing hormone in patients with p disorder. 1999 , 24, 155-60	anic 12
Benzodiazepine-induced chemotaxis is impaired in monocytes from patients with generalized anxiety disorder. 1999 , 24, 243-9	18
1314 Platelet peripheral-type benzodiazepine in pregnancy and lactation. 1999 , 21, 513-8	2
1313 A discriminant analysis extension to mixed models. 1999 , 18, 1249-60	35
1312 Predicting treatment outcome for panic disorder and agoraphobia in primary care. 1999 , 6, 336	-348 13
Procaine administration and behavioral responsivity in post-traumatic stress disorder: a pilot st of tolerability. 1999 , 14, 105-111	udy 2
1310 The anatomy of a clinical trial. 1999 , 14, S103-S108	
1309 Anxiolytic effect of hydroxyzine: a double-blind trial versus placebo and buspirone. 1999 , 14, S9	4-S102
$_{1308}$ Short Anxiety Screening Testa brief instrument for detecting anxiety in the elderly. 1999 , 14, $^{\circ}$	1 062-71 58
1307 Relation of marital status to social phobia severity. 1999 , 10, 28-32	28
Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety. 1999 , 9, 131-134	91

1305	Paroxetine open-label treatment of pediatric outpatients with obsessive-compulsive disorder. 1999 , 38, 1180-5	54
1304	Neuropsychiatric assessment as a secondary outcome measure in a multiple sclerosis intravenous immunoglobulin L(IMg) trial. 1999 , 3, 31-4	5
1303	Cognitive distortions in panic disorder and major depression: Specificity for depressed mood. 1999 , 53, 459-464	9
1302	Changes in personality characteristics in women treated in a therapeutic community. 1999 , 16, 137-42	18
1301	Prevention of post-rape psychopathology: preliminary findings of a controlled acute rape treatment study. 1999 , 13, 359-70	64
1300	Family dimensions in anxious-depressed school refusers. 1999 , 13, 513-28	53
1299	Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity. 1999 , 83, 137-45	139
1298	Effects of the CCK(B) antagonist CI-988 on responses to mCPP in generalized anxiety disorder. 1999 , 85, 225-40	19
1297	Platelet alpha2A-adrenoceptor function in major depression: Gi coupling, effects of imipramine and relationship to treatment outcome. 1999 , 89, 73-95	30
1296	Prediction of treatment outcome in cocaine dependent males using quantitative EEG. 1999 , 54, 35-43	26
1295	Corpus callosal signal intensity in treatment-naive pediatric obsessive compulsive disorders. 1999 , 23, 601-12	41
1294	Prefrontal enlargement of CSF spaces in agoraphobia: a qualitative CT-scan study. 1999 , 23, 823-30	3
1293	A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. 1999 , 21, 643-58	174
1292	The effect of presynaptic catecholamine depletion on 6-hydroxymelatonin sulfate: a double blind study of alpha-methyl-para-tyrosine. 1999 , 9, 61-6	7
1291	A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder. 1999 , 9, 191-6	25
1290	A preliminary report on pain thresholds in bulimia nervosa during a bulimic episode. 1999 , 40, 229-33	14
1289	Depression in coronary heart disease. What is the appropriate diagnostic threshold?. 1999 , 40, 286-92	35
1288	Personality dimensions in chronic fatigue syndrome and depression. 1999 , 46, 395-400	37

1287	Cognitions in generalized anxiety disorder and panic disorder patients. A prospective approach. 1999 , 37, 533-44	44
1286	The Overvalued Ideas Scale: development, reliability and validity in obsessive-compulsive disorder. 1999 , 37, 881-902	119
1285	Functional magnetic resonance imaging study of frontal lobe activation during word generation in obsessive-compulsive disorder. 1999 , 45, 891-7	52
1284	Platelet cytosolic calcium hyperresponsivity to serotonin in patients with hypertension and depressive symptoms. 1999 , 45, 1035-41	13
1283	Low platelet-poor plasma concentrations of serotonin in patients with combat-related posttraumatic stress disorder. 1999 , 45, 840-5	55
1282	Effect of catecholamine depletion on lithium-induced long-term remission of bipolar disorder. 1999 , 45, 972-8	55
1281	The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. 1999 , 45, 1170-7	67
1280	Tryptophan depletion and depressive vulnerability. 1999 , 46, 498-505	85
1279	Comparative efficacy of sertraline vs. fluoxetine in patients age 70 or over with major depression. 1999 , 7, 221-7	42
1278	Olfactory loss in multiple sclerosis. 1999 , 168, 127-30	61
1277	Impairment in visual-spatial function in catatonia: a neuropsychological investigation. 1999 , 37, 133-47	42
1276	Depression and anxiety in Parkinson's disease: possible effect of genetic variation in the serotonin transporter. 1999 , 12, 49-52	93
1275	Sexual dysfunction in multiple sclerosis: II. Correlation analysis. 1999 , 5, 428-31	80
1274	Home-based, interactive videoconferencing for adolescents with epilepsy and their families 1999 , 44, 176-193	53
1273	Predictors of individual differences in alprazolam self-medication 1999 , 7, 379-390	12
1272	Pharmacotherapy for social phobia. 1999 ,	O
1271	Low platelet monoamine oxidase activity in sensation-seeking bullfighters. 1999 , 4, 21-4	10
1270	Relationship between clinical pain complaints and pain sensitivity in patients with depression and panic disorder. 1999 , 61, 822-7	140

1269	Comparative efficacy and safety of sertraline versus nortriptyline in major depression in patients 70 and older. 1999 , 11, 85-99	44
1268	Reduced activation and altered laterality in two neuroleptic-naive catatonic patients during a motor task in functional MRI. 1999 , 29, 997-1002	67
1267	Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. 1999 , 13, 1763-9	448
1266	Alliance predicts patients' outcome beyond in-treatment change in symptoms 2000, 68, 1027-1032	219
1265	Gender differences and similarities in the personality correlates of adolescent alcohol problems 2000 , 14, 121-133	52
1264	CognitiveBehavioral stress management intervention effects on anxiety, 24-hr urinary norepinephrine output, and T-cytotoxic/suppressor cells over time among symptomatic HIV-infected gay men 2000 , 68, 31-45	129
1263	Realism of confidence in obsessive-compulsive checkers 2000 , 109, 673-678	51
1262	Difference in symptom profile between generalized anxiety disorder and anxiety secondary to hyperthyroidism. 2000 , 30, 71-81	10
1261	Reductions in herpes simplex virus type 2 antibody titers after cognitive behavioral stress management and relationships with neuroendocrine function, relaxation skills, and social support in HIV-positive men. 2000 , 62, 828-37	76
1260	Long-term treatment of panic disorder with agoraphobia in private practice. 2000 , 6, 140-6	1
1259	Right lower prefronto-parietal cortical dysfunction in akinetic catatonia: a combined study of neuropsychology and regional cerebral blood flow. 2000 , 30, 583-96	69
1258	Elevated circulatory level of GABA(A)antagonistic neurosteroids in patients with combat-related post-traumatic stress disorder. 2000 , 30, 1227-31	119
1257	An empirical approach to subtype identification in individuals with social phobia. 2000 , 30, 1345-57	40
1256	Autonomic reactivity of panic patients during a CO2 inhalation procedure. 2000 , 11, 15-26	40
1255	Cell-surface expression of L-selectin (CD62L) by blood lymphocytes: Correlates with affective parameters and severity of panic disorder. 2000 , 11, 31-37	18
1254	Therapist contact in cognitive behaviour therapy for panic disorder and agoraphobia in primary care. 2000 , 7, 37-46	14
1253	Validity and test-retest reliability of a disability questionnaire for essential tremor. 2000 , 15, 516-23	68
1252	Plasma noradrenaline response to a cognitive stressor in subtypes of depressive illness. 2000 , 15, 265-274	4

(2000-2000)

1251	Efficacy, safety, and tolerability of venlafaxine XR in generalized anxiety disorder. 2000 , 12 Suppl 1, 81-4	15
1250	Nonlinear measures of heart period variability: decreased measures of symbolic dynamics in patients with panic disorder. 2000 , 12, 67-77	49
1249	Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. 2000 , 2, 249-55	211
1248	Efficacy of Dexfenfluramine in the Treatment of Alcohol Dependence. 2000 , 24, 1534-1541	4
1247	A customisable framework for the assessment of therapies in the solution of therapy decision tasks. 2000 , 18, 57-82	4
1246	History of childhood attention deficit hyperactivity disorder (ADHD) features among adults with panic disorder. 2000 , 58, 99-106	34
1245	Differential clinical features of late-onset panic disorder. 2000 , 57, 115-24	18
1244	Executive dysfunction predicts nonresponse to fluoxetine in major depression. 2000 , 60, 13-23	171
1243	Treatment of separation anxiety in dogs with clomipramine: results from a prospective, randomized, double-blind, placebo-controlled, parallel-group, multicenter clinical trial. 2000 , 67, 255-275	122
1242	The primary care evaluation of mental disorders (PRIME-MD), German version: a comparison with the CIDI. 2000 , 34, 211-20	34
1241	Adding subjects or adding measurements: Which increases the precision of longitudinal research?. 2000 , 34, 449-55	6
1240	Explicit memory bias for threat words in generalized anxiety disorder. 2000 , 31, 745-756	66
1239	Five-year prospective study of the effects of anxiety and depression in patients with coronary artery disease. 2000 , 86, 1135-8, A6, A9	82
1238	Operative stress response is reduced after laparoscopic compared to open cholecystectomy: the relationship with postoperative pain and ileus. 2000 , 45, 1703-13	53
1237	The SociotropyAutonomy Scale: Structure and Implications. 2000 , 24, 763-780	65
1236	Optimism, distress, and immunologic status in HIV-infected gay men following hurricane andrew. 2000 , 7, 160-182	17
1235	Anxiety disorders in the elderly. 2000 , 2, 13-9	15
1234	Anxiety among Israeli soldiers during the Gulf War. 2000 , 250, 148-51	1

1233	United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. 2000 , 35, 176-87	152
1232	Borderline personality and obsessive-compulsive symptoms. 2000 , 14, 57-63	13
1231	Psychiatric and psychosocial disorders in patients with systemic lupus erythematosus: a longitudinal study of active and inactive stages of the disease. 2000 , 9, 584-8	49
1230	Course and Severity of Substance Abuse in Women with Comorbid Eating Disorder. 2000 , 21, 137-147	5
1229	Anti-anxiety medications: a review for social workers. 1999 , 30, 31-49	1
1228	Pharmacotherapy for posttraumatic stress disorder. 2000 , CD002795	30
1227	Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. 2000 , 35, 202-9	115
1226	[Acupuncture in patients with minor depressive episodes and generalized anxiety. Results of an experimental study]. 2000 , 68, 137-44	50
1225	Cocaine, Crime, Family History of Deviance-Are Psychosocial Correlates Related to These Phenomena in Male Cocaine Abusers?. 2000 , 21, 67-78	12
1224	Fluvoxamine pharmacotherapy of anxiety disorders in later life: preliminary open-trial data. 2000 , 13, 43-8	14
1223	A randomized clinical trial of repetitive transcranial magnetic stimulation in the treatment of major depression. 2000 , 47, 332-7	239
1222	Proton spectroscopic imaging of the thalamus in treatment-naive pediatric obsessive-compulsive disorder. 2000 , 47, 174-82	106
1221	Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial. 2000 , 355, 792-7	121
1220	Prolactin response to D-fenfluramine and suicidal behavior in depressed patients. 2000 , 93, 189-99	56
1219	Increased QT variability in patients with panic disorder and depression. 2000 , 93, 225-35	107
1218	Mixed anxiety-depressive disorder and major depressive disorder: comparison of the severity of illness and biological variables. 2000 , 94, 59-66	28
1217	Prolactin response to TRH in patients with panic disorder. 2000 , 95, 75-81	1
1216	Diurnal variation of cortisol in panic disorder. 2000 , 95, 245-50	43

(2000-2000)

1215	cortico-striatal circuitry in mediating awareness. 2000 , 111, 61-9	13
1214	Anxiety disorders. 2000 , 20, 731-54	66
1213	Sleep disturbance in generalized anxiety disorder and its treatment. 2000 , 4, 263-276	158
1212	Premature ejaculation: a psychophysiological approach for assessment and management. 2000 , 26, 293-320	75
1211	Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. 2000 , 39, 1096-103	319
1210	Comorbid generalized anxiety disorder in primary social phobia: symptom severity, functional impairment, and treatment response. 2000 , 14, 325-43	57
1209	A comparison of the efficacy of clonazepam and cognitive-behavioral group therapy for the treatment of social phobia. 2000 , 14, 345-58	116
1208	Assessment of anxiety in older adults: current status. 2000 , 14, 109-32	119
1207	Columbia University Assessment of Disability in Essential Tremor (CADET): methodological issues in essential tremor research. 2000 , 6, 17-23	13
1206	Psychometric properties of the credibility/expectancy questionnaire. 2000 , 31, 73-86	1165
	Psychometric properties of the credibility/expectancy questionnaire. 2000, 31, 73-86 Applied relaxation vs. cognitive therapy in the treatment of generalized anxiety disorder. 2000, 38, 777-90	1165 151
1205		
1205	Applied relaxation vs. cognitive therapy in the treatment of generalized anxiety disorder. 2000 , 38, 777-90	151
1205 1204	Applied relaxation vs. cognitive therapy in the treatment of generalized anxiety disorder. 2000 , 38, 777-90 Depersonalization in panic disorder: a clinical study. 2000 , 41, 172-8 Cobalamin level is related to self-reported and clinically rated mood and to syndromal depression	151 41
1205 1204 1203	Applied relaxation vs. cognitive therapy in the treatment of generalized anxiety disorder. 2000, 38, 777-90 Depersonalization in panic disorder: a clinical study. 2000, 41, 172-8 Cobalamin level is related to self-reported and clinically rated mood and to syndromal depression in bereaved HIV-1(+) and HIV-1(-) homosexual men. 2000, 48, 177-85	151 41 27
1205 1204 1203 1202	Applied relaxation vs. cognitive therapy in the treatment of generalized anxiety disorder. 2000, 38, 777-90 Depersonalization in panic disorder: a clinical study. 2000, 41, 172-8 Cobalamin level is related to self-reported and clinically rated mood and to syndromal depression in bereaved HIV-1(+) and HIV-1(-) homosexual men. 2000, 48, 177-85 A Pilot Study of Mood in Epilepsy Patients Treated with Vagus Nerve Stimulation. 2000, 1, 93-99	151 41 27 187
1205 1204 1203 1202	Applied relaxation vs. cognitive therapy in the treatment of generalized anxiety disorder. 2000, 38, 777-90 Depersonalization in panic disorder: a clinical study. 2000, 41, 172-8 Cobalamin level is related to self-reported and clinically rated mood and to syndromal depression in bereaved HIV-1(+) and HIV-1(-) homosexual men. 2000, 48, 177-85 A Pilot Study of Mood in Epilepsy Patients Treated with Vagus Nerve Stimulation. 2000, 1, 93-99 Risk factors for suicide in psychiatric outpatients: A 20-year prospective study 2000, 68, 371-377 Impact of the earthquake of September 26, 1997 in Umbria, Italy on the socioenvironmental and	151 41 27 187 871

1197	Hypericum Perforatum - St. John's Wort Chemical, Pharmacological and Clinical Aspects. 2000 , 22, 643-716	9
1196	Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. 2000 , 54, 2061-6	256
1195	The relationship between anxiety levels and outcome of cocaine abuse treatment. 2000, 26, 179-94	22
1194	Group Interventions with Cancer Patients. 2000 , 18, 67-85	39
1193	SPECT [I-123]iomazenil measurement of the benzodiazepine receptor in panic disorder. 2000 , 47, 96-106	146
1192	Delayed onset of late movement-related cortical potentials and abnormal response to lorazepam in catatonia. 2000 , 44, 193-211	54
1191	Efficacy of short and long-term venlafaxine ER treatment on somatic and psychic symptoms of GAD. 2000 , 10, 337	
1190	Basal plasma dehydroepiandrosterone sulfate level: a possible predictor for response to electroconvulsive therapy in depressed psychotic inpatients. 2000 , 48, 693-701	58
1189	Thalamic volume in pediatric obsessive-compulsive disorder patients before and after cognitive behavioral therapy. 2000 , 48, 294-300	76
1188	Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline. 2000 , 48, 894-901	113
1187	Separation anxiety disorder in children and adolescents: epidemiology, diagnosis and management. 2001 , 15, 93-104	54
1186	Occurrence and clinical correlates of psychiatric co-morbidity in delusional disorder. 2001 , 16, 222-8	32
1185	Differences in interleukins' patterns between dysthymia and major depression. 2001 , 16, 317-9	25
1184	Sumatriptan, 5-HT(1D) receptors and obsessive-compulsive disorder. 2001 , 11, 169-72	51
1183	Gabapentin and the Prophylaxis of Bipolar Disorders in Patients Intolerant to Lithium. 2001 , 21, 169-74	1
1182	Mexazolam and Alprazolam in the Treatment of Generalised Anxiety Disorder. 2001 , 21, 257-263	7
1181	Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa. 2001 , 49, 644-52	274
1180	Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. 2001 , 49, 914-21	402

(2001-2001)

1179	Increased pituitary and adrenal reactivity in premenopausal women with posttraumatic stress disorder. 2001 , 50, 965-77	159
1178	Prevalence and pattern of cognitive impairment in systemic lupus erythematosus patients with and without overt neuropsychiatric manifestations. 2001 , 184, 33-9	116
1177	Sexual dysfunction in multiple sclerosis: a 2-year follow-up study. 2001 , 187, 1-5	92
1176	Mood Changes in Epilepsy Patients Treated with Vagus Nerve Stimulation. 2001 , 2, S17-S20	7
1175	Adjunctive behavioural treatment in adolescents and young adults with juvenile myoclonic epilepsy. 2001 , 10, 42-7	28
1174	Panic disorder in a Spanish sample of 89 patients with pure alcohol dependence. 2001 , 63, 117-21	11
1173	Evaluation of combining kava extract with hormone replacement therapy in the treatment of postmenopausal anxiety. 2001 , 39, 185-8	22
1172	An open study of paroxetine in hypochondriasis. 2001 , 25, 1023-33	33
1171	Personality dimensions in pathological gambling disorder and obsessive-compulsive disorder. 2001 , 104, 205-12	98
1170	A psychometric evaluation of the BDI-II in treatment-seeking substance abusers. 2001 , 20, 197-204	111
1169	The impact of impulsivity on cocaine use and retention in treatment. 2001 , 21, 193-8	328
1168	Vestibular rehabilitation for patients with agoraphobia and vestibular dysfunction: a pilot study. 2001 , 15, 131-46	54
1167	White matter abnormalities in HIV-1 infection: a diffusion tensor imaging study. 2001, 106, 15-24	157
1166	Cognitive-behavior therapy vs exposure therapy in the treatment of PTSD in refugees. 2001 , 39, 1183-97	251
1165	The nonpharmacologic treatment of generalized anxiety disorder. 2001 , 24, 99-117, vii	7
1164	Estrogen Replacement Therapy and Antidepressant Response to Sertraline in Older Depressed Women. 2001 , 9, 393-399	84
1163	Generalized anxiety disorder in children and adolescents. 2001 , 24, 139-53	18
1162	[Efficiency of multidisciplinary treatment of chronic pain with locomotor disability]. 2001 , 117, 401-5	12

1161	Anxiety and Alzheimer's disease. 2001 , 14, 52-8	131
1160	Case study: caudate glutamatergic changes with paroxetine persist after medication discontinuation in pediatric OCD. 2001 , 40, 903-6	57
1159	The self-assessment of resilience and anxiety: psychometric properties. 2001 , 6, 854-7	4
1158	Mirtazapine versus fluoxetine in the treatment of panic disorder. 2001 , 34, 1303-7	59
1157	Comparative analysis of the performance of the Postpartum Depression Screening Scale with two other depression instruments. 2001 , 50, 242-50	162
1156	Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. 2001 , 21, 335-9	63
1155	Olanzapine treatment for post-traumatic stress disorder: an open-label study. 2001 , 16, 331-7	76
1154	The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period. 2001 , 16, 363-8	20
1153	An open naltrexone treatment study in pathological gambling disorder. 2001 , 16, 285-9	95
1152	Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study. 2001 , 16, 317-24	41
1151	Comparative study of tropisetron with the addition of dexamethasone or alprazolam in breast cancer patients receiving adjuvant chemotherapy with CEF (cyclophosphamide, epirubicin and 5-fluorouracil). 2001 , 13, 641-7	4
1150	Isokinetic muscle performance in major depressive disorder: alterations by antidepressant therapy. 2001 , 109, 149-64	2
1149	A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. 2001 , 13, 233-40	108
1148	Comparisons of Different Measures for Cognitions in Agoraphobic Patients. 2001 , 30, 188-201	1
1147	Therapists, therapist variables, and cognitive-behavioral therapy outcome in a multicenter trial for panic disorder 2001 , 69, 747-755	164
1146	A randomized trial of the effectiveness of cognitive-behavioral therapy and supportive counseling for anxiety symptoms in older adults 2001 , 69, 756-762	100
1145	Adverse-effect profile of kava. 2001 , 6, 848, 850-3	28
1144	Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. 2001 , 179, 15-22	147

(2001-2001)

1143	external v. interoceptive self-exposure. 2001 , 178, 331-6	46
1142	Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. 2001 , 4, 119-25	79
1141	Further investigation of citalopram on alcohol consumption in heavy drinkers: responsiveness possibly linked to the DRD2 A2/A2 genotype. 2001 , 24, 15-23	11
1140	A double blind parallel group placebo controlled comparison of sedative and mnesic effects of etifoxine and lorazepam in healthy subjects [corrected]. 2001 , 15, 209-16	42
1139	Nefazodone for chronic daily headache prophylaxis: an open-label study. 2001, 41, 465-74	37
1138	Correlates of functional disability in essential tremor. 2001 , 16, 914-20	164
1137	The prediction of nonresponse to pharmacotherapy in panic disorder: a review. 2001 , 14, 112-22	68
1136	Psychometric evaluation of the Beck Depression Inventory in adults with social anxiety disorder. 2001 , 14, 145-8	50
1135	Plasma serotonin response to carbohydrate-rich food in chronic schizophrenic patients: clozapine versus classic antipsychotic agents. 2001 , 16, 403-407	2
1134	Differential subtyping of depression. 2001 , 13, 11-7	31
1133	Psychosocial adjustment in gynecologic cancer survivors: a longitudinal study on risk factors for maladjustment. 2001 , 80, 387-94	42
1132	Assessment of state and trait anxiety in subjects with anxiety and depressive disorders. 2001 , 72, 263-76	116
1131	Defense styles and Personality dimensions of research subjects with anxiety and depressive disorders. 2001 , 72, 251-62	42
1130	The ability of the Symptom Checklist SCL-90 to differentiate various anxiety and depressive disorders. 2001 , 72, 277-88	33
1129	Open trial of nefazodone for combat veterans with posttraumatic stress disorder. 2001 , 14, 453-60	11
1128	Development of a depersonalization severity scale. 2001 , 14, 341-9	21
1127	The Psychosocial Functioning of HIV+ and HIV[African American Recent Mothers. 2001 , 5, 219-231	14
1126	Social Problem Solving, Mood, and Suicidality Among Inpatient Adolescents. 2001 , 25, 743-756	43

1125	Correlation between cortisol level and serotonin uptake in patients with chronic stress and depression. 2001 , 1, 388-93	56
1124	The effect of tobacco smoking on subjective symptoms of inadequacy ("not holding") of methadone dose among opiate addicts in methadone maintenance treatment. 2001 , 6, 137-145	22
1123	Health Problems in Adolescents With Alcohol Use Disorders: Self-Report, Liver Injury, and Physical Examination Findings and Correlates. 2001 , 25, 1350-1359	74
1122	Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. 2001 , 64, 43-51	551
1121	Does pretreatment anxiety predict response to either bupropion SR or sertraline?. 2001, 64, 81-7	25
1120	Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder. 2001 , 32, 371-390	414
1119	An interpersonal problem approach to the division of social phobia subtypes. 2001 , 32, 479-501	106
1118	Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. 2001 , 25, 131-8	33
1117	Cognitive therapy for panic disorder: The impact of medication discontinuation on symptoms. 2001 , 8, 240-245	O
1116	Blood, solidarity, status, and honor. 2001 , 22, 295-328	78
1116	Blood, solidarity, status, and honor. 2001, 22, 295-328 A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment. 2001, 15, 161-5	78
	A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment	
1115	A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment. 2001 , 15, 161-5 Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled	11
1115	A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment. 2001 , 15, 161-5 Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study. 2001 , 36, 329-34 Cerebral blood flow and glucose metabolism in hypothyroidism: a positron emission tomography	11 59
1115 1114 1113	A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment. 2001 , 15, 161-5 Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study. 2001 , 36, 329-34 Cerebral blood flow and glucose metabolism in hypothyroidism: a positron emission tomography study. 2001 , 86, 3864-70 A multidimensional meta-analysis of treatments for depression, panic, and generalized anxiety	11 59 117
1115 1114 1113 1112	A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment. 2001, 15, 161-5 Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study. 2001, 36, 329-34 Cerebral blood flow and glucose metabolism in hypothyroidism: a positron emission tomography study. 2001, 86, 3864-70 A multidimensional meta-analysis of treatments for depression, panic, and generalized anxiety disorder: An empirical examination of the status of empirically supported therapies 2001, 69, 875-899	11 59 117 493
1115 1114 1113 1112 1111	A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment. 2001, 15, 161-5 Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study. 2001, 36, 329-34 Cerebral blood flow and glucose metabolism in hypothyroidism: a positron emission tomography study. 2001, 86, 3864-70 A multidimensional meta-analysis of treatments for depression, panic, and generalized anxiety disorder: An empirical examination of the status of empirically supported therapies 2001, 69, 875-899 Prevalence and correlates of parkinsonism in patients with primary depression. 2001, 57, 553-5	11 59 117 493

1107	Effect of kava extract on vagal cardiac control in generalized anxiety disorder: preliminary findings. 2001 , 15, 283-6	20
1106	A component analysis of cognitive-behavioral therapy for generalized anxiety disorder and the role of interpersonal problems 2002 , 70, 288-298	401
1105	Specific Interrelationship of Combined Psychopharmacotherapy and Psychotherapy in the Treatment of Mentally Ill Patients. 2002 , 31, 98-106	1
1104	Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder. 2002 , 181, 315-20	98
1103	Outcome related electrophysiological subtypes of cocaine dependence. 2002 , 33, 8-20	31
1102	Case-control study of neurocognitive function in euthymic patients with bipolar disorder: an association with mania. 2002 , 180, 320-6	196
1101	Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. 2002 , 17, 239-47	271
1100	A placebo-controlled study of Kava kava in generalized anxiety disorder. 2002 , 17, 185-8	35
1099	Interactive model of therapeutic response in panic disorder: moclobemide, a case in point. 2002 , 22, 275-84	15
1098	Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. 2002 , 22, 257-62	63
1097	Methylphenidate in treatment of adults with Attention-Deficit/Hyperactivity Disorder. 2002 , 6 Suppl 1, S101-7	30
1096	Oxcarbazepine treatment of posttraumatic stress disorder. 2002 , 47, 973-4	17
1095	Heart rate variability as predictor of nonresponse to mirtazapine in panic disorder: a preliminary study. 2002 , 17, 69-74	14
1094	Specific side effects of long-term imipramine management of panic disorder. 2002 , 22, 155-61	15
1093	INTERDEPENDENCE OF STRESS PROCESSES AMONG AFRICAN AMERICAN FAMILY MEMBERS: INFLUENCE OF HIV SEROSTATUS AND A NEW INFANT. 2002 , 17, 339-363	22
1092	Release from proactive inhibition in schizophrenia and its potential as a genotypic marker. 2002 , 24, 67-81	5
1091	Recognizing and treating dual diagnosis in general health care settings: core competencies and how to achieve them. 2002 , 23, 143-54	2
1090	Anxiety, depression and anger suppression in infertile couples: a controlled study. 2002 , 17, 2986-94	118

1089	Acute and Chronic Effects of Citalopram on Cerebral Glucose Metabolism in Geriatric Depression. 2002 , 10, 715-723	2
1088	Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. 2002 , 51, 753-61	45
1087	Proton magnetic resonance spectroscopic imaging in pediatric major depression. 2002 , 52, 86-92	95
1086	rCBF differences between panic disorder patients and control subjects during anticipatory anxiety and rest. 2002 , 52, 126-35	150
1085	Context in the clinic: how well do cognitive-behavioral therapies and medications work in combination?. 2002 , 52, 987-97	154
1084	Alcohol dependence and gender-role orientation. 2002 , 17, 1-8	23
1083	Residual symptoms and comorbidity in panic disorder. 2002 , 17, 399-406	11
1082	ECNP Consensus Meeting March 2000. Guidelines for investigating efficacy in GAD. 2002 , 12, 81-7	7
1081	The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties. 2002, 41, 1061-9	379
1080	Does concurrent psychopathology at presentation influence response to treatment for bulimia nervosa?. 2002 , 7, 168-81	17
1079	[Validation of the Spanish versions of the Montgomery-Asberg depression and Hamilton anxiety rating scales]. 2002 , 118, 493-9	157
1078	Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. 2002 , 41, 1205-15	431
1077	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. 2002 , 3, 171-99	133
1076	The Bech-Rafaelsen Mania Scale in clinical trials of therapies for bipolar disorder: a 20-year review of its use as an outcome measure. 2002 , 16, 47-63	69
1075	Nefazodone in the treatment of elderly patients with depressive disorders: a prospective, observational study. 2002 , 16, 635-43	3
1074	Cognitive behavior therapy in treatment-naive children and adolescents with obsessive-compulsive disorder: an open trial. 2002 , 40, 529-39	72
1073	An open-label clinical trial of nefazodone in hypochondriasis. 2002 , 43, 290-4	20
1072	Screening for anxiety in an epidemiological sample: predictive accuracy of questionnaires. 2002 , 16, 113-34	40

1071	Nightmare frequency in sexual assault survivors with PTSD. 2002, 16, 175-90	110
1070	Comparison of clinical characteristics in good and poor insight obsessive-compulsive disorder. 2002 , 16, 413-23	59
1069	Panic disorder and immunity: few effects on circulating lymphocytes, mitogen response, and NK cell activity. 2002 , 16, 698-705	24
1068	A novel cognitive-behavioral approach for treatment-resistant drug dependence. 2002 , 23, 335-42	43
1067	Post-traumatic stress disorder in burned patients. 2002 , 28, 647-50	42
1066	Depression and anxiety symptoms in relation to anthropometry and metabolism in men. 2002 , 112, 101-10	78
1065	Is long-term heavy alcohol consumption toxic for brain serotonergic neurons? Relationship between years of excessive alcohol consumption and serotonergic neurotransmission. 2002 , 65, 159-65	22
1064	Auditory event-related potentials in panic and generalised anxiety disorders. 2002 , 26, 123-6	19
1063	Treatment of social anxiety disorder with citalopram. 2002 , 26, 205-8	9
1062	Clinical outcome and tolerability of sertraline in major depression: a study with plasma levels. 2002 , 26, 597-601	28
1061	Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors. 2002 , 26, 1129-34	27
1060	Ten-year review of rating scales. II: Scales for internalizing disorders. 2002 , 41, 634-59	282
1059	Citalopram for social anxiety disorder: an open-label pilot study in refractory and nonrefractory patients. 2002 , 7, 655-7	10
1058	References. 2002 , 179-224	
1057	What happens to anxiety disorders in later life?. 2002 , 24, 74-80	11
1056	Cognitive-behavioral group therapy in obsessive-compulsive disorder: a clinical trial. 2002 , 24, 113-120	22
1055	Assessment of Anxiety Disorders in Older Adults: Current Concerns, Future Prospects. 2002 , 43-48	
1054	Prevalence of post-traumatic stress disorder in fibromyalgia patients: overlapping syndromes or post-traumatic fibromyalgia syndrome?. 2002 , 32, 38-50	138

1053	Long-term effects of child punishment on Mexican women: a structural model. 2002, 26, 371-86	36
1052	Prevalence and prognostic significance of psychiatric disorders in patients evaluated for recurrent unexplained syncope. 2002 , 89, 530-5	58
1051	Case review vs. usual care in primary care patients with depression: a pilot study. 2002 , 24, 71-80	14
1050	Allergy in panic disorder patients: a preliminary report(1). 2002 , 24, 265-8	14
1049	Treatment of generalised anxiety disorder with a short course of psychological therapy, combined with buspirone or placebo. 2002 , 72, 267-71	17
1048	Panic disorder patients have reduced cyclic AMP in platelets. 2002 , 36, 105-10	9
1047	Global benefit-risk assessment of antidepressants: venlafaxine XR and fluoxetine. 2002, 36, 111-8	20
1046	Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. 2002 , 36, 209-17	51
1045	Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder. 2002 , 36, 229-36	25
1044	Depression and anxiety in hyperthyroidism. 2002 , 33, 552-6	63
1043	Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease. 2002 , 41, 382-6	57
1042	The European Study of the Epidemiology of Mental Disorders (ESEMeD/MHEDEA 2000) project: rationale and methods. 2002 , 11, 55-67	72
1041	Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study. 2002 , 17, 181-5	28
1040	Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. 2002 , 17, 401-5	12
1039	Affect expression in prenatally psychotropic exposed and nonexposed motherInfant dyads. 2002 , 23, 403-416	24
1038	A controlled comparison of eye movement desensitization and reprocessing versus exposure plus cognitive restructuring versus waiting list in the treatment of post-traumatic stress disorder. 2002 , 9, 299-318	120
1037	Citalopram treatment of paroxetine-intolerant depressed patients. 2002, 16, 128-33	10
1036	Psychoeducation in panic disorder patients: effect of a self-information booklet in a randomized, masked-rater study. 2002 , 16, 71-6	22

1035 Fluvoxamine treatment in veterans	with combat-related post-traumatic stress disorder. 2002 , 15, 29-33	36
Effect of a very low calorie diet on t disorder. 2002 , 31, 49-56	the diagnostic category of individuals with binge eating	34
Treatment of PTSD: stress inoculati 58, 1071-89	on training with prolonged exposure compared to EMDR. 2002,	163
1032 Medicamenteuze behandeling van a	angststoornissen bij kinderen en adolescenten. 2002 , 23, 179-189	3
1031 Pharmacotherapy of childhood anxi	ety disorders. 2002 , 4, 264-9	3
1030 Olanzapine in diverse syndromal an	d subsyndromal exacerbations of bipolar disorders. 2002 , 4, 328-34	10
Knowledge model reuse: therapy do 23, 113-135	ecision through specialisation of a generic decision model. 2002,	4
Influence du pronostic de la patholo parentfale Edomicile. 2002 , 16, 26-30	ogie initiale sur le vāu maternel d'enfants en nutrition 0	2
Relationship of criminality to endog 56, 153-9	geneity and anxiety in patients with unipolar depression. 2002,	6
1026 Depressive symptoms and MRI char	nges in multiple sclerosis. 2002 , 9, 491-6	63
	nges in multiple sclerosis. 2002 , 9, 491-6 uodenojejunal motility in humans. 2002 , 14, 279-85	63 4
1025 The effect of cholecystectomy on d	uodenojejunal motility in humans. 2002 , 14, 279-85 ract) in generalized anxiety disorder: a randomized	
The effect of cholecystectomy on d Effect of valepotriates (valerian ext placebo-controlled pilot study. 200) Identifying mothers at risk for posti	uodenojejunal motility in humans. 2002 , 14, 279-85 ract) in generalized anxiety disorder: a randomized	4
The effect of cholecystectomy on d Effect of valepotriates (valerian ext placebo-controlled pilot study. 2003) Identifying mothers at risk for postiperinatal posttraumatic stress disorday. Does mechanical massage of the above	uodenojejunal motility in humans. 2002 , 14, 279-85 ract) in generalized anxiety disorder: a randomized 2 , 16, 650-4 natal emotional distress: further evidence for the validity of the	101
The effect of cholecystectomy on d 1024 Effect of valepotriates (valerian ext placebo-controlled pilot study. 200) 1023 Identifying mothers at risk for post perinatal posttraumatic stress disorder post post post post post post post post	uodenojejunal motility in humans. 2002, 14, 279-85 ract) in generalized anxiety disorder: a randomized 2, 16, 650-4 natal emotional distress: further evidence for the validity of the rder questionnaire. 2002, 22, 448-54 dominal wall after colectomy reduce postoperative pain and	4 101 43
The effect of cholecystectomy on d Effect of valepotriates (valerian ext placebo-controlled pilot study. 2002) Identifying mothers at risk for posts perinatal posttraumatic stress disorder perinatal posttraumatic stress disorder the duration of ileus? Resultable Clinical characteristics and treatment Changes in Mood and Depressive Systems.	uodenojejunal motility in humans. 2002, 14, 279-85 ract) in generalized anxiety disorder: a randomized 2, 16, 650-4 natal emotional distress: further evidence for the validity of the der questionnaire. 2002, 22, 448-54 dominal wall after colectomy reduce postoperative pain and ts of a randomized study. 2002, 6, 43-9	4 101 43 45
The effect of cholecystectomy on d Effect of valepotriates (valerian ext placebo-controlled pilot study. 2002 Identifying mothers at risk for posts perinatal posttraumatic stress disor Does mechanical massage of the ab shorten the duration of ileus? Resul Clinical characteristics and treatment Changes in Mood and Depressive Sy CognitiveBehavioral Stress Manage	uodenojejunal motility in humans. 2002, 14, 279-85 ract) in generalized anxiety disorder: a randomized 2, 16, 650-4 natal emotional distress: further evidence for the validity of the rder questionnaire. 2002, 22, 448-54 dominal wall after colectomy reduce postoperative pain and its of a randomized study. 2002, 6, 43-9 nt response to SSRI in a female pedophile. 2002, 31, 211-5 mptoms and Related Change Processes During	4 101 43 45 28

1017	Evaluation of regional cerebral blood flow changes in panic disorder with Tc99m-HMPAO SPECT. 2003 , 123, 135-43	45
1016	Glasgow Anxiety Scale for people with an Intellectual Disability (GAS-ID): development and psychometric properties of a new measure for use with people with mild intellectual disability. 2003 , 47, 22-30	169
1015	Predictors of somatic symptoms in depressive disorder. 2003 , 25, 108-14	90
1014	Alcoholism in 274 patients with panic disorder in Spain, one of the main producers of wine worldwide. 2003 , 75, 237-45	8
1013	Anxiety and impulsivity levels identify relevant subtypes in adolescents with at-risk behavior. 2003 , 74, 219-27	50
1012	Panic disorder phenomenology in urban self-identified Caucasian-Non-Hispanics and Caucasian-Hispanics. 2003 , 18, 7-17	13
1011	Duloxetine in treatment of anxiety symptoms associated with depression. 2003 , 18, 53-61	74
1010	Association of a MAOA gene variant with generalized anxiety disorder, but not with panic disorder or major depression. 2003 , 117B, 1-6	82
1009	Severe depression determines quality of life in urinary incontinent women. 2003 , 22, 563-8	58
1008	Anterior cingulotomy for refractory obsessive-compulsive disorder. 2003 , 107, 283-90	71
1007	Effective open-label treatment of premenstrual dysphoric disorder with venlafaxine. 2003, 57, 317-21	10
1006	Tobacco use is associated with reduced central serotonergic neurotransmission in type 1 alcohol-dependent individuals. 2003 , 27, 1257-61	4
1005	Anxiety disorders in older adults. 2003 , 19, 721-41	32
1004	Juego patolgico: un trastorno emergente. 2003 , 5, 75-87	1
1003	Anxiety disorders in the child and teen. 2003 , 50, 1107-38	18
1002	Neurochemical analyses in pediatric obsessive-compulsive disorder in patients treated with cognitive-behavioral therapy. 2003 , 42, 1279-85	54
1001	[A validation study of the Spanish versions of the Clinical Anxiety Scale and the Physician Questionnaire for the assessment of anxiety disorders]. 2003 , 121, 367-74	9
1000	Single photon emission computed tomography imaging in obsessive-compulsive disorder and for stereotactic bilateral anterior cingulotomy. 2003 , 14, 237-50	4

(2003-2003)

999	Treatment of Poststroke Generalized Anxiety Disorder Comorbid With Poststroke Depression: Merged Analysis of Nortriptyline Trials. 2003 , 11, 320-327	16
998	Evidence for disturbed cortical signal processing and altered serotonergic neurotransmission in generalized anxiety disorder. 2003 , 53, 304-14	65
997	An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder. 2003 , 54, 9-16	62
996	A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. 2003 , 216, 113-8	65
995	Psychomotor and anxiolytic effects of mexazolam in patients with generalised anxiety disorder. 2003 , 23, 235-43	5
994	Venlafaxine treatment of fibromyalgia. 2003 , 37, 1561-5	135
993	The relation of psychogenic excoriation with psychiatric disorders: a comparative study. 2003, 44, 256-61	39
992	Clinical characteristics in obsessive-compulsive disorder with schizophrenia. 2003, 44, 311-6	19
991	Characteristics of inmates receiving prescribed benzodiazepines in a high-security Greek prison. 2003 , 44, 409-14	6
990	An open-label pilot study of divalproex sodium for posttraumatic stress disorder related to childhood abuse. 2003 , 64, 45-54	8
989	Increased medial thalamic choline found in pediatric patients with obsessive-compulsive disorder versus major depression or healthy control subjects: a magnetic resonance spectroscopy study. 2003 , 54, 1399-405	77
988	Alzheimer's disease disrupts arithmetic fact retrieval processes but not arithmetic strategy selection. 2003 , 52, 302-18	25
987	Audioverbal cognitive dysfunction in depression. Factors involved. 2003, 27, 37-42	9
986	Event-related potentials and neuropsychological tests in obsessive-compulsive disorder. 2003, 27, 601-6	24
985	Open-label nefazodone in patients with a major depressive episode and alcohol dependence. 2003 , 27, 681-5	8
984	The N200 abnormalities of auditory event-related potentials in patients with panic disorder. 2003 , 27, 1013-21	16
983	A pilot trial of olanzapine for the treatment of cocaine dependence. 2003 , 70, 265-73	68
982	Pattern-reversed visual evoked potentials in subtypes of major depression. 2003 , 118, 259-71	34

981	Respiratory panic disorder subtype: acute and long-term response to nortriptyline, a noradrenergic tricyclic antidepressant. 2003 , 120, 283-93	32
980	Basal norepinephrine in depersonalization disorder. 2003 , 121, 93-7	52
979	Long-term immune-endocrine effects of bereavement: relationships with anxiety levels and mood. 2003 , 121, 145-58	89
978	Psychiatric symptoms after hepatic resection. 2003 , 44, 86-7	2
977	An open trial of fluvoxamine for hypochondriasis. 2003 , 44, 298-303	37
976	Failure to find DUP25 in patients with anxiety disorders, in control individuals, or in previously reported positive control cell lines. 2003 , 72, 535-8	43
975	Exploring the psychometric properties and construct validity of the MCMI-III anxiety and avoidant personality scales. 2003 , 81, 237-41	13
974	Correlation of sexual dysfunction and brain magnetic resonance imaging in multiple sclerosis. 2003 , 9, 108-10	30
973	The use of antidepressants to treat attention deficit hyperactivity disorder in adults. 2003, 17, 332-6	27
972	Efficacy of stimulants in adult ADHD. 2003 , 37, 1884-90	9
972 971	Efficacy of stimulants in adult ADHD. 2003 , 37, 1884-90 Auditory P300 event related potentials and serotonin reuptake inhibitor treatment in patients with fibromyalgia. 2003 , 62, 551-5	9
	Auditory P300 event related potentials and serotonin reuptake inhibitor treatment in patients with	
971	Auditory P300 event related potentials and serotonin reuptake inhibitor treatment in patients with fibromyalgia. 2003 , 62, 551-5 Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy	34
971	Auditory P300 event related potentials and serotonin reuptake inhibitor treatment in patients with fibromyalgia. 2003, 62, 551-5 Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. 2003, 17, 276-82 Do comorbid anxiety disorders in alcohol-dependent patients need specific treatment to prevent	34 90
971 970 969	Auditory P300 event related potentials and serotonin reuptake inhibitor treatment in patients with fibromyalgia. 2003, 62, 551-5 Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. 2003, 17, 276-82 Do comorbid anxiety disorders in alcohol-dependent patients need specific treatment to prevent relapse?. 2003, 38, 255-62	34 90 25
971 970 969 968	Auditory P300 event related potentials and serotonin reuptake inhibitor treatment in patients with fibromyalgia. 2003, 62, 551-5 Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. 2003, 17, 276-82 Do comorbid anxiety disorders in alcohol-dependent patients need specific treatment to prevent relapse?. 2003, 38, 255-62 Mood States. 2003, 53-88	34 90 25 4
971 970 969 968 967	Auditory P300 event related potentials and serotonin reuptake inhibitor treatment in patients with fibromyalgia. 2003, 62, 551-5 Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. 2003, 17, 276-82 Do comorbid anxiety disorders in alcohol-dependent patients need specific treatment to prevent relapse?. 2003, 38, 255-62 Mood States. 2003, 53-88 Psychological treatment of late-life anxiety: an empirical review. 2003, 71, 643-51	34 90 25 4 54

(2003-2003)

963	Does cognitive-behavioural therapy influence the long-term outcome of generalized anxiety disorder? An 8-14 year follow-up of two clinical trials. 2003 , 33, 499-509	65
962	Amantadine as augmentation therapy in the management of treatment-resistant depression. 2003 , 18, 93-6	79
961	A score for predicting response to pharmacotherapy in obsessive-compulsive disorder. 2003 , 18, 315-22	40
960	Treatment of depression with comorbid anxiety disorders: differential efficacy of paroxetine versus moclobemide. 2003 , 18, 15-21	11
959	Valproic acid for the treatment of social anxiety disorder. 2003 , 18, 169-172	7
958	Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies. 2003 , 23, 250-9	26
957	Butting a Facelon HIV Infection/AIDS in Older Adults. 2003, 33, S171-S184	14
956	Imipramine and buspirone in patients with panic disorder who are discontinuing long-term benzodiazepine therapy. 2003 , 23, 505-8	14
955	St. John's wort in generalized anxiety disorder: three more case reports. 2003 , 23, 531-2	9
954	An open clinical trial of reboxetine in the treatment of social phobia. 2003 , 23, 417-9	6
953	Valproic acid for the treatment of social anxiety disorder. 2003 , 18, 169-72	37
952	Cognitive-behavioral therapy for generalized anxiety disorder with integrations from interpersonal and experiential therapies. 2003 , 8, 382-9	37
951	Quality of life in geriatric patients with mood and anxiety disorders. 2003 , 8, 35-47	12
950	WCA recommendations for the long-term treatment of generalized anxiety disorder. 2003, 8, 53-61	78
949	Group comparisons of DSM-IV subtypes of chronic depression: validity of the distinctions, part 2. 2003 , 112, 614-22	79
948	Psychometric properties of the Spanish Beck Depression Inventory-II in a medical sample. 2003 , 15, 569-77	68
947	Assessing worry in older adults: confirmatory factor analysis of the Penn State Worry Questionnaire and psychometric properties of an abbreviated model. 2003 , 15, 173-83	179
946	Treatment of generalized anxiety disorder in older adults 2003 , 71, 31-40	179

945	The time course and significance of cannabis withdrawal. 2003, 112, 393-402	316
944	Cognitive-behavioral treatment of late-life generalized anxiety disorder. 2003 , 71, 309-19	190
943	Treatment-resistant bipolar disorder: a comparison of rapid cyclers and nonrapid cyclers. 2003, 8, 948-52	4
942	The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. 2003 , 48, 546-54	60
941	Standardisierte psychiatrische Befunddiagnostik. 2003 , 400-423	
940	The early impact of therapeutic alliance in brief psychodynamic psychotherapy. 2003 , 25, 78-86	5
939	Correlates of therapeutic response in panic disorder presenting with palpitations: heart rate variability, sleep, and placebo effect. 2003 , 48, 381-7	11
938	Bethanecol chloride for treatment of clomipramine-induced orgasmic dysfunction in males. 2004 , 59, 357-60	9
937	[Psychodynamic group treatment for generalized social phobia]. 2004, 26, 77-81	45
936	Amygdala volume reductions in pediatric patients with obsessive-compulsive disorder treated with paroxetine: preliminary findings. 2004 , 29, 826-32	109
935	Mirtazapine in the treatment of adolescents with major depression: an open-label, multicenter pilot study. 2004 , 14, 175-84	25
934	Reducing anxiety in Alzheimer's disease family caregivers: the effectiveness of a nine-week cognitive-behavioral intervention. 2004 , 19, 117-23	71
933	Pulmonary muscle strength, pulmonary function tests, and dyspnea in women with major depression. 2004 , 13, 93-8	3
932	Deep brain stimulation of the ventral caudate nucleus in the treatment of obsessive-compulsive disorder and major depression. Case report. 2004 , 101, 682-6	228
931	Plasma antioxidant status, immunoglobulin g oxidation and lipid peroxidation in demented patients: relevance to Alzheimer disease and vascular dementia. 2004 , 18, 265-70	88
930	Orbitofrontal cortical dysfunction in akinetic catatonia: a functional magnetic resonance imaging study during negative emotional stimulation. 2004 , 30, 405-27	97
929	Differences in brain function between relapsing and abstaining alcohol-dependent patients, evaluated by EEG mapping. 2004 , 39, 233-40	71
928	Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. 2004 , 101, 4531-6	390

(2004-2004)

927	A pilot study of subjective daytime alertness and mood in primary insomnia participants using ecological momentary assessment. 2004 , 2, 113-31	19
926	Use of reboxetine in bulimia nervosa: a pilot study. 2004 , 18, 423-8	29
925	Childhood trauma in alcoholics. 2004 , 39, 126-9	16
924	Women's sexual dysfunction: a pathophysiological review. 2004 , 93, 1156-64	85
923	No correlation of depression and anxiety to plasma estrogen and progesterone levels in patients with premenstrual dysphoric disorder. 2004 , 58, 593-9	36
922	An audit of clinical outcomes and client and referrer satisfaction with a Mood and Anxiety Disorders Unit. 2004 , 10, 549-52	6
921	Psychiatric comorbidity in a population of Parkinson's disease patients. 2004 , 11, 315-20	155
920	Testing the efficacy of a creative-arts intervention with family caregivers of patients with cancer. 2004 , 36, 214-9	51
919	Cognitive and affective status in mild hypothyroidism and interactions with L-thyroxine treatment. 2004 , 110, 59-66	78
918	Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. 2004 , 9, 1075-82	144
917	Mood improvement after surgery for obstructive sleep apnea. 2004 , 114, 1098-102	22
916	A prospective trial of sertraline for chronic subjective dizziness. 2004 , 114, 1637-41	73
915	Nefazodone treatment of comorbid alcohol dependence and major depression. 2004, 28, 433-40	29
914	Assessing subjective and psychomotor effects of the herbal medication valerian in healthy volunteers. 2004 , 78, 57-64	30
913	Reduced brain serotonin transporter binding in patients with panic disorder. 2004, 132, 173-81	54
912	Effects of citalopram on worry and brain activation in patients with generalized anxiety disorder. 2004 , 131, 11-21	114
911	Hormonal changes when falling in love. 2004 , 29, 931-6	121
910	Decreased TNF-alpha and NK activity in obsessive-compulsive disorder. 2004 , 29, 945-52	74

909	Developmentally sensitive assessment of social anxiety. 2004 , 11, 13-28	23
908	Assessing the effects of bupropion SR on mood dimensions of depression. 2004 , 78, 235-41	94
907	Axis I and II comorbidity in a large sample of patients with obsessive-compulsive disorder. 2004 , 80, 155-62	92
906	The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials. 2004 , 4, 26	40
905	Thyroid function in clinical subtypes of major depression: an exploratory study. 2004 , 4, 6	52
904	A randomized, placebo-controlled trial of buspirone for the treatment of anxiety in opioid-dependent individuals. 2004 , 13, 53-63	23
903	Physiological responsiveness of motor vehicle accident survivors with chronic posttraumatic stress disorder. 2004 , 29, 51-62	26
902	Depression and its 6-month course in untreated hemodialysis patients: a preliminary prospective follow-up study in Turkey. 2004 , 11, 243-6	11
901	Clinical Validation of the Swedish Version of the Quality of Life Inventory in Crime Victims with Posttraumatic Stress Disorder and a Nonclinical Sample. 2004 , 26, 15-21	19
900	Is female predominance in irritable bowel syndrome related to fibromyalgia?. 2004 , 24, 106-9	18
899	A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder. 2004 , 171, 390-7	57
898	A practical guide to using ratings of depression and anxiety in child psychiatric practice. 2004 , 6, 108-16	11
897	A comparison of the efficacy and acceptability of group versus individual cognitive behaviour therapy in the treatment of panic disorder and agoraphobia in primary care. 2004 , 11, 73-82	65
896	Cognitive behaviour therapy for good and poor prognosis generalized anxiety disorder: a clinical effectiveness study. 2004 , 11, 145-157	26
895	Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorder. 2004 , 19, 127-32	31
894	Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. 2004 , 19, 234-40	133
893	Comparison of nefazodone and sertraline for the treatment of posttraumatic stress disorder. 2004 , 19, 190-6	47
892	Sleep variables in anorexia nervosa: evolution with weight restoration. 2004 , 35, 342-7	22

(2004-2004)

891	The Diagnostic Inventory for Depression: a self-report scale to diagnose DSM-IV major depressive disorder. 2004 , 60, 87-110	87
890	Serum cytokine concentrations in alcohol-dependent individuals without liver disease. 2004 , 32, 243-7	20
889	Explanatory attributions of anxiety and recovery in a study of kava. 2004 , 10, 556-9	4
888	Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. 2004 , 43, 1146-53	207
887	Reduced anterior cingulate cortex glutamatergic concentrations in childhood major depression. 2004 , 43, 341-8	105
886	Pharmacotherapy for social phobia. 2004 , CD001206	45
885	Double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of a fixed combination containing two plant extracts (Crataegus oxyacantha and Eschscholtzia californica) and magnesium in mild-to-moderate anxiety disorders. 2004 , 20, 63-71	61
884	The role of captodiamine in the withdrawal from long-term benzodiazepine treatment. 2004 , 20, 1347-55	17
883	Gender, AIDS, and bereavement: a comparison of women and men living with HIV. 2004, 28, 225-41	20
882	Addictive disorders. 2004 , 27, xi-xviii	2
881	Stimulant treatment of adult attention-deficit/hyperactivity disorder. 2004, 27, 361-72	39
880	Dimensions of Sexual Dysfunction in Parkinson Disease. 2004 , 12, 221-226	27
879	Effects of glucocorticoids on declarative memory function in major depression. 2004 , 55, 811-5	62
878	Central type benzodiazepine receptors in Gulf War veterans with posttraumatic stress disorder. 2004 , 56, 95-100	51
877	Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. 2004 , 56, 101-12	411
876	Increased circulatory dehydroepiandrosterone and dehydroepiandrosterone-sulphate in first-episode schizophrenia: relationship to gender, aggression and symptomatology. 2004 , 71, 427-34	76
875	Cognitive impairment in Behët's disease patients without overt neurological involvement. 2004 , 220, 99-104	53
874	Tandospirone in the treatment of generalised anxiety disorder and mixed anxiety-depression: results of a comparatively high dosage trial. 2004 , 24, 121-6	29

873	The Millon Adolescent Clinical Inventory: is it valid and reliable for Mexican American youth?. 2004 , 83, 64-74	9
872	Psychosocial treatments for adults with attention-deficit/hyperactivity disorder. 2004 , 27, 349-60	62
871	Gender-related differences among Turkish patients with obsessive-compulsive disorder. 2004 , 45, 362-6	42
870	A critical review of the empirical literature on coping and panic disorder. 2004 , 24, 123-48	50
869	Cognitive behavior therapy vs exposure in vivo in the treatment of panic disorder with agoraphobia (corrected from agrophobia). 2004 , 42, 1105-27	82
868	The relationship of regional cerebral blood flow with subtypes of major depression. 2004 , 28, 537-46	53
867	Clinical response to antidepressant treatment and 3-methoxy-4-hydroxyphenylglycol levels: mini review. 2004 , 28, 611-6	29
866	Use of factor analysis to detect potential phenotypes in obsessive-compulsive disorder. 2004 , 128, 273-80	77
865	Effects of depressive symptoms and anxiety on hemostatic responses to acute mental stress and recovery in the elderly. 2004 , 126, 253-64	47
864	Predictors of improved mood over time in clinical trials for major depression. 2004 , 127, 73-84	9
863	Preliminary validity and reliability testing of a structured clinical interview for pathological gambling. 2004 , 128, 79-88	205
862	Changes in lymphocyte subsets after short-term pharmacotherapy in patients with panic disorder. 2004 , 128, 183-90	12
861	Lymphocyte subsets and lymphokine production in patients with melancholic versus nonmelancholic depression. 2004 , 128, 259-65	37
860	Effects of dexamethasone on declarative memory function in posttraumatic stress disorder. 2004 , 129, 1-10	39
859	The role of catastrophic misinterpretation of bodily sensations and panic self-efficacy in predicting panic severity. 2004 , 18, 325-40	37
858	Audiovestibular functioning in patients with panic disorder. 2004 , 57, 177-82	25
857	Effectiveness of inpatient dialectical behavioral therapy for borderline personality disorder: a controlled trial. 2004 , 42, 487-99	319
856	Mental disorders in adolescents with celiac disease. 2004 , 45, 325-35	51

(2004-2004)

855	neuropsychological indices. 2004 , 115, 1340-8	42
854	Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. 2004 , 14, 457-70	219
853	Differences in beta-adrenergic receptor sensitivity between women and men with panic disorder. 2004 , 14, 515-20	9
852	Comorbid psychiatric diagnoses in kleptomania and pathological gambling: a preliminary comparison study. 2004 , 19, 299-302	28
851	Social adjustment in generalised anxiety disorder: a long-term placebo-controlled study of venlafaxine extended release. 2004 , 19, 272-9	9
850	Pituitary-adrenal responses to standard and low-dose dexamethasone suppression tests in adult survivors of child abuse. 2004 , 55, 10-20	147
849	Neurobiological correlates of diagnosis and underlying traits in patients with borderline personality disorder compared with normal controls. 2004 , 121, 239-52	67
848	The adequacy of measurement of short and long-term consequences of false-positive screening mammography. 2004 , 11, 39-44	48
847	Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. 2004 , 19, 271-80	151
846	Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. 2004 , 24, 30-5	35
845	Mean Deviation of Inter-rater Scoring (MDIS): a simple tool for introducing conformity into groups of clinical investigators. 2004 , 19, 209-13	2
844	A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study. 2004 , 24, 291-7	49
843	The value of pseudoneurological symptoms for assessing psychopathology in primary care. 2004 , 66, 141-6	25
842	Prevalence and clinical correlates of disinhibition in dementia. 2004 , 17, 139-47	33
841	Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. 2004 , 24, 389-99	235
840	Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. 2004 , 24, 141-9	138
839	Tranquilliser Use in Elderly Psychiatric Patients. 2004 , 34, 183-186	
838	Hypochondriacal concerns in panic disorder and major depressive disorder: a comparison. 2004 , 34, 143-54	10

837	Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. 2004 , 34, 973-82	144
836	Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology. 2004 , 19, 23-6	39
835	Low-dose diazepam primes motivation for alcohol and alcohol-related semantic networks in problem drinkers. 2004 , 15, 503-12	22
834	The Consumer Reports effectiveness score: What did consumers report?. 2004 , 51, 25-37	29
833	"Scared stiff": catatonia as an evolutionary-based fear response. 2004 , 111, 984-1002	124
832	The validity of the five-factor model prototypes for personality disorders in two clinical samples. 2004 , 16, 310-22	76
831	Relation between prenatal maternal mood and anxiety and neonatal health. 2004, 49, 684-9	39
830	Strategies for managing sexual dysfunction induced by antidepressant medication. 2004 , CD003382	23
829	Fluoxetine therapy in depersonalisation disorder: randomised controlled trial. 2004, 185, 31-6	43
828	Insomnia in HIV infection: a systematic review of prevalence, correlates, and management. 2005 , 67, 260-9	95
827	The efficacy of divalproex sodium in the treatment of agitation associated with major depression. 2005 , 25, 476-9	16
826	Reality orientation therapy combined with cholinesterase inhibitors in Alzheimer's disease: randomised controlled trial. 2005 , 187, 450-5	117
825	A patient with a resistant major depression disorder treated with deep brain stimulation in the inferior thalamic peduncle. 2005 , 57, 585-93; discussion 585-93	245
824	Gender Differences Among MDMA Users on Psychological and Drug History Variables. 2005 , 4, 43-48	4
823	Is anyone really M.A.D.?: the occurrence and course of mixed anxiety-depressive disorder in a sample of primary care patients. 2005 , 193, 223-30	20
822	A placebo-controlled, randomized withdrawal study of sertraline for panic disorder in Japan. 2005 , 20, 265-73	14
821	Psychosocial interventions for conversion disorder. 2005 , CD005331	55
820	Randomized placebo-controlled trial of a selective serotonin reuptake inhibitor in the treatment of nondepressed tinnitus subjects. 2005 , 67, 981-8	64

(2005-2005)

819	Hormonal profile effects following dehydroepiandrosterone (DHEA) administration to schizophrenic patients. 2005 , 28, 265-9	15
818	Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study. 2005 , 25, 593-6	62
817	Coping processes and hemostatic reactivity to acute stress in dementia caregivers. 2005 , 67, 964-71	34
816	Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study. 2005 , 28, 6-10	70
815	Patients with generalized anxiety disorder and a history of trauma: somatic symptom endorsement. 2005 , 11, 212-5	10
814	Interpersonal Problems and the Outcome of Interpersonally Oriented Psychodynamic Treatment of GAD 2005 , 42, 211-224	66
813	Major depression in patients with borderline personality disorder: a clinical investigation. 2005 , 50, 234-8	32
812	Pharmacotherapy of panic disorder in the elderly: a naturalistic 12-month follow-up outcome study. 2005 , 2, 249-254	
811	Efficacy of the 5-HT1A agonist, buspirone hydrochloride, in migraineurs with anxiety: a randomized, prospective, parallel group, double-blind, placebo-controlled study. 2005 , 45, 1004-11	26
810	Putaminal gray matter volume decrease in panic disorder: an optimized voxel-based morphometry study. 2005 , 22, 2089-94	88
809	Psychiatric disorders and large interdialytic weight gain in patients on chronic haemodialysis. 2005 , 10, 15-20	58
808	A medication screening trial evaluation of reserpine, gabapentin and lamotrigine pharmacotherapy of cocaine dependence. 2005 , 100 Suppl 1, 58-67	50
807	A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. 2005 , 100 Suppl 1, 68-77	73
806	Selective cognitive deficits in obsessive-compulsive disorder compared to panic disorder with agoraphobia. 2005 , 111, 150-8	81
805	Structured assessment of current mental state in clinical practice: an international study of the reliability and validity of the Current Psychiatric State interview, CPS-50. 2005 , 111, 44-50	7
804	Sertraline in generalized anxiety disorder: efficacy in treating the psychic and somatic anxiety factors. 2005 , 111, 429-35	24
803	Executive functioning in depressed patients with suicidal ideation. 2005 , 112, 294-301	163
802	Mood, cognition and EEG changes during interferon alpha (alpha-IFN) treatment for chronic hepatitis C. 2005 , 84, 93-8	45

801	Divalproex in the treatment of bipolar depression: a placebo-controlled study. 2005 , 85, 259-66	141
800	Do venlafaxine XR and paroxetine equally influence negative and positive affect?. 2005 , 85, 333-9	21
799	Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. 2005 , 87, 161-7	98
798	Strategies for managing antidepressant-induced sexual dysfunction: systematic review of randomised controlled trials. 2005 , 88, 241-54	85
797	The effect of pharmacotherapy on personality disorders in panic disorder: a one year naturalistic study. 2005 , 89, 189-94	17
796	Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients. 2005, 36, 159-65	58
795	Clinical biologic pathophysiologies of women's sexual dysfunction. 2005 , 2, 4-25	99
794	Decreased thalamic blood flow in obsessive-compulsive disorder patients responding to fluvoxamine. 2005 , 138, 89-97	41
793	Cognitive-behavioral therapy for late-life generalized anxiety disorder: Who gets better?. 2005 , 36, 147-156	36
792	Gender differences in clinical presentation and response to sertraline treatment of generalized anxiety disorder. 2005 , 20, 3-13	34
791	Assessment of sexual functioning in depressed patients treated with mirtazapine: a naturalistic 6-month study. 2005 , 20, 435-40	27
790	Influence of age of onset on clinical features in obsessive-compulsive disorder. 2005, 21, 112-7	60
789	Evaluation of the psychometric properties of the Beck Depression Inventory in a non-elderly adult sample of patients with generalized anxiety disorder. 2005 , 22, 41-4	25
788	Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression. 2005 , 22, 94-7	42
787	Psychometric properties of a Swedish translation of the Clinician-Administered PTSD ScaleDiagnostic Version. 2005 , 18, 161-4	18
786	Sex-related elevation in cortisol during chronic treatment with alprazolam associated with enhanced cognitive performance. 2005 , 182, 414-9	6
785	Impaired platelet [3H]paroxetine binding in female patients with borderline personality disorder. 2005 , 182, 447-51	6
7 ⁸ 4	A positron emission tomography (PET) study of cerebral dopamine D2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian). 2005 , 180, 377-84	81

(2005-2005)

783	Benign paroxysmal positional vertigo and post-treatment quality of life. 2005 , 262, 627-30	25
782	The Beck Anxiety Inventory in Older Adults With Generalized Anxiety Disorder. 2005, 27, 17-24	52
781	Reliability and validity of the pathological gambling adaptation of the Yale-Brown Obsessive-Compulsive Scale (PG-YBOCS). 2005 , 21, 431-43	170
78o	The Looming Cognitive Style and Generalized Anxiety Disorder: Distinctive Danger Schemas and Cognitive Phenomenology. 2005 , 29, 7-27	52
779	Is there a dysfunction in the visual system of depressed patients?. 2005 , 4, 7	17
778	Lymphocyte subsets and mood states in panic disorder patients. 2005 , 20, 215-9	19
777	Estudo para a constru 0 de uma escala de ansiedade para adolescentes. 2005 , 22, 347-354	1
776	Comorbidity issues in the pharmacological treatment of Pathological Gambling: a critical review. 2005 , 1, 21	34
775	A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. 2005 , 17, 65-9	78
774	Right basal ganglion hypoperfusion in obsessive compulsive disorder patients demonstrated by Tc-99m-HMPAO brain perfusion spect: a controlled study. 2005 , 115, 1643-55	5
773	An open-label study of tiagabine as augmentation therapy for anxiety. 2005, 17, 167-72	14
772	Multicomponent behavioral treatment for chronic combat-related posttraumatic stress disorder: trauma management therapy. 2005 , 29, 39-69	35
771	Group cognitive behaviour therapy in obsessive-compulsive disorder (OCD): a controlled study. 2005 , 9, 257-63	16
770	Somatic symptoms in late-life anxiety: treatment issues. 2005 , 18, 89-96	41
769	Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator. 2005 , 102, 7380-5	101
768	Open trial of pindolol in the treatment of fibromyalgia. 2005 , 39, 1812-6	28
767	Nutrients, Stress, and Medical Disorders. 2005,	5
766	Effects of phenytoin on memory, cognition and brain structure in post-traumatic stress disorder: a pilot study. 2005 , 19, 159-65	81

765	A multicenter study about Neurobiology of Suicidal Behavior: design, development, and preliminary results. 2005 , 9, 19-26	4
764	Open-label pilot study of St. John's wort in adolescent depression. 2005 , 15, 293-301	33
763	Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder. 2005 , 90 Suppl 1, i26-9	38
762	A double-blind, placebo-controlled trial of modafinil for cocaine dependence. 2005 , 30, 205-11	302
761	Sustained-release bupropion in the treatment of SSRI nonresponder pathologic gamblers: pilot study and review of the literature. 2005 , 2, 753-757	8
760	Similar neurocognitive performance of adults with and without a history of parental Alzheimer's disease: a pilot study. 2005 , 18, 208-12	7
759	Middle-aged children of Alzheimer parents, a pilot study: stable neurocognitive performance at 20-year follow-up. 2005 , 18, 187-91	10
758	The illusion of mental health: in the mind of which beholder?. 2005 , 85, 92-7	6
757	On the overlap between apathy and depression in dementia. 2005 , 76, 1070-4	153
756	Meta-analysis of cognitive-behavioral treatments for generalized anxiety disorder: a comparison with pharmacotherapy. 2005 , 131, 785-95	154
755	Randomized controlled trial comparing brief dynamic and supportive therapy with waiting list condition in minor depressive disorders. 2005 , 74, 43-50	86
754	Relationship between alexithymia and panic disorder: a longitudinal study to answer an open question. 2005 , 74, 56-60	87
753	A randomized controlled trial of Japanese patients with obsessive-compulsive disordereffectiveness of behavior therapy and fluvoxamine. 2005 , 74, 269-76	64
75 ²	Quels sont les marqueurs du tabagisme ?. 2005 , 34, 154-170	3
751	Self-mutilation and symptoms of depression, anxiety, and borderline personality disorder. 2005 , 35, 581-91	133
750	Age at Onset of Generalized Anxiety Disorder in Older Adults. 2005 , 13, 23-30	57
749	MEhodes d☑aluation des troubles anxieux (2e partie). 2005 , 2, 37-40	1
748	Social anxiety disorder: current treatment recommendations. 2005 , 19, 377-91	18

(2021-2005)

747	Specificity of Symptoms of Depression in Alzheimer Disease: A Longitudinal Analysis. 2005 , 13, 802-807	24
746	Pregabalin: a new neuromodulator with broad therapeutic indications. 2005 , 39, 2029-37	133
745	An Evaluation of Outcome Measures Used in Humanistic Psychotherapy Research: Using Thermometers to Weigh Oranges 2005 , 33, 113-130	24
744	Cognitive behavioral and attachment based family therapy for anxious adolescents: Phase I and II studies. 2005 , 19, 361-81	97
743	NAG level differences in panic disorder and agoraphobia. 2005 , 19, 818-25	2
742	Clinical consequences of initial duloxetine dosing strategies: Comparison of 30 and 60 mg QD starting doses. 2005 , 66, 522-40	24
741	Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. 2005 , 43, 831-42	317
74º	You are not alone: Smartphone use, friendship satisfaction, and anxiety during the COVID-19 crisis 2022 , 10, 294-315	7
739	The association of saccadic abnormalities with rem sleep in patients with Huntington's disease. 2021 ,	1
738	Autonomic vulnerability to biased perception of social inclusion in borderline personality disorder. 2021 , 8, 28	O
737	Subjective Cognitive Complaints in Newly-Diagnosed Parkinson's Disease With and Without Mild Cognitive Impairment 2021 , 15, 761817	1
736	Involvement of mucosal flora and enterochromaffin cells of the caecum and descending colon in diarrhoea-predominant irritable bowel syndrome. 2021 , 21, 316	O
735	Anxiety Disorders. 2022 , 161-179	
734	Adverse clinical outcomes in people at clinical high-risk for psychosis related to altered interactions between hippocampal activity and glutamatergic function. 2021 , 11, 579	1
733	Can Cranioplasty Be Considered a Tool to Improve Cognitive Recovery Following Traumatic Brain Injury? A 5-Years Retrospective Study. 2021 , 10,	2
732	A Generalizable Speech Emotion Recognition Model Reveals Depression and Remission. 2021,	2
73 ¹	Efficacy of sequential N-butylphthalide therapy on psychiatric and behavioral functions in acute ischemic stroke. 2021 , 100, e27860	2
730	Functional MRI connectivity of the primary motor cortex in functional dystonia patients. 2021 , 1	1

729	A double-blind placebo-controlled study of brexpiprazole for the treatment of borderline personality disorder 2021 , 1-6	2
728	Minor hallucinations in isolated rapid eye movement sleep behavior disorder indicative of early phenoconversion: A preliminary study. 2021 ,	O
727	Depressive symptomatology in adults during the COVID-19 pandemic. 2021 ,	2
726	Effectiveness of noninvasive brain stimulation in the treatment of anxiety disorders: a meta-analysis of sham or behaviour-controlled studies. 2021 , 46, E592-E614	3
725	Comparison of mood state in advanced pelvic organ prolapse patients before and after surgery. 2021 , 1, 220-220	
724	Functional connectivity changes in insomnia disorder: A systematic review 2021 , 61, 101569	1
723	Caregiver burden and influencing factors among family caregivers of patients with glioma: A cross-sectional survey. 2021 ,	0
722	Association Between Obesity and Post-stroke Anxiety in Patients With Acute Ischemic Stroke 2021 , 8, 749958	
721	Which mixed depression model? A comparison between DSM-5-defined mixed features and Koukopoulos' criteria. 2021 ,	1
720	Effects of a Novel, Transdiagnostic, Hybrid Ecological Momentary Intervention for Improving Resilience in Youth (EMIcompass): Protocol for an Exploratory Randomized Controlled Trial. 2021 , 10, e27462	3
719	Preliminary Analysis of Brain Footprints in Multiple Sclerosis Females with Detrusor Sphincter Dyssynergia: A Concurrent Urodynamic and Functional Magnetic Resonance Imaging Study. 2021 ,	O
718	Anthropophobia (Taijin Kyofusho) beyond the Boundaries of a Culture-Bound Syndrome: A Case Series from India. 025371762110532	O
717	Effect of onset age on the levodopa threshold dosage for dyskinesia in Parkinson's disease. 2021 , 1	O
716	44. L'approche statistique de la psychiatrie de l'enfant. 693-730	
715	Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders 2021 , 11, 20451253211056743	1
714	COGNITIVE FUNCTIONS IN MULTIPLE SCLEROSIS PATIENTS DEPENDING ON THE DIFFERENT RISK FACTORS PRESENCE. 2021 , 74, 2444-2451	
713	Effects of a Novel, Transdiagnostic, Hybrid Ecological Momentary Intervention for Improving Resilience in Youth (EMIcompass): Protocol for an Exploratory Randomized Controlled Trial (Preprint).	1
712	DISTRIBUTION OF PHANTOM VIBRATION SYNDROME AND ITS ASSOCIATION ON PSYCHOLOGICAL MORBIDITY AMONG MEDICAL STUDENTS, SOUTH INDIA. 2021 , 1	

711	The impact of interaction with orphanage children on quality of life of elderly females residing in old-age homes in a South Indian District: A comparative study. 2021 , 8, 82	
710	Evaluating the 3Cs Program for Caregivers of Young Children Affected by the Armed Conflict in Colombia. 2021 , 7, 212	O
709	Diagnostik in der Klinischen Psychologie und Psychotherapie. 2021 , 689-730	
708	Unbalanced fronto-pallidal neurocircuit underlying set shifting in obsessive-compulsive disorder 2022 , 145, 979-990	1
707	When to Choose Paroxetine Treatment in Skin-Picking Disorder: A Case Report 2022 , 15500594211073390	
706	Metagenomic analysis reveals gut bacterial signatures for diagnosis and treatment outcome prediction in bipolar depression 2022 , 307, 114326	1
705	Abnormal dynamic brain activity and functional connectivity of primary motor cortex in blepharospasm 2021 ,	0
704	Volume deficits in hippocampal subfields in unaffected relatives of schizophrenia patients with high genetic loading but without any psychiatric symptoms 2022 , 240, 125-131	O
703	Evaluation of the correlation between gaze avoidance and schizophrenia psychopathology with deep learning-based emotional recognition 2021 , 68, 102974	
702	Sleep quality and emotion recognition in individuals with and without internalizing psychopathologies 2021 , 75, 101719	O
701	Programa de formacili en Psico-Oncologii para residentes de Psiquiatrii y Psicologii Clilica: modelo de interconsulta. 2003 , 5, 443-449	
700	Trajectories of change in well-being during cognitive behavioral therapies for anxiety disorders: Quantifying the impact and covariation with improvements in anxiety 2020 , 57, 379-390	Ο
699	A transdiagnostic approach to conceptualizing depression across the perinatal period in a high-risk sample 2020 , 129, 689-700	2
698	RELATIONSHIP BETWEEN READINESS AND ANXIETY LEVEL IN ELEMENTARY SCHOOL STUDENTS FACING MENARCHE IN PADEMAWU SUB-DISTRICT, PAMEKASAN. 2020 , 9, 95	
697	A Clinicoepidemiological Study of Psychiatric Co-Morbidity in Hansen's Disease 2021 , 12, 847-851	
696	Informatics Technologies for the Acquisition of Psychological, Behavioral, Interpersonal, Social and Environmental Data. 2021 , 217	O
695	PRBENTATION. 2021 , 42, 1	
694	Fatigue in Patients With Multiple System Atrophy: A Prospective Cohort Study. 2021 ,	1

693	Examining Differences in Fear Learning in Patients With Obsessive-Compulsive Disorder With Pupillometry, Startle Electromyography and Skin Conductance Responses. 2021 , 12, 730742	1
692	Resting-State Functional Connectivity in Frontostriatal and Posterior Cortical Subtypes in Parkinson's Disease-Mild Cognitive Impairment 2021 ,	O
691	Chemokine profile in women with moderate to severe anxiety and depression during pregnancy. 2021 , 21, 807	0
690	Adjunctive vagus nerve stimulation for treatment-resistant depression: a preliminary study 2022 , 1-6	O
689	Repetitive Transcranial Magnetic Stimulation Modulates Frontal and Temporal Time-Varying EEG Network in Generalized Anxiety Disorder: A Pilot Study 2021 , 12, 779201	2
688	Analysis of Psychological and Gut Microbiome Characteristics in Patients With Non-erosive Reflux Disease 2021 , 12, 741049	
687	Negative symptoms in Huntington's disease 2022 , 1	
686	Intersections between Copper, EArrestin-1, Calcium, FBXW7, CD17, Insulin Resistance and Atherogenicity Mediate Depression and Anxiety Due to Type 2 Diabetes Mellitus: A Nomothetic Network Approach 2022 , 12,	2
685	Functional connectivity in Parkinson's disease candidates for deep brain stimulation 2022, 8, 4	2
684	Neuroimmunological investigations of cerebrospinal fluid in patients with recent onset depression - a study protocol 2022 , 22, 35	1
683	A Retrospective Naturalistic Study Comparing the Efficacy of Ketamine and Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression 2021 , 12, 784830	0
682	The effectiveness of psychological interventions for anxiety in the perinatal period: A systematic review and meta-analysis.	
681	Scales and Scores for Comprehensive Geriatric Assessment in Primary Care. 2022 , 121-137	0
680	Anxiety Disorders. 2022 , 421-434	
679	Potentially modifiable associates of anxiety in people with multiple sclerosis: a systematic review 2022 , 1-12	0
6 7 8	Correlations between cerebrospinal fluid biomarkers, neurocognitive tests, and resting-state electroencephalography (rsEEG) in patients with HIV-associated neurocognitive disorders 2022 , 1	1
677	A novel peripheral biomarker for depression and antidepressant response 2022,	3
676	Bronchial asthma control, quality of life, and psychiatric disorders vicious cycle: Asyut society point of view. 2022 , 16,	O

675	Sexual Habits and Sexual Dysfunctions in a Sample of Patients with Psychotic Disorders Compared to a Group of Healthy Adults 2022 , 11,	О
674	Parkinson's disease patients with freezing of gait have more severe voice impairment than non-freezers during "ON state" 2022 , 129, 277	O
673	The psychopathological impact of the SARS-CoV-2 epidemic on subjects suffering from different mental disorders: An observational retrospective study 2021 , 307, 114334	2
672	Psychiatric Comorbidities and Liver Injury Are Associated With Unbalanced Plasma Bile Acid Profile During Methamphetamine Withdrawal 2021 , 12, 801686	1
671	Family Conflict Associated With Intrinsic Hippocampal-OFC Connectivity in Adolescent Depressive Disorder 2021 , 12, 797898	O
670	Is music listening an effective intervention for reducing anxiety? A systematic review and meta-analysis of controlled studies. 102986492110469	O
669	Association Between Socio-Affective Symptoms and Glutathione and CD4 and CD8 Lymphocytes in College Students 2021 , 12, 666347	O
668	Use of 30-Hz Accelerated iTBS in Drug-Resistant Unipolar and Bipolar Depression in a Public Healthcare Setting: A Case Series 2021 , 12, 798847	
667	Acupuncture combined with traditional Chinese medicine e-aid cognitive behavioral therapy for insomnia (TCM-eCBT-I) for chronic insomnia: study protocol for a randomized controlled trial 2022 , 23, 86	0
666	Reclassification of patients with tremor syndrome and comparisons of essential tremor and essential tremor-plus patients 2022 , 1	1
665	Prevalence of mental health disorders among health-care providers of COVID-19 positive and suspected cases. 2022 ,	
664	Impaired Ocular Tracking and Cortical Atrophy in Idiopathic Rapid Eye Movement Sleep Behavior Disorder 2022 ,	О
663	DNA-methylation dynamics across short-term, exposure-containing CBT in patients with panic disorder 2022 , 12, 46	1
662	The United States index of socioeconomic deprivation for individuals (USiDep). 2022 , 31-32, 100091	O
661	Correlation between preoperative psychological personality traits of glioma patients and psychological distress in their primary caregivers 2022 , 214, 107144	0
660	Abnormal white matter structure in hoarding disorder 2022 , 148, 1-8	0
659	Alterations of default mode and cingulo-opercular salience network and frontostriatal circuit: A candidate endophenotype of obsessive-compulsive disorder 2022 , 116, 110516	1
658	The quality of life in patients with Parkinson's disease: Focus on gender difference 2022 , e2517	2

657	Reduced paraoxonase 1 activities may explain the comorbidities between temporal lobe epilepsy and depression, anxiety and psychosis. 2022 , 12, 317-332	О
656	A novel pathway phenotype of temporal lobe epilepsy and comorbid psychiatric disorders: results of precision nomothetic medicine.	1
655	Influence of adjuvant nortriptyline on the efficacy of electroconvulsive therapy: a randomized controlled trial and one-year follow-up 2022 ,	0
654	Early pharmacological interventions for universal prevention of post-traumatic stress disorder (PTSD) 2022 , 2, CD013443	3
653	Self-Stigma in Parkinson's Disease: A 3-Year Prospective Cohort Study 2022 , 14, 790897	0
652	Towards personalizing cognitive remediation therapy: Examining moderators of response for euthymic people with bipolar disorder 2022 , 151, 104054	1
651	Metabolomic and inflammatory signatures of symptom dimensions in major depression 2022 , 102, 42-52	1
650	Prevalence of depression and anxiety in irritable bowel syndrome: A clinic based study from India - Comments on the article. 2014 , 56, 409	1
649	Bibliographie. 2015 , 314-328	
648	A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials 2021 ,	10
648 647		10
Í	clinical trials 2021, The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in	
647	clinical trials 2021, The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. 1997, 247, 71-80 Influence of Plasma Concentration of Hsa-Mir-370-3p and Cyp2d6*4 On Equilibrium Concentration	
647	Clinical trials 2021, The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. 1997, 247, 71-80 Influence of Plasma Concentration of Hsa-Mir-370-3p and Cyp2d6*4 On Equilibrium Concentration of Phenazepam in Patients with Recurrent Depressive Disorder. 2021, 51, 87-104	
647 646 645	Clinical trials 2021, The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. 1997, 247, 71-80 Influence of Plasma Concentration of Hsa-Mir-370-3p and Cyp2d6*4 On Equilibrium Concentration of Phenazepam in Patients with Recurrent Depressive Disorder. 2021, 51, 87-104 Measuring Symptoms and Monitoring Progress in Functional Movement Disorder. 2022, 401-413	
647 646 645	Clinical trials 2021, The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. 1997, 247, 71-80 Influence of Plasma Concentration of Hsa-Mir-370-3p and Cyp2d6*4 On Equilibrium Concentration of Phenazepam in Patients with Recurrent Depressive Disorder. 2021, 51, 87-104 Measuring Symptoms and Monitoring Progress in Functional Movement Disorder. 2022, 401-413 Az endometri\(\mathbb{E}\) is pszichol\(\mathbb{E}\) iai t\(\mathbb{E}\) inogat\(\mathbb{E}\)a. 2022, 247-262	
647 646 645 643	Clinical trials 2021, The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. 1997, 247, 71-80 Influence of Plasma Concentration of Hsa-Mir-370-3p and Cyp2d6*4 On Equilibrium Concentration of Phenazepam in Patients with Recurrent Depressive Disorder. 2021, 51, 87-104 Measuring Symptoms and Monitoring Progress in Functional Movement Disorder. 2022, 401-413 Az endometri\(\mathbb{E}\) is pszichol\(\mathbb{G}\) jai t\(\mathbb{T}\) nogat\(\mathbb{S}\)a. 2022, 247-262 Management of psychiatric disorders in patients with cardiovascular diseases. 2022, 64, 355	

639	Aberrant salience relationship with first rank symptoms 2022 , 21, 8	О
638	Exploring the psychological effects of sharps injuries sustained by healthcare workers 2022,	O
637	Anxiety, Stress, and Resilience Strategies in Parents of Children with Typical and Late Psychosocial Development: Comparative Analysis 2022 , 19,	
636	Global Functional Connectivity Analysis Indicating Dysconnectivity of the Hate Circuit in Major Depressive Disorder 2021 , 13, 803080	O
635	Fatigue in Chinese Patients With Amyotrophic Lateral Sclerosis: Associated Factors and Impact on Quality of Life 2022 , 13, 806577	
634	A longitudinal evaluation of the impact of the COVID-19 pandemic on a cohort of patients treated with clozapine 2022 , 1-6	O
633	Focal Dystonia: Functional Connectivity Changes in Cerebellar-Basal Ganglia-Cortical Circuit and Preserved Global Functional Architecture 2022 ,	2
632	Analysis of Postoperative Gait, Hip Strength, and Patient Reported Outcomes Following OTA/AO 61-B and 61-C Pelvic Ring Fractures 2022 ,	O
631	Adherence to Medication among Parkinson Disease Patients Using the Adherence to Refills and Medications Scale. 2022 , 2022, 1-7	O
630	Long-Term Sequelae of COVID-19: A Systematic Review and Meta-Analysis of One-Year Follow-Up Studies on Post-COVID Symptoms 2022 , 11,	28
629	Response Efficacy and Self-Efficacy Mediated the Relationship between Perceived Threat and Psychic Anxiety among College Students in the Early Stage of the COVID-19 Pandemic 2022 , 19,	1
628	Huntingtin gene intermediate alleles influence the progression from subjective cognitive decline to mild cognitive impairment: A 14-year follow-up study 2022 ,	1
627	Reduced paraoxonase 1 activities may explain the comorbidities between temporal lobe epilepsy and depression, anxiety and psychosis 2022 , 12, 308-322	2
626	Alcohol Use and Prefrontal Cortex Volume Trajectories in Young Adults with Mood Disorders and Associated Clinical Outcomes 2022 , 12,	O
625	Efficacy of Deep TMS with the H1 Coil for Anxious Depression 2022, 11,	1
624	The interleukin-6/interleukin-23/Thelper-17-axis as a driver of neuro-immune toxicity in the major neurocognitive psychosis or deficit schizophrenia: a precision nomothetic psychiatry analysis.	O
623	Differential response to three antidepressants in patients with major depressive episode who suffered Covid-19-related trauma 2022 ,	O
622	Integration of hatha yoga and evidence-based psychological treatments for common mental disorders: An evidence map 2022 ,	1

621	Abnormal functional connectivity of brain regions associated with fear network model in panic disorder 2022 , 1-9	1
620	The Effect of Perceived Threat Avoidability of COVID-19 on Coping Strategies and Psychic Anxiety Among Chinese College Students in the Early Stage of COVID-19 Pandemic 2022 , 13, 854698	1
619	Impact of Housing First on Psychiatric Symptoms, Substance Use, and Everyday Life Skills Among People Experiencing Homelessness 2022 , 1-10	
618	Pharmacotherapy for post traumatic stress disorder (PTSD) 2022 , 3, CD002795	1
617	Region-Specific Disturbed Iron Redistribution in Cushing's Disease Measured by MRI-based Quantitative Susceptibility Mapping 2022 ,	0
616	Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy 2022 , e2555	1
615	Studying the relationship between clinical features and mental health among late-onset myasthenia gravis patients 2022 , 12, 470-482	
614	Medication management and treatment adherence in Parkinson's disease patients with mild cognitive impairment 2022 , 1	
613	Disrupted Brain Functional Network Topology in Essential Tremor Patients With Poor Sleep Quality 2022 , 16, 814745	
612	Cognitive and quality-of-life related factors of body mass index (BMI) improvement after deep brain stimulation in the subcallosal cingulate and nucleus accumbens in treatment-refractory chronic anorexia nervosa 2022,	O
611	Associations of Vitamin D, chronic obstructive pulmonary disease and acute exacerbations of COPD with anxiety and depression: a nested case control study. 7, 86	O
610	Gray matter volume reduction in the emotional brain networks in adults with anosmia 2022,	
609	Hydroxychloroquine non-availability during COVID-19 pandemic and its relation to anxiety level and disease activity in rheumatoid arthritis and lupus patients: a cross-sectional study. 2022 , 49,	
608	Pathway Phenotypes Underpinning Depression, Anxiety, and Chronic Fatigue Symptoms Due to Acute Rheumatoid Arthritis: A Precision Nomothetic Psychiatry Analysis 2022 , 12,	Ο
607	Amplitude setting and dopamine response of finger tapping and gait are related in Parkinson's disease 2022 , 12, 4180	
606	Anxiety and Depression among Hypertensive Adults in Tertiary Care Hospitals of Nepal 2022 , 2022, 1098625	O
605	Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited 2022 , 1	1
604	Human state anxiety classification framework using EEG signals in response to exposure therapy 2022 , 17, e0265679	O

603	Attachment insecurity partially mediates the relationship between childhood trauma and depression severity in bipolar disorder 2022 ,	О
602	Long-term cognitive impairments following COVID-19: a possible impact of hypoxia 2022 , 1	2
601	Hypnosis and music interventions for anxiety, pain, sleep and well-being in palliative care: systematic review and meta-analysis 2022 ,	О
600	Yoga Prevents Gray Matter Atrophy in Women at Risk for Alzheimer's Disease: A Randomized Controlled Trial 2022 ,	1
599	Clinical Efficacy of the Chinese Herbal Medicine Shumian Capsule for Insomnia: A Randomized, Double-Blind, Placebo-Controlled Trial 2022 , 18, 669-679	O
598	Comprehensive preoperative psychological assessment of breast cancer patients 2022, 1-16	
597	Effects of repeated transcranial magnetic stimulation in the dorsolateral prefrontal cortex versus motor cortex in patients with neuropathic pain after spinal cord injury: a study protocol 2022 , 12, e053476	O
596	Electro-acupuncture for protracted amphetamine abstinence syndrome: study protocol for a pragmatic randomized controlled trial 2022 , 23, 216	
595	Validity and Reliability of the Staden Schizophrenia Anxiety Rating Scale 2022, 12,	О
594	Analgesic Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Advanced Non-Small-Cell Lung Cancer: A Randomized, Sham-Controlled, Pilot Study 2022 , 12, 840855	1
593	Pregnant women with bipolar disorder who have a history of childhood maltreatment: Intergenerational effects of trauma on fetal neurodevelopment and birth outcomes 2022 ,	О
592	Hyperhidrosis in Parkinson's disease: a 3-year prospective cohort study 2022 ,	1
591	Nature-Based Interventions for Psychological Wellbeing in Long-Term Conditions: A Systematic Review 2022 , 19,	0
590	Mesolimbic Neurobehavioral Mechanisms of Reward Motivation in Anorexia Nervosa: A Multimodal Imaging Study 2022 , 13, 806327	1
589	Predicting non-response to multimodal day clinic treatment in severely impaired depressed patients: a machine learning approach 2022 , 12, 5455	O
588	Heterogeneity of patients with functional/dissociative seizures: Three multidimensional profiles 2022 ,	1
587	Psychopathological and neuropsychological outcomes of deep brain stimulation for severe-treatment-resistant obsessive-compulsive disorder: An open-label case series 2022 , 98, 229-234	О
586	Efficacy of Brahmi vati in generalised anxiety disorder - Randomized double blind comparative clinical trial 2022 , 13, 100552	

585	Guidelines for Diagnosis and Treatment of Depression in Older Adults: a Report from the Japanese Society of Mood Disorders 2022 ,	1
584	Evaluation of periprocedural anxiety during Gamma Knife radiosurgery (GKRS) frame fixation for brain lesions 2022 , 217, 107242	o
583	A case report of clozapine-treatment-resistant schizophrenia successfully managed with brexpiprazole combination therapy 2022 , 72, 103121	2
582	The relationship between ecological executive function and stigma among patients with epilepsy: The mediating effect of social support 2022 , 182, 106919	
581	The Effects of the Solution-Focused Model on Anxiety and Postpartum Depression in Nulliparous Pregnant Women 2022 , 13, 814892	
580	Neurocognition and Metacognition in Anxiety Disorders. 025371762110724	
579	Gut microbiome-linked metabolites in the pathobiology of depression and anxiety - a role for bile acids.	0
578	Comparison of the severity of depressive and anxiety symptoms, biomarkers, and childhood trauma among bipolar smokers and non-smokers, and controls. 2022 , 8, 100336	
577	Prevalence and risk factors for depression and anxiety in adult patients with epilepsy: Caregivers' anxiety and place of residence do mater 2022 , 129, 108628	1
576	The correlation between genetic factors and freezing of gait in patients with Parkinson's disease 2022 , 98, 7-12	О
575	A cross-sectional healthy-control study of serum inflammatory biomarkers interleukin (IL)-1B and IL-2R in panic disorder patients and their offspring 2022 , 149, 260-264	1
574	Real-world demotivation as a predictor of continued video game playing: A study on escapism, anxiety and lack of intrinsic motivation. 2022 , 53, 101147	o
573	Determinants of family functioning in caregivers of persons with obsessive-compulsive disorder 2022 ,	0
572	Dynamic connectivity alterations in anterior cingulate cortex associated with suicide attempts in bipolar disorders with a current major depressive episode 2022 , 149, 307-314	o
571	White matter predictors of worsening of subthreshold hypomania severity in non-bipolar young adults parallel abnormalities in individuals with bipolar disorder 2022 , 306, 148-156	0
570	Electrophysiological Evidence of Impaired Cognitive Reappraisal in Amnestic Mild Cognitive Impairment: An Event-related Potential Study 2022 , 113800	1
569	Comparison of the Efficiency of Psychological Assessment Tests Used in the Diagnosis of Fibromyalgia Syndrome with ANN. 2021 ,	
568	Are All Anxieties Created Equal? Stress-related Networks and Anxiety Phenotypes in Old Age 2021	o

567	Habenular and mediodorsal thalamic connectivity predict persistent weight loss after laparoscopic sleeve gastrectomy. 2021 ,	О
566	COVID-19 Pandemi Sfecinin Sa fk Ellenlar-Zerindeki Psikiyatrik YEL	
565	Efficacy of Cognitive Behavioral Therapy on Mood Disorders, Sleep, Fatigue, and Quality of Life in Parkinson's Disease: A Systematic Review and Meta-Analysis 2021 , 12, 793804	2
564	Depression with Mixed Features (for DSM-5): Distinguishing Indicators Imaginary Coherence EEG Rest. 2021 , 19, 61-75	
563	Locus of control as a moderator of the effects of COVID-19 perceptions on job insecurity, psychosocial, organisational, and job outcomes for MENA region hospitality employees.	3
562	Antidepressant efficacy of low-frequency repetitive transcranial magnetic stimulation in antidepressant-nonresponding bipolar depression: a single-blind randomized sham-controlled trial. 2021 , 9, 40	O
561	Evaluation of The Relationship Between Apelin 36 and Oxidative Stress In Patients With General Anxiety Disorder.	
560	Factors Associated with Depression and Anxiety Severity in Multiple Sclerosis Patients. 2021 , 1, 69-74	
559	Loneliness, Circulating Endocannabinoid Concentrations, and Grief Trajectories in Bereaved Older Adults: A Longitudinal Study 2021 , 12, 783187	0
558	The psychological impact of inflammatory bowel disease as regards anxiety and depression: a single-center study. 2021 , 28,	2
557	How Do You Treat in Your Practice?. 2021, 33, 447-449	0
556	Differential Dynamical Pattern of Regional Homogeneity in Bipolar and Unipolar Depression: A Preliminary Resting-State fMRI Study 2021 , 12, 764932	O
555	IMPACT OF CORONA PANDEMIC IN PEOPLE'S DAILY LIFE AND ALSO ON MENTAL HEALTH. 2021, 61-63	
554	Social Isolation, Illness Anxiety, and Quality of Life in Corona Survivors. 2022 , 36, 515-528	Ο
553	The Cold Hand Sign in Multiple System Atrophy: Frequency-Associated Factors and Its Impact on Survival 2021 , 13, 767211	0
552	Home-Based Transcranial Direct Current Stimulation for the Treatment of Symptoms of Depression and Anxiety in Temporal Lobe Epilepsy: A Randomized, Double-Blind, Sham-Controlled Clinical Trial 2021 , 15, 753995	1
551	Assessment of Anxiety in Cognitive-Behavior Therapy in Young University Students with Autism Spectrum Disorders: A Review 2021 , 11, 1571-1580	О
550	Impact of COVID-19 on Infertility Treatments: Not Even a Global Pandemic Was Strong Enough to Hamper Successful Pregnancies 2021 , 12,	

549	P.0067 Lurasidone in the treatment of comorbid anxiety symptoms in bipolar depression. 2021 , 53, S48-S49	
548	The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors 2021 , 20, 233	1
547	Cytokine profile in drug-na∏e panic disorder patients 2022 , 12, 75	1
546	Bibliographie. 2020 , 228-249	
545	Predictors of Psychotic and Depressive Symptoms in Metamphetamine Users.	
544	Infralow-Frequency Transcranial Magnetic Stimulation as a Therapy for Generalized Anxiety Disorder: A Randomized Clinical Trial.	
543	Cyclic Versus Continuous Deep Brain Stimulation in Patients with Obsessive Compulsive Disorder: A Randomized Controlled Trial.	0
542	[Anxiety-depressive disorders and stress factors in patients with systemic lupus erythematosus and antiphospholipid syndrome] 2022 , 122, 65-71	
541	Your Smartphone Knows you Better than you May Think: Emotional Assessment 6 n the Go L Via TapSense. 2022 , 209-267	
540	Unified protocols for transdiagnostic treatment versus the Beckian approach of cognitive behavioral therapy for medical students with emotional disorders. 2022 , 68, 12-16	
539	Evidence based Acupuncture-Moxibustion Acupunctrue for the pain of postherpetic neuralgia: A scoping review. 2022 ,	
538	Assessing Mental Pain as a Predictive Factor of Suicide Risk in a Clinical Sample of Patients with Psychiatric Disorders 2022 , 12,	О
537	The Validation Study of the Stress and Anxiety to Viral Epidemics-6 Scale Among Patients With Cancer in the COVID-19 Pandemic 2022 , 13, 811083	О
536	Lowered oxygen saturation and increased body temperature in acute COVID-19 largely predict chronic fatigue syndrome and affective symptoms due to LONG COVID: a precision nomothetic approach.	Ο
535	Neuroinflammatory biomarkers in the cerebrospinal fluid from 106 patients with recent onset depression compared to 106 individually matched healthy controls. 2022 ,	1
534	Functional dyspepsia symptom diary is correlated with other questionnaires and associated with severity in patients with functional dyspepsia: a multicenter, prospective observational study 2022	
533	A Novel Pathway Phenotype of Temporal Lobe Epilepsy and Comorbid Psychiatric Disorders: Results of Precision Nomothetic Medicine. 2022 , 11, 803	Ο
532	Multi-omics analyses of serum metabolome, gut microbiome and brain function reveal dysregulated microbiota-gut-brain axis in bipolar depression 2022 ,	2

(2018-2022)

Neural oscillations while remembering traumatic memories in post-traumatic stress disorder.. 2022, 531 139, 58-68 Effects of Repetitive Transcranial Magnetic Stimulation on Cognitive Function in Patients With 530 Stress-Related Depression: A Randomized Double-Blind fMRI and H-MRS Study.. 2022, 13, 844606 Disruption of the brain-esophagus axis in obese patients with heartburn.. 2022, 529 О Data_Sheet_1.DOC. 2018, 528 Image1.PDF. 2017, 527 Table1.docx. 2017, 526 Image_1.PNG. 2019, 525 Image_2.PNG. **2019**, 524 Table_1.DOCX. 2019, 523 Table_1.docx. 2020, 522 Data_Sheet_1.pdf. 2020, 521 520 Data_Sheet_1.docx. 2020, Data_Sheet_1.pdf. 2019, 519 Data_Sheet_1.docx. 2019, 518 Image_1.TIF. 2018, 517 516 Image_2.TIF. **2018**, Presentation_1.PDF. 2018, 515 Data_Sheet_1.docx. 2018, 514



(2022-2019)

495	Table_1.pdf. 2019 ,	
494	DataSheet_1.xlsx. 2019 ,	
493	DataSheet_1.pdf. 2019 ,	
492	Table_1.docx. 2019 ,	
491	DataSheet_1.xlsx. 2020 ,	
490	Table_1.docx. 2020 ,	
489	DataSheet_1.pdf. 2020 ,	
488	Anxiety and depression in Alzheimer's disease: a systematic review of pathogenetic mechanisms and relation to cognitive decline 2022 , 1	3
487	Breathing and Relaxation Exercises Help Improving Fear of COVID-19, Anxiety, and Sleep Quality: A Randomized Controlled Trial 2022 ,	0
486	Hierarchical Denoising of Ordinal Time Series of Clinical Scores 2022 , PP,	1
485	The Ohio State University Early Psychosis Intervention Center (EPICENTER) step-based care programme for individuals at clinical high risk for psychosis: study protocol for an observational study. 2020 , 10, e034031	0
484	Obsessive-compulsive disorder symptoms before and after recovery from bulimia nervosa. 1999 , 156, 1703-8	39
483	Duration of periods of euthymia in patients with dysthymic disorder. 1999 , 156, 1992-3	6
482	Deep Transcranial Magnetic Stimulation Effects on the Electrophysiological Parameters in Obsessive-Compulsive Disorder 2022 , 15500594221095385	
481	Suicidal Ideation Is Associated With Reduced Functional Connectivity and White Matter Integrity in Drug-NaWe Patients With Major Depression 2022 , 13, 838111	1
480	Efficacy of the Cooperative Assessment Method (COOPAS) to Improve the Psychiatric Care of Help-Seeking Adolescents 2019 , 16, 189-196	1
479	School Refusal Behavior: Role of Personality Styles, Social Functioning, and Psychiatric Symptoms in a Sample of Adolescent Help-Seekers 2022 , 19, 20-28	
478	Protein Biomarkers in Monocytes and CD4 Lymphocytes for Predicting Lithium Treatment Response of Bipolar Disorder: a Feasibility Study with Tyramine-Based Signal-Amplified Flow Cytometry 2022 , 52, 8-35	O

477	Making Sense of the Matrix: A Qualitative Assessment and Commentary on Connecting Psychiatric Symptom Scale Items to the Research Domain Criteria (RDoC) 2022 , 19, 26-32	
476	Improvement in quality of life of postmenopausal women with depression with commonly used antidepressants (Escitalopram vs. Desvenlafaxine): A randomized controlled trial in a tertiary care teaching hospital of North India. 2022 , 13, 80	
475	Habenular connectivity predict weight loss and negative emotional-related eating behavior after laparoscopic sleeve gastrectomy 2022 ,	
474	Assessment of Anxiety in Patients With Epilepsy: A Literature Review 2022 , 13, 836321	O
473	Correlation Between Brain Structure Atrophy and Plasma Amyloid-land Phosphorylated Tau in Patients With Alzheimer's Disease and Amnestic Mild Cognitive Impairment Explored by Surface-Based Morphometry 2022 , 14, 816043	1
472	Deep Brain Stimulation of the Nucleus Accumbens in Severe Enduring Anorexia Nervosa: A Pilot Study 2022 , 16, 842184	O
471	Depression in patients with ankylosing spondylitis.	О
470	Lower dACC glutamate in cannabis users during early phase abstinence 2022,	O
469	Effect of Probiotic Supplements on Oxidative Stress Biomarkers in First-Episode Bipolar Disorder Patients: A Randomized, Placebo-Controlled Trial 2022 , 13, 829815	0
468	Is Poor Lithium Response in Individuals with Bipolar Disorder Associated with Increased Degradation of Tryptophan along the Kynurenine Pathway? Results of an Exploratory Study 2022 , 11,	2
467	Vocal Acoustic Features as Potential Biomarkers for Identifying/Diagnosing Depression: A Cross-Sectional Study 2022 , 13, 815678	
466	Role of Lactiumlin Psychodermatology: The CERTAIN Trial on Patients with Acne Vulgaris 2022 , 2022, 2916317	o
465	Inverse Association Between Resting-State Putamen Activity and Iowa Gambling Task Performance in Patients With Obsessive-Compulsive Disorder and Control Subjects. 2022 , 13,	
464	A Whole Transcriptome Analysis in Peripheral Blood Suggests That Energy Metabolism and Inflammation Are Involved in Major Depressive Disorder. 2022 , 13,	o
463	Neuropsychological measures of Elong COVID-19 FogEn older subjects. 2022 ,	0
462	In schizophrenia, the effects of the IL-6/IL-23/Th17 axis on health-related quality of life and disabilities are partly mediated by generalized cognitive decline and the symptomatome.	o
461	Differences in social brain function in autism spectrum disorder are linked to the serotonin transporter: A randomised placebo-controlled single-dose crossover trial 2022 , 2698811221092509	О
460	Association Between Mild Neurocognitive Disorder Due to Alzheimer's Disease and Possible Attention-deficit/Hyperactivity Disorder: A Case Report 2022 , 28, 251-258	1

459	Brain Activation Alterations With Adjunctive Deep Transcranial Magnetic Stimulation (dTMS) In Obsessive Compulsive Disorder: A fMRI Study 2022 , 1-20	0
458	Exploring Association Between Serotonin and Neurogenesis Related Genes in Obsessive-Compulsive Disorder in Chinese Han People: Promising Association Between DMRT2, miR-30a-5p, and Early-Onset Patients. 2022 , 13,	
457	Morphological Biomarkers in the Amygdala and Hippocampus of Children and Adults at High Familial Risk for Depression. 2022 , 12, 1218	1
456	Transcutaneous Electrical Cranial-Auricular Acupoint Stimulation vs. Escitalopram for Patients With Mild-to-Moderate Depression (TECAS): Study Design for a Randomized Controlled, Non-inferiority Trial. 2022 , 13,	1
455	Treatment Outcome Measures for Spasmodic Dysphonia: A Systematic Review 2022,	1
454	Visual P300 as a neurophysiological correlate of symptomatic improvement by a virtual reality-based computer AT system in patients with auditory verbal hallucinations: A Pilot study 2022 , 151, 261-271	O
453	The role of compulsivity in body-focused repetitive behaviors 2022, 151, 365-367	
452	Impact of COVID Pandemic on Psychological Health and Academics of Undergraduate Students. 2021 , 9, 87	
451	Dynamics of intrinsic whole-brain functional connectivity in abstinent males with methamphetamine use disorder. 2022 , 100065	
450	Transcranial Direct Current Stimulation Does Not Improve Clinical and Neurophysiological Outcomes in Panic Disorder: A Randomized Sham-Controlled Trial 2022 ,	
449	Where do you live? North versus Central-South differences in relation to Italian patients with oral lichen planus: a cross-sectional study from the SIPMO (Italian Society of Oral Pathology and Medicine) 2022 , 22, 184	0
448	Topologically Disrupted Gray Matter Networks in Drug-NaWe Essential Tremor Patients With Poor Sleep Quality 2022 , 13, 834277	
447	Long-COVID post-viral chronic fatigue syndrome and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: a proof of concept and mechanism study.	0
446	Subjects with bipolar disorder showed different reward system activation than subjects with major depressive disorder in the monetary incentive delay task.	0
445	Different symptomatic improvement pattern revealed by factor analysis between placebo response and response to Esketamine in treatment resistant depression.	O
444	Some psychiatric comorbidity among patients with substance abuse disorder related to pregabalin. 2022 , 29,	
443	A Pilot Study of Telehealth Mindfulness-Based Cognitive Therapy for Depression in Parkinson Disease. 089198872211035	O
442	Resting-state functional connectivity correlates of anxiety co-morbidity in major depressive disorder. 2022 , 138, 104701	0

441	Efficacy and Safety of Repeated Subcutaneous Ketamine Injections for Treatment Resistant Depression - The KADS Study: A Randomised, Double-Blind, Comparator-Controlled Trial.	
440	Multi-modality connectome-based predictive modeling of individualized compulsions in obsessive-compulsive disorder. 2022 ,	
439	Heterogeneity of PD-MCI in Candidates to Subthalamic Deep Brain Stimulation: Associated Cortical and Subcortical Modifications. 2022 , 1-20	
438	Hypogyrification in Generalized Anxiety Disorder and Associated with Insomnia Symptoms. Volume 14, 1009-1019	O
437	A Longitudinal Magnetoencephalographic Study of the Effects of Deep Brain Stimulation on Neuronal Dynamics in Severe Anorexia Nervosa. 16,	
436	Glutamic Acid Decarboxylase 1 Gene Methylation and Panic Disorder Severity: Making the Connection by Brain Gray Matter Volume. 2022 , 13,	O
435	The Relationship Among Anxiety Sensitivity, Psychache, and Suicidality in Patients With Generalized Anxiety Disorder. 12 , Publish Ahead of Print,	O
434	Clinical and cVEMP Evaluation Predict Short-Term Residual Dizziness After Successful Repositioning in Benign Paroxysmal Positional Vertigo. 2022 , 9,	O
433	Dynamic Effective Connectivity Patterns During Rapid Face Stimuli Presentation in Body Dysmorphic Disorder. 2022 , 16,	
432	Stigma and unhealthy psychological characteristics in patients with acromegaly: A cross-sectional study and identification of the associated factors.	
431	A study protocol for an ongoing multi-arm, randomized, double-blind, sham-controlled clinical trial with digital features, using portable transcranial electrical stimulation and internet-based behavioral therapy for major depression disorders: The PSYLECT study.	0
430	Levodopa ONOFF-state freezing of gait: Defining the gait and non-motor phenotype. 2022 , 17, e0269227	1
429	Shared Transdiagnostic Neuroanatomical Signatures Across First-episode Patients with Major Psychiatric Diseases and Individuals at Familial Risk. 2022 , 103074	O
428	The effects of the COVID-19 pandemic on patients with obsessive-compulsive disorder. 1-7	
427	Neurocircuit dynamics of arbitration between decision-making strategies across obsessive-compulsive and related disorders. 2022 , 103073	O
426	Attention allocation to negatively-valenced stimuli in PTSD is associated with reward-related neural pathways. 1-9	O
425	Symptomwahrnehmung und -Berbewertung bei der Hypochondrie. 1977 , 224, 235-245	O
424	Predictive validity of the CognitiveVs. Somatic Anxiety Distinction. 1985 , 20, 177-180	2

423	Anxiety treatment of methamphetamine-dependent patients with buprenorphine: A randomized, double-blind, clinical trial. 2022 ,	
422	Setting up of an integrative center for the management of mild-moderate COVID-19. 2022, 3, 21	
421	Correlations of plasma oxytocin with clinical and hormonal parameters in panic disorder. 1-6	О
420	Effect of a Dietary Supplement Combining Bioactive Peptides and Magnesium on Adjustment Disorder with Anxiety: A Clinical Trial in General Practice. 2022 , 14, 2425	1
419	Association of Subclinical Hypothyroidism With Anxiety Symptom in Young First-Episode and Drug-NaWe Patients With Major Depressive Disorder. 13,	
418	Can living with COVID-19 patients in a hospital increase anxiety levels? A survey-based single-center study in Peru. 2022 , 19, em389	1
417	Efficacy and Tolerability of Cranial Electrotherapy Stimulation in the Treatment of Anxiety: A Systemic Review and Meta-Analysis. 13,	О
416	Health-Related Quality of Life in Cervical Dystonia Using EQ-5D-5L: A Large Cross-Sectional Study in China. 13,	O
415	Clinical Variants and Types of Course of Separation Anxiety Disorder in Adults.	
414	Relationship between Interpersonal Sensitivity Measure score and clinical symptoms in patients with major psychiatric disorders and healthy individuals. 2022 , 1,	
413	Defining brain-based OCD patient profiles using task-based fMRI and unsupervised machine learning.	
412	Neurological Symptoms and Their Associations With Inflammatory Biomarkers in the Chronic Phase Following Traumatic Brain Injuries. 13,	O
411	Successful psychopharmacotherapy of anxiety and depressive disorders improve functional limitations in patients with rheumatoid arthritis. 2022 , 94, 616-621	
410	Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice. Volume 18, 1175-1193	O
409	Baseline overly accommodating interpersonal problems in relation to parsed alliance-outcome associations in cognitive behavioral therapy for generalized anxiety disorder. 1-13	1
408	WHODAS Assessment Feasibility and Mental Health Impact on Functional Disability in Systemic Lupus Erythematosus. 2022 , 10, 1053	1
407	Acupuncture in the treatment of Dry Eye Syndrome with anxiety symptoms. A case report.	0
406	Cognitive Behavioral Therapy Program for Cannabis Use Cessation in First-Episode Psychosis Patients: A 1-Year Randomized Controlled Trial. 2022 , 19, 7325	

405	The Relationship Among BDNF Val66Met Polymorphism, Plasma BDNF Level, and Trait Anxiety in Chinese Patients With Panic Disorder. 13,	O
404	Psychotherapy for advanced cancer patients: A meta-analysis of the quality of life and survival assessments. 1-7	O
403	Infralow-frequency transcranial magnetic stimulation as a therapy for generalized anxiety disorder: A randomized clinical trial. 2022 , 117, 152332	
402	The prevalence and clinical correlates of suicide attempts in comorbid subclinical hypothyroidism in patients with never-treated major depressive disorder in China. 2022 , 312, 54-60	Ο
401	Rationale for the Development of the Standard for Clinicians Interview in Psychiatry (SCIP). 2022 , 21-69	
400	Historical Perspectives on the History of Measurement in Psychiatry. 2022 , 1-20	
399	Epidemiological Concepts and Measures in Psychiatry. 2022 , 177-192	
398	Body image and its association with depression, anxiety, and self-esteem among college going students: A study from Northeast India. 2022 , 47, 218	
397	Prevalencia de depresifi, ansiedad y factores asociados en mflicos residentes de centros hospitalarios durante la pandemia de COVID-19. 2022 , 69, 1-6	
396	The interplay between psychopathological symptoms: transdiagnostic cross-lagged panel network model. 2022 , 8,	
395	Differences in Brain Activity Between Dopa-Responsive and -Unresponsive Pain in Parkinson Disease.	
394	Mitochondrial modulators for obsessiveDompulsive and related disorders: a systematic review and meta-analysis. 2022 , 12,	1
393	Morning light treatment for traumatic stress: The role of amygdala reactivity study protocol. 2022 , 17, e0269502	О
392	Adverse childhood experiences and psychopathology in patients with OCD. 2022 , 23, 84-90	
391	Chronic fatigue, depression and anxiety symptoms in Long COVID are strongly predicted by neuroimmune and neuro-oxidative pathways which are caused by the inflammation during acute infection.	0
390	Apathy and impulsiveness in Parkinson disease: Two faces of the same coin?. 2022 , 101, e29766	О
389	Depression and anxiety in different hypertension phenotypes: a cross-sectional study. 2022 , 21,	O
388	Association between post-stroke psychological disorders, activity limitations and health-related quality of life in chronic stroke survivors in Benin. 1-8	1

387	Psychomotor semiology in depression: a standardized clinical psychomotor approach. 2022 , 22,	0
386	A systematic review and meta-analysis of treatments for rapid cycling bipolar disorder.	1
385	Prediction of the cognitive impairment development in patients with autoimmune thyroiditis and hypothyroidism. 2022 , 56, 178-189	
384	Incompleteness features in the descriptive discourse of Chinese elders with and without Alzheimer disease. 1-16	
383	Linked brain connectivity patterns with psychopathological and cognitive phenotypes in drug-naWe first-episode schizophrenia. 2022 , 2, 43-51	
382	Is auriculotherapy effective and safe for the treatment of anxiety disorders? [A systematic review and meta-analysis. 2022, 102157	O
381	Nonalcoholic Fatty Liver Disease and Altered Neuropsychological Functions in Patients with Subcortical Vascular Dementia. 2022 , 12, 1106	O
380	The physio-affective phenome of major depression is strongly associated with biomarkers of astroglial and neuronal projection toxicity which in turn are associated with peripheral inflammation, insulin resistance and lowered calcium.	O
379	Alterations in Functional and Structural Connectivity of Basal Ganglia Network in Patients with Obesity.	0
378	Effects of long-term supplementation of probiotics on cognitive function and emotion in temporal lobe epilepsy. 13,	O
377	What Works for Whom: Patients' Psychological Resources and Vulnerabilities as Common and Specific Predictors of Working Alliance in Different Psychotherapies. 13,	1
376	Retinal markers of therapeutic responses in major depressive disorder: Effects of antidepressants on retinal function. 2022 ,	
375	Pain-Related Factors and Their Impact on Quality of Life in Chinese Patients With Amyotrophic Lateral Sclerosis. 16,	
374	Association between the loudness dependence of auditory evoked potentials and age in patients with schizophrenia and depression. 2022 , 50, 030006052211097	
373	Trait Anxiety Mediates Impulsivity and Suicidal Ideation in Depression During COVID-19 Pandemic. 13,	1
372	Effects of group mindfulness-based cognitive therapy and group cognitive behavioural therapy on symptomatic generalized anxiety disorder: a randomized controlled noninferiority trial. 2022 , 22,	0
371	Demographic and clinical characteristics of lithium-treated older adults with bipolar disorder.	0
370	Reduced hippocampal gray matter volume is a common feature of patients with major depression, bipolar disorder, and schizophrenia spectrum disorders.	O

369	Cognitive Stimulation as Alternative Treatment to Improve Psychological Disorders in Patients with Mild Cognitive Impairment. 2022 , 11, 3947	0
368	Dehydroepiandrosterone sulfate levels predict weight gain in women with anorexia nervosa.	
367	Disentangling subjective symptom complaints and objective cognitive performance in veterans: Impact of posttraumatic stress disorder and lifetime traumatic brain injury burden. 1-16	
366	Association of Serum Interleukin-8 and Serum Amyloid A With Anxiety Symptoms in Patients With Cerebral Small Vessel Disease. 13,	1
365	Neural reactivity to affective stimuli and internalizing symptom dimensions in a transdiagnostic patient sample.	
364	Raga based music therapy amongst prediabetic: An analysis by HAM- A clinical anxiety scale. 2022 , 9, 103-106	
363	Safety and Efficacy of Continuous Theta Burst Intensivel Stimulation in Acute-Phase Bipolar Depression. Publish Ahead of Print,	О
362	Characteristics of 262 adults with skin picking disorder. 2022 , 117, 152338	O
361	Adjunctive home-based transcranial direct current stimulation treatment for major depression with real-time remote supervision: An open-label, single-arm feasibility study with long term outcomes. 2022 , 153, 197-205	О
3 60	What about mental health after one year of COVID-19 pandemic? A comparison with the initial peak. 2022 , 153, 104-108	O
359	A resting state fMRI study of major depressive disorder with and without anxiety. 2022 , 315, 114697	O
358	Gut Microbiome-Linked Metabolites in the Pathobiology of Major Depression With or Without Anxiety Role for Bile Acids. 16,	2
357	Cognitive behavioural therapy (group) for schizophrenia. 2022 , 2022,	1
356	Prevalence and factors associated with depression in people living with HIV/AIDS in a Brazilian metropolitan region. 1-6	
355	Differences in neuroanatomy and functional connectivity between motor subtypes of Parkinson disease. 16,	
354	Avalialo da ansiedade e depresso em familiares de crianlas em tratamento quimioterpico. 220-241	
353	The Reliability of symptom assessment by telepsychiatry compared with Face to Face Psychiatric Interviews. 2022 , 114728	
352	Lowered quality of life in Long COVID is strongly predicted by affective symptoms and chronic fatigue syndrome which are associated with inflammatory processes during the acute infectious phase and consequent neuroimmunotoxic pathways.	

351	Severity of depressive but not anxiety symptoms impacts glucose metabolism among patients with type 2 diabetes in primary care. 9,	
350	Characteristics of prefrontal activity during emotional and cognitive processing in patients with bipolar disorder: A multi-channel functional near-infrared spectroscopy study. 16,	
349	Neuronal Activity during Exposure to Specific Phobia through fMRI: Comparing Therapeutic Components of Cognitive Behavioral Therapy. 2022 , 12, 1132	O
348	Aripiprazole Improved Post-Streptococcal Dyskinesia by Modulating Dopaminergic Activity: A Case Report. 2022 , 20, 581-583	O
347	Aberrant brain dynamics in major depressive disorder with suicidal ideation. 2022, 314, 263-270	O
346	Analysis of the correlation between neuroimaging markers of the brain damage and the severity of postural instability in patients with chronic cerebrovascular insufficiency (NEMAN open observational study). 2022 , 122, 66	
345	Consistency Checks to Improve Measurement with the Hamilton Rating Scale for Anxiety (HAM-A).	
344	Shared and distinct patterns of dynamical degree centrality in bipolar disorder across different mood states. 13,	1
343	Educational intervention through a comic book for preoperative anxiety in children, adolescents, and their parents: A randomized clinical trial. 2022 ,	
342	World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders (Version 3. Part I: Anxiety disorders. 1-39	3
341	Case report: The feasibility of rTMS with intrathecal baclofen pump for the treatment of unresolved neuropathic pain following spinal cord injury. 3,	
340	Anxiety Disorders and Prediction of Their Development in Patients with Hypothyroidism and Autoimmune Thyroiditis. 2022 , 10, 1-10	
339	Goal Setting and Health-Related Outcomes in Chronic Diseases: A Systematic Review and Meta-Analysis of the Literature From 2000 to 2020. 107755872211132	1
338	Gut microbiome characteristics of comorbid generalized anxiety disorder and functional gastrointestinal disease: Correlation with alexithymia and personality traits. 13,	
337	Use of Artificial Intelligence for the Development of Predictive Model to Help in Decision-Making for Patients with Degenerative Lumbar Spine Disease.	
336	Audiological, Phonatory and Cardiac Correlates of Individuals Exposed to Low-Frequency Noise or at Risk of Vibroacoustic Disease.	
335	Serum brain-derived neurotrophic factor and glial cell-derived neurotrophic factor in patients with first-episode depression at different ages. 1-9	
334	Prognostic value of depression, anxiety disorders and inflammatory markers in patients with reduced and mildly reduced ejection fraction heart failure. 2022 , 19, 4-12	

333	Common and differential neural mechanisms underlying mood disorders.	
332	Lowered Quality of Life in Long COVID Is Predicted by Affective Symptoms, Chronic Fatigue Syndrome, Inflammation and Neuroimmunotoxic Pathways. 2022 , 19, 10362	1
331	Exploring the pathological relationships between adamantinomatous craniopharyngioma and contiguous structures with tumor origin.	
330	Identifying Biomarkers of Subjective Cognitive Decline Using Graph Convolutional Neural Network for fMRI Analysis. 2022 ,	
329	Sleep alterations following COVID-19 are associated with both neuroinflammation and psychological disorders, although at different times. 13,	O
328	The aberrant dynamic amplitude of low-frequency fluctuations in melancholic major depressive disorder with insomnia. 13,	
327	Acupuncture combined with auricular acupressure for smoking cessation and its effects on tobacco dependence and smoking behavior among Hong Kong smokers: a multicenter pilot clinical study. 2022 , 17,	
326	Neuromodulation of OCD: A review of invasive and non-invasive methods. 13,	1
325	Quantitative susceptibility mapping of basal ganglia iron is associated with cognitive and motor functions that distinguish spinocerebellar ataxia type 6 and type 3. 16,	
324	The relationship between resilience, anxiety, and depression in Chinese collegiate athletes. 13,	1
323	Differences between bipolar disorder types 1 and 2 support the DSM two-syndrome concept. 2022 , 10,	O
322	Reduced glucocorticoid receptor expression in blood mononuclear cells of patients with borderline personality disorder. 13,	
321	A Cross-sectional Study on Covid-19 Pandemic and Mental Illness in Healthcare Professionals.	
320	Anxiety-like behavior and tectal gene expression in a foraging/predator avoidance tradeoff task using adult African clawed frogs Xenopus laevis. 2022 , 76,	O
319	Integrity of cerebellar tracts associated with the risk of bipolar disorder. 2022, 12,	
318	Development and validation of a maternal anxiety for neonatal jaundice scale in China. 2022 , 22,	O
317	Pharmacological and psychological treatment have common and specific effects on brain activity in obsessive-compulsive disorder.	
316	Evaluation of the relationship between death anxiety and clinical features of the disease and functionality in patients with schizophrenia. 2022 , 8, e09911	0

315	Automated detection of panic disorder based on multimodal physiological signals using machine learning.	Ο
314	Online Yoga and Ayurveda Intervention as Tertiary Prevention of Psychological Comorbidities in COVID-19 Survivors: A Randomized Controlled Trial. 097275312211176	1
313	Blood neuroexosomal excitatory amino acid transporter-2 is associated with cognitive decline in Parkinson disease with RBD. 14,	Ο
312	Cerebellar engagement in the attachment behavioral system. 2022 , 12,	O
311	Freezing of gait in Parkinson disease is associated with the microstructural and functional changes of globus pallidus internus. 14,	0
310	Misophonia: Analysis of the neuroanatomic patterns at the basis of psychiatric symptoms and changes of the orthosympathetic/parasympathetic balance. 16,	
309	Time-dependent affective disturbances in abstinent patients with methylphenidate use disorder. 2022 , 22,	
308	Psychiatric Screening for Spinal Cord Stimulation for Complex Regional Pain Syndrome: A Literature Review and Practical Recommendations for Implementation. 2022 , 101633	
307	Efficacy and safety of deep brain stimulation for treatment-refractory anorexia nervosa: a systematic review and meta-analysis. 2022 , 12,	
306	Psychiatric and Psychosocial Characteristics of a Cohort of Spanish Individuals Attending Genetic Counseling Due to Risk for Genetically Conditioned Dementia. 2022 , 6, 461-478	
305	Neural and behavioral effects of modification of visual attention in body dysmorphic disorder. 2022 , 12,	
304	Body mass index related to executive function and hippocampal subregion volume in subjective cognitive decline. 14,	O
303	RORA rs8042149 polymorphism moderates the association between PTSD symptom severity and transverse temporal gyrus thickness in Han Chinese adults who lost their only child. 2022 , 314, 318-324	
302	Prevalence and related factors of anxiety in first episode and drug nalle Chinese Han outpatients with psychotic major depression. 2022 , 316, 217-222	O
301	Cognitive impairment, childhood trauma, sedentary behaviour, and elevated C-reactive protein levels in major affective disorders. 2022 , 155, 1-9	
300	Strategies to cope with stress and anxiety during the menopausal transition. 2022 , 166, 1-13	
299	Monospot and VP1 Tests in Chronic Fatigue Syndrome and Major Depression. 1992 , 85, 537-540	О
298	Effects of nursing support workers participation on negative emotions, quality of life and life satisfaction of patients with cerebral hemorrhage: a quasi-experimental study. 2022 , 21,	O

297	A multi-center, randomized, double-blinded, parallel, placebo-controlled study to assess the efficacy and safety of Shenqisuxin granule in complex coronary artery disease after PCI: Study protocol. 9,	O
296	Tractography-based versus anatomical landmark-based targeting in vALIC deep brain stimulation for refractory obsessive-compulsive disorder.	O
295	Anxiolytic and antidepressive potentials of rosmarinic acid: A review with a focus on antioxidant and anti-inflammatory effects. 2022 , 184, 106421	1
294	Multi-omics study reveals associations among neurotransmitter, extracellular vesicle-derived microRNA and psychiatric comorbidities during heroin and methamphetamine withdrawal. 2022 , 155, 113685	O
293	Disorder-specific impaired neurocognitive function in major depression and generalized anxiety disorder. 2022 , 318, 123-129	O
292	Impaired interhemispheric synchrony in Parkinson's disease patients with apathy. 2022 , 318, 283-290	O
291	Antidepressants. 2022 , 1139-1156	O
290	Altered dynamic amplitude of low-frequency fluctuation between bipolar type I and type II in the depressive state. 2022 , 36, 103184	O
289	Bibliographie. 2022 , 269-280	0
288	The role of premorbid personality in the genesis of psychopathological symptomatology in patients with organic anxiety-depressive disorder, schizophrenia and endogenous depression. 2022 , 122, 94	1
287	Executive dysfunction in eating disorders: Relationship with clinical features. 2023, 120, 110649	O
286	Telomerase enzyme activity in patients with major depressive disorder: A pre and post-treatment study. 2023 , 320, 268-274	O
285	Challenges in Recruiting University Students for Web-based Indicated Prevention of Depression and Anxiety: Results from a Randomized Controlled Trial (ICare Prevent) (Preprint).	0
284	The correlation of body mass index with clinical factors in patients with first-episode depression. 13,	O
283	Inhibition Predicts the Course of Depression and Anxiety Symptoms Among Adolescents. Publish Ahead of Print,	O
282	Analysing the influencing factors on caregivers Durden among amyotrophic lateral sclerosis patients in China: a cross-sectional study based on data mining. 2022 , 12, e066402	O
281	Cognitive impairment in Chinese patients with cervical dystonia. 13,	О
280	Metabolic parameters and thyroid hormones in relation to suicide attempts in patients with first-episode and drug-naive major depressive disorder with comorbid glucose disturbances: a large cross-sectional study.	O

279	Supplementary motor area driving changes of structural brain network in blepharospasm.	O
278	Mental health and cognitive outcomes in patients six months after testing positive compared with matched patients testing negative for COVID-19 in a non-hospitalized sample: A prospective cohort study.	O
277	Are bowel symptoms and psychosocial features different in irritable bowel syndrome patients with abdominal discomfort compared to abdominal pain?. 2022 , 28, 4861-4874	0
276	Research and Diagnostic Algorithmic Rules (RADAR) for mood disorders, recurrence of illness, suicidal behaviors, and the patient lifetime trajectory.	O
275	The clinical characterization of the adult patient with bipolar disorder aimed at personalization of management. 2022 , 21, 364-387	5
274	Deep Brain Stimulation in Obsessive-Compulsive disorder: results from meta-analysis. 2022 , 114869	O
273	Adjunctive neuronavigated accelerated continuous theta-burst stimulation in obsessive-compulsive disorder: a randomized sham-controlled study. 1-10	0
272	The impact of anxiety on the cognitive function of informal Parkinson disease caregiver: Evidence from task-based and resting-state fNIRS. 13,	O
271	Lowered oxygen saturation and increased body temperature in acute COVID-19 largely predict chronic fatigue syndrome and affective symptoms due to Long COVID: A precision nomothetic approach. 1-12	0
270	Depressive symptoms anticipate behavioral and emotional factors among older adults: A prospective cross-lagged panel design.	O
269	Abnormal resting-state functional connectivity of the insula in medication-free patients with obsessive-compulsive disorder.	0
268	Accumulation of evidence during decision making in OCD patients. 13,	O
267	Standard CBT versus integrative and multimodal CBT assisted by virtual-reality for generalized anxiety disorder. 13,	O
266	Prevalence and Predictive Factors of Masked Depression and Anxiety among Jordanian and Palestinian Couples: A Cross-Sectional Study. 2022 , 10, 1679	O
265	Associations of Mental Health Measures and Retention in a Community-Based Perinatal Care Recovery Support Program for Women of Childbearing Age With Substance Use Disorder. 1-9	0
264	White matter hyperintensities in Burning Mouth Syndrome assessed according to the Age-Related White Matter Changes scale. 14,	2
263	The Relationship Between Fear of COVID-19, Fear of Death and Anxiety in the Accompanists of Patients Diagnosed with COVID-19. 2022 , 38, 171-177	0
262	Complexity changes in functional state dynamics suggest focal connectivity reductions. 16,	O

261	Low frequency repetitive transcranial magnetic stimulation to the right dorsolateral prefrontal cortex engages thalamus, striatum, and the default mode network. 16,	0
260	Trauma exposure among cannabis use disorder individuals was associated with a craving-correlated non-habituating amygdala response to aversive cues 2022 , 100098	О
259	Mental health and quality of life in patients with craniofacial movement disorders: A cross-sectional study. 13,	O
258	Effectiveness and safety of Jiuwei Zhenxin granules for treating generalized anxiety disorder: A randomized controlled trial. 13,	О
257	Stress reduction interventions: A scoping review to explore progress toward use of haptic feedback in virtual reality. 3,	0
256	Effect of priming on adjunctive repetitive transcranial magnetic stimulation in treatment of late life depression: Protocol of a prospective randomized sham-controlled study. 1-21	О
255	The neuroscience of spirituality, religion, and mental health: A systematic review and synthesis. 2022 ,	O
254	Self-Management and Its Influential Factors Among Individuals With Anxiety Disorders: A Cross-Sectional Study. 1-9	О
253	The relevant research of adverse childhood experiences and fisky drinking In children of alcoholics in China.	O
252	Trait somatic anxiety is associated with reduced directed exploration and underestimation of uncertainty.	О
251	The role of the anterior insular cortex in self-monitoring: A novel study protocol with electrical stimulation mapping and functional magnetic resonance imaging. 2022 ,	0
250	Sensory processing in depression: Assessment and intervention perspective.	О
249	Neural effects of childhood maltreatment on dynamic large-scale brain networks in major depressive disorder. 2022 , 317, 114870	0
248	Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study). 2022 , 319, 646-654	1
247	Intrasubject subcortical quantitative referencing to boost MRI sensitivity to Parkinson's disease. 2022 , 36, 103231	O
246	Clinical Rating Instruments in Tourette Syndrome. 2022 , 343-365	О
245	EFFECT OF PRANAYAMA (SPECIFIED BREATHING EXERCISE) ON STRESS & AMP; ANXIETY AMONG THE STUDENTS IN TRINCOMALEE CAMPUS, EASTERN UNIVERSITY SRI LANKA. 2022 , 11, 124-130	O
244	Effects of reminiscence therapy on anxiety and depression during acute hospitalization in older patients: Controlled study.	О

243	High-definition transcranial direct current stimulation (HD-tDCS) as augmentation therapy in late-life depression (LLD) with suboptimal response to treatment study protocol for a double-blinded randomized sham-controlled trial. 2022 , 23,	O
242	The effect of body satisfaction on female sexual life after bariatric surgery: a follow-up study. 2022 , 4, 401-406	O
241	Telomere Length and Mitochondrial DNA Copy Number Variations in Patients with Obesity: Effect of Diet-Induced Weight Loss Pilot Study. 2022 , 14, 4293	О
240	Psyche: The 5th Pland its Impact on the Second Stage of Labor.	O
239	Psychiatric Symptoms in Parkinson Disease Patients before and One Year after Subthalamic Nucleus Deep Brain Stimulation Therapy: Role of Lead Positioning and Not of Total Electrical Energy Delivered. 2022 , 12, 1643	O
238	Comparison of Obsessive-Compulsive Disorder and Schizophrenia With Comorbid Obsessive-Compulsive Disorder in Terms of Insight, Metacognitive Beliefs, and Clinical Features. Publish Ahead of Print,	O
237	The influence of ideological education on students[mental health during the pandemic: An empirical analysis based on big data and intelligent model. 13,	O
236	Effect of anxiolytic drug silexan on sleep 🗈 narrative review. 1-8	2
235	Polygenic heterogeneity in antidepressant treatment and placebo response. 2022 , 12,	О
234	The effect of an integrated care intervention of multidisciplinary mental health treatment and employment services for trauma-affected refugees: study protocol for a randomised controlled trial. 2022 , 23,	1
233	Structural hyperconnectivity of the subthalamic area with limbic cortices underpins anxiety and impulsivity in Tourette syndrome.	O
232	Executive dysfunction in affective disorders: differences in bipolar affective disorder and depressive episode. 2022 , 21, 28-33	O
231	Motor progression marker for newly diagnosed drug-naWe patients with Parkinson's disease: A resting-state functional MRI study.	О
230	How do customer anxiety levels impact relationship marketing in electronic commerce?. 2022 , 9,	O
229	Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: a proof of concept and mechanism study.	1
228	Cortical gyrification differences between early- and late-onset obsessivedompulsive disorder: neurobiological evidence for neurodevelopmentally distinct subtypes. 1-10	O
227	Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial. 2022 , 2,	1
226	The Potential Impact of Age on Gut Microbiota in Patients with Major Depressive Disorder: A Secondary Analysis of the Prospective Observational Study. 2022 , 12, 1827	O

225	Characteristics of sleep structure in Parkinson's disease patients with hallucinations based on polysomnography. 13,	0
224	The effectiveness of postpartum interventions aimed at improving women mental health after medical complications of pregnancy: a systematic review and meta-analysis. 2022 , 22,	O
223	Prevalence and correlates of sleep quality in the Chinese college students with migraine: a cross-sectional study. 16,	0
222	Genetic analysis of and clinical characteristics associated with ANXA11 variants in a Chinese cohort with amyotrophic lateral sclerosis. 2022 , 175, 105907	O
221	Ventral striatal subregional dysfunction in late-life grief: Relationships with yearning and depressive symptoms. 2022 , 156, 252-260	0
220	A double blind randomized clinical trial of the effectiveness of low frequency rTMS over right DLPFC or OFC for treatment of obsessive-compulsive disorder. 2022 , 156, 122-131	O
219	Randomized Controlled Trials and the Efficacy of Psychotropic Medications. 2022, 305-359	Ο
218	Psychopathology: Rating Scales for the Assessment of Mental Status. 2022 , 245-267	O
217	Psychosocial factors associated with anxious depression. 2023 , 322, 39-45	О
216	Cognitive behavioral therapy in patients with deep brain stimulation for obsessive-compulsive disorder: a matched controlled study. 1-7	O
215	Efficacy of whole system ayurveda protocol in irritable bowel syndrome IA Randomized controlled clinical trial. 2022 , 100592	О
214	Long-lasting cognitive effects of COVID-19: is there a role of BDNF?.	1
213	A Hybrid Ecological Momentary Compassion E ocused Intervention for Enhancing Resilience in Help-Seeking Young People: Prospective Study of Baseline Characteristics in the EMIcompass Trial. 2022 , 6, e39511	0
212	Psychometric properties of the Italian body shape questionnaire: an investigation of its reliability, factorial, concurrent, and criterion validity.	Ο
211	Genetic and clinical characteristics of ALS patients with NEK1 gene variants. 2022,	О
210	Alteration of gut microbiota in migraine patients with irritable bowel syndrome in a Chinese Han population. 13,	O
209	Research and Diagnostic Algorithmic Rules (RADAR) for mood disorders, recurrence of illness, suicidal behaviors, and the patient lifetime trajectory. 1-42	0
208	Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: A double-blind, randomized, placebo-controlled trial.	O

207	Psychopathological profile and sagittal alignment in low-back pain. 2022, 103474	O
206	Anxious fluctuators subgroup of Parkinson's disease with high anxiety and problematic on-off fluctuations. 2022 , 105, 62-68	O
205	Illegal behaviors as a consequence of gambling disorder.	О
204	The effect of mindfulness and metacognition on anxiety symptoms: a case-control study. 2022 , 29,	O
203	Density-Based Unsupervised Learning Algorithm to Categorize College Students into Dropout Risk Levels. 2022 , 7, 165	2
202	Retrospective chart review-based assessment scale for adverse childhood events and experiences. 2022 , 1,	O
201	Specific and common functional connectivity deficits in drug-free generalized anxiety disorder and panic disorder: A data-driven analysis. 2023 , 319, 114971	0
200	Employment Inclusion Policies and Evidence-Based Policy: Incorporating Qualitative Significance Into a Mixed-Methods Study Protocol. 2022 , 21, 160940692211452	O
199	A preliminary descriptive report of the longevity of the effects of Swedish Massage therapy for subjects with Generalized Anxiety Disorder. 2023 , 33, 176-181	0
198	Reduction of anxiety and pain in primigravida mothers with modified lyengar yoga: A clinical study. 2023 , 14, 100584	O
197	Clinical correlates of autoimmune thyroiditis and non-autoimmune hypothyroidism in treatment-nalle patients with major depressive disorders. 2023 , 323, 755-761	O
196	Depressive symptoms anticipate behavioral and emotional factors among older adults: A prospective cross-lagged panel design. 2023 , 3, 100096	O
195	Comparison of bipolar disorder type II and major depressive disorder. 2023 , 323, 204-212	O
194	Alternations of vitamin D and cognitive function in first-diagnosed and drug-nalle BD patients: Physical activity as a moderator. 2023 , 323, 153-161	O
193	Memory-driven eye movements prospectively predict dementia in people at risk of Alzheimer's disease. 2022 , 14,	0
192	Attentional bias to negative emotions in anxious individuals: an eye tracking study. 2022,	O
191	Proactive psychological and psychiatric support of patients with chronic non-communicable diseases in a randomised trial: a Ukrainian experience. 2022 , 35, e100881	0
190	Characteristics of suicidal poisoned patients admitted to tertiary care center during COVID-19 pandemic. 2022 , 58,	O

189	Genetic and phenotypic spectrum of amyotrophic lateral sclerosis patients with CCNF variants from a large Chinese cohort.	0
188	In Schizophrenia, the Effects of the IL-6/IL-23/Th17 Axis on Health-Related Quality of Life and Disabilities Are Partly Mediated by Generalized Cognitive Decline and the Symptomatome. 2022 , 19, 15281	o
187	Abnormal resting-state functional connectivity of the insula in medication-free patients with obsessive-compulsive disorder. 2022 , 22,	0
186	Can Circadian Rhythm Predict Neurocognitive Functioning and Treatment Response in Bipolar Disorder Patients: Protocol of A 12-month Prospective Observational Study.	o
185	Associations between adverse childhood experiences and depressive and anxiety symptoms in adolescents and young adults.	O
184	The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial. 2022 , 22,	o
183	Effects of Toxoplasma gondii infection on cognition, symptoms, and response to digital cognitive training in schizophrenia. 2022 , 8,	О
182	Mechanisms of improvement in generalized anxiety disorder: A mediation and moderated mediation analysis from a randomized controlled trial.	О
181	Plasma complement C3 and C3a are increased in major depressive disorder independent of childhood trauma. 2022 , 22,	O
180	Disrupted topological organization of the motor execution network in Wilson's disease. 13,	o
179	The efficacy of a transdiagnostic group cognitive behavioral intervention for Chinese elderly with emotional disorders: A one-year follow-up randomized clinical trial. 13,	0
178	Anxiety Levels of Hypertensive Patients Against the Implementation of Covid-19 Vaccination in the Work Area of the Kawatuna Health Center. 2022 , 1, 129-132	o
177	Menopause: Questions and Answers for Improving Homeopathic Clinical Practice.	0
176	Evaluation of Electroconvulsive Therapy in Adolescents With Major Depressive and Bipolar Disorders. Publish Ahead of Print,	o
175	Cerebral Venous-Associated Brain Damage May Lead to Anxiety and Depression. 2022 , 11, 6927	0
174	Nomogram for Prediction of Postoperative Delirium after Deep Brain Stimulation of Subthalamic Nucleus in Parkinson Disease under General Anesthesia. 2022 , 2022, 1-12	o
173	Impact of direct-acting antivirals on neuropsychiatric and neurocognitive dysfunction in chronic hepatitis C patients. 2022 , 58,	0
172	A 19-Year-Old Adolescent with Probable Alzheimer Disease. 2022, 1-8	2

171	Laparoscopic sleeve gastrectomy induces simultaneous changes in brain functions and structures that are associated with weight loss. 1-26	O
170	Association of violent video gaming with mental health among male teenagers in Lebanon. 1-11	O
169	A transdiagnostic systematic review and meta-analysis of ketaminell anxiolytic effects.	О
168	The impact of cerebral small vessel disease burden and its imaging markers on gait, postural control, and cognition in Parkinson disease.	O
167	Brief online psychotherapy for psychogenic non-epileptic seizures using the psychoeducation-motivational interviewing- self appraisal- grounding (PMSG) model: A multiple baseline case series study. 2022 , 1, 100080	O
166	Causal Model Analysis of the Effect of Policy Formalism, COVID-19 Fear, Social Support and Work Stress on Construction Workers Anxiety during the Epidemic. 2023 , 13, 10	1
165	Clinical and Sociodemographic Variables as Risk Factors for Suicidal Behavior in Borderline Personality Disorder: A Restrospective Study. 2022 ,	0
164	Augmentation therapy with tandospirone citrate in vascular depression patients with mild cognitive impairment: A prospective randomized clinical trial. 2022 ,	O
163	Altered patterns of central executive, default mode and salience network activity and connectivity are associated with current and future depression risk in two independent young adult samples.	O
162	Post-COVID-19 Psychiatric Symptoms in the Elderly: The Role of Gender and Resilience. 2022 , 12, 2016	O
161	Suicide Risk in Post-COVID-19 Syndrome. 2022 , 12, 2019	1
160	Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review.	O
159	Transcutaneous electrical cranial-auricular acupoint stimulation versus escitalopram for mild-to-moderate depression: An assessor-blinded, randomized, non-inferiority trial.	O
158	Research and Diagnostic Algorithmic Rules (RADAR) and RADAR plots for the first episode of major depressive disorder: effects of childhood and recent adverse experiences on suicidal behaviors, neurocognition and phenome features.	O
157	QUALITY OF LIFE AND MENTAL HEALTH IN MULTIPLE SLCEROSIS PATIENTS DURING THE COVID-19 PANDEMIC 2022 , 104487	1
156	A scoping review to identify process and outcome measures used in acceptance and commitment therapy research, with adults with acquired neurological conditions. 026921552211445	O
155	Clinical health psychology and cardiac surgery. 1996 , 1, 5-8	O
154	Conceptual framework for a positive psychology coaching practice. 2018 , 14, 16-25	O

153	Psychometric evaluation of the Chinese version of fear of hospitalization scale among outpatients: A validation study. 13,	О
152	The Rossy Progressive Supranuclear Palsy Centre: creation and initial experience. 1-28	О
151	Altered Fractional Amplitude of Low-Frequency Fluctuation in Anxious Parkinson Disease. 2023 , 13, 87	O
150	Prevalence of suicide attempts and correlates among first-episode and untreated major depressive disorder patients with comorbid dyslipidemia of different ages of onset in a Chinese Han population: a large cross-sectional study. 2023 , 23,	O
149	Acupoint stimulation for alcohol use disorder: A systematic review and meta-analysis. 2023, 102, e32614	O
148	Psychoneurological symptoms and inflammatory markers in patients with glioma in China: a network analysis.	O
147	The relevant research of adverse childhood experiences and l isky drinkinglin children of alcoholics in China. 2023 , 23,	O
146	Add-On Intermittent Theta Burst Stimulation Improves the Efficacy of First-Episode and Recurrent Major Depressive Disorder: Real-World Clinical Practice. Volume 19, 109-116	Ο
145	Duration of untreated illness and clinical correlates in first-episode and drug-naMe patients with major depressive disorder. 2023 , 115056	0
144	Into the Unknown: Exploration of Search Engines[Responses to Users with Depression and Anxiety.	O
143	In end-stage kidney disease, inflammation, erythron abnormalities and declined kidney function tests are accompanied by increased affective symptoms, chronic-fatigue, and fibromyalgia.	O
142	How Does Anxiety Affect the Relationship between the Customer and the Omnichannel Systems?. 2023 , 18, 130-149	1
141	Chronic Fatigue, Depression and Anxiety Symptoms in Long COVID Are Strongly Predicted by Neuroimmune and Neuro-Oxidative Pathways Which Are Caused by the Inflammation during Acute Infection. 2023 , 12, 511	0
140	Dissociable salience and default mode network modulation in generalized anxiety disorder: a connectome-wide association study.	O
139	A prospective cohort study of depression (PROUD) in China: rationale and design. 2023, 2,	0
138	Prevalence and risk factors of psychotic symptoms in middle-aged patients with first-episode drug-nale major depressive disorder: A large-scale cross-sectional study. 2023 , 325, 102-109	O
137	Consistency checks to improve measurement with the Hamilton Rating Scale for Anxiety (HAM-A). 2023 , 325, 429-436	0
136	Metabolic characteristics, prevalence of anxiety and its influencing factors in first-episode and drug-na∏e major depressive disorder patients with impaired fasting glucose. 2023 , 324, 341-348	O

135	State of illness-dependent associations of neuro-cognition and psychopathological syndromes in a large transdiagnostic cohort. 2023 , 324, 589-599	О
134	Effects of attention bias modification for anxiety: Neurophysiological indices and moderation by symptom severity. 2023 , 147, 45-57	Ο
133	The prevalence and clinical correlates of anxiety in Chinese patients with first-episode and drug-nalle major depressive disorder at different ages of onset. 2023 , 325, 306-312	0
132	Asociacifi de sobrepeso u obesidad con trastornos del estado de filmo en adolescentes. 2018 , 68, 321-327	O
131	Clinical Psychiatry in the Nursing Home. 2022 ,	О
130	Orbitofrontal Cortex Volumes in Patients Diagnosed with Somatic Symptom Disorder.	O
129	Bilateral Theta Burst Stimulation on Emotional Processing in Major Depressive Disorder: A Functional Neuroimaging Study from a Randomized, Double-blind, Sham-controlled Trial.	Ο
128	The Effect of Zao Ren An Shen Capsule on Insomnia among Patients with Anxiety: A Randomized Controlled Trial. 2022 , 2022, 1-8	O
127	1999 19	О
126	Assessing the Mental Condition of Paramedics and Nurses during the SARS-CoV-2 Pandemic. 2023 , 13, 70	O
125	Complementary and alternative therapies for generalized anxiety disorder: A protocol for systematic review and network meta-analysis. 2022 , 101, e32401	О
124	Mood symptoms and chronic fatigue syndrome due to relapsing remitting multiple sclerosis are associated with immune activation and aberrations in the erythron.	O
123	A nomogram based on iron metabolism can help identify apathy in patients with Parkinson disease. 14,	О
122	Prevalence and Correlates of Police Contact Anxiety among Male and Female Black Emerging Adults in St. Louis, Missouri.	O
121	Importancia y generalidades de la valoracifi gerifirica integral como herramienta de abordaje de la persona mayor en atencifi domiciliaria. 2022 , 63,	О
120	Cyclic versus continuous deep brain stimulation in patients with obsessive compulsive disorder: A randomized controlled trial. 2023 , 16, 82-87	O
119	The Role of Lifestyle on Adherence to Treatment in a Sample of Patients with Unipolar and Bipolar Depression. 2023 , 20, 1994	0
118	Pharmacological Treatment of Bipolar Depression: A Review of Observational Studies. 2023 , 16, 182	Ο

117	Burning Mouth Syndrome and Hypertension: Prevalence, Gender Differences and Association with Pain and Psycho-Social Characteristics Case Control Study. 2023 , 20, 2040	1
116	Understanding the Psychological Well-being of Patients With Locked-in Syndrome: A Scoping Review. 2023 ,	О
115	Graph analysis of diffusion tensor imaging-based connectome in young men with internet gaming disorder. 16,	О
114	Cognitive-behavioral therapy for anxiety disorders in Italian mental health services. 2023 , 343-354	О
113	Low Levels of Adenosine and GDNF Are Potential Risk Factors for Parkinson® Disease with Sleep Disorders. 2023 , 13, 200	0
112	Prevalence of hypertension and correlation with mental health in women with burning mouth syndrome: A case-control study. 9,	О
111	Vortioxetine in patients with major depressive disorder and high levels of anxiety symptoms: An updated analysis of efficacy and tolerability. 2023 ,	0
110	Assessing Gambling Disorder Using Semistructured Interviews or Self-Report? Evaluation of the Structured Clinical Interview for Gambling Disorder Among Swedish Gamblers. 107319112211470	O
109	A multimodal imaging approach to foreign accent syndrome. A case report. 1-10	0
108	Low oxytocin levels are broadly associated with more pronounced psychopathology in anorexia nervosa with primarily restricting but not binge/purge eating behavior. 13,	О
107	Efficacy of Silexan in patients with anxiety disorders: a meta-analysis of randomized, placebo-controlled trials.	0
106	The Change of Suicidal Ideation Over a 12-Week Naturalistic Treatment of Depression: Comparison Between Young People and Older Adults. 2023 , 20, 9-17	O
105	Cognitive stimulation to improve cognitive functioning in people with dementia. 2023, 2023,	1
104	Estr§ postraumtico y su relacifi con la ansiedad en Bomberos operativos. 2023 , 4,	О
103	Effects of a Novel, Transdiagnostic Ecological Momentary Intervention for Prevention, and Early Intervention of Severe Mental Disorder in Youth (EMIcompass): Findings From an Exploratory Randomized Controlled Trial.	О
102	The role of baseline insomnia in moderating the hypnotic properties of quetiapine. 2023 , 140, 107622	O
101	A cross sectional study of quality of sleep, burnouts, anxiety and depression in rotatory shift workers of sir T hospital bhavnaga. 2023 , 0	О
100	Early outcomes, associated factors and predictive values of clinical outcomes of tandospirone in generalized anxiety disorder: a post-hoc analysis of a randomized, controlled, multicenter clinical trial. 2023 , 39, 597-603	O

99	A Systematic Review and Meta-analysis of the Psychiatric Morbidities and Quality of Life Differences Between Men and Women in Infertile Couples. 2023 ,	O
98	Salivary Biomarkers Analysis and Neurobehavioral Assessment in Nurses Working Rotation Shifts: A Pilot Study. 2023 , 20, 5376	O
97	Decision-Making Capacity of Elderly Patients with Mixed Depression-Anxiety Disorder.	O
96	The association between antihypertensive medications and mental health outcomes among Syrian war refugees with stress and hypertension. 2023 , 168, 111200	O
95	Multiple sclerosis and anxiety: Is there an untapped opportunity for exercise?. 2023, 73, 104698	O
94	Associations of blood UCH-L1 and NfL levels with cognitive dysfunction in Parkinson⊠ disease patients. 2023 , 804, 137219	O
93	Neurophysiological markers of depression detection and severity prediction in first-episode major depressive disorder. 2023 , 331, 8-16	O
92	The physio-affective phenome of major depression is strongly associated with biomarkers of astroglial and neuronal projection toxicity which in turn are associated with peripheral inflammation, insulin resistance and lowered calcium. 2023 , 331, 300-312	O
91	Stress levels, psychological symptoms, and C-reactive protein levels in COVID-19: A cross-sectional study. 2023 , 330, 216-226	O
90	Psychological Distress and Quality of Life Among Childless Couples Undergoing Infertility Treatment: A Narrative Review. 2022 , 18, 396-401	O
89	Altered gray matter volumes and plasma IL-6 level in major depressive disorder patients with suicidal ideation. 2023 , 103403	0
88	Dynamic flexibility and controllability of network communities in juvenile myoclonic epilepsy. 2023 , 179, 106055	O
87	Prevalence and risk factors of thyroid dysfunction in outpatients with overweight or obese first-episode and drug-nalle major depressive disorder. 2023 , 328, 135-140	0
86	Methylome changes associated with functional movement/conversion disorder: Influence of biological sex and childhood abuse exposure. 2023 , 125, 110756	O
85	First episode psychosis during the Covid-19 pandemic in Milan, Italy: Diagnostic outcomes at 1-year follow-up. 2023 , 321, 115068	0
84	Efficacy and Safety of Escitalopram, Desvenlafaxine, and Vortioxetine in the Acute Treatment of Anxious Depression: A Randomized Rater-blinded 6-week Clinical Trial. 2023 , 21, 135-146	O
83	Hair cortisol as a biomarker for mood in bipolar disorder: a pilot study.	0
82	Profil psycho-pathologique et alignement sagittal chez des patients lombalgiques. 2023 , 109, 192-196	Ο

81	An Intervention on Anxiety Symptoms in Moderate Alzheimer Disease through Virtual Reality: A Feasibility Study and Lessons Learned. 2023 , 20, 2727	2
80	The understated issue of caregiver anxiety for pediatric surgical hospital admissions: opening the blindfolds. 2023 , 39,	O
79	Latent class analysis of psychotic-affective disorders with data-driven plasma proteomics. 2023, 13,	0
78	Transcutaneous Electrical Cranial-Auricular Acupoint Stimulation Modulating the Brain Functional Connectivity of Mild-to-Moderate Major Depressive Disorder: An fMRI Study Based on Independent Component Analysis. 2023 , 13, 274	O
77	Meta-analysis of the effects of adjuvant drugs in co-occurring bipolar and substance use disorder. 2023 ,	0
76	Systematic review of probiotics as an adjuvant treatment for psychiatric disorders. 17,	1
75	Effect of botulinum toxin type A on non-motor symptoms and quality of life in Meige syndrome. 14,	o
74	Mood symptoms and chronic fatigue syndrome due to relapsing remitting multiple sclerosis are associated with immune activation and aberrations in the erythron	О
73	Anxiety and depression in keratotic oral lichen planus: a multicentric study from the SIPMO.	0
72		
72	Headache comorbidity in refugees and migrants with post-traumatic stress disorder. 2023 , 43, 033310242	211475
71	Headache comorbidity in refugees and migrants with post-traumatic stress disorder. 2023 , 43, 033310242 Association of thyroid function with abnormal lipid metabolism in young patients with first-episode and drug nale major depressive disorder. 14,	0
	Association of thyroid function with abnormal lipid metabolism in young patients with first-episode	
71	Association of thyroid function with abnormal lipid metabolism in young patients with first-episode and drug nalle major depressive disorder. 14, Caudate gray matter volumes and risk of relapse in Type A alcohol-dependent patients: A 7-year	О
7 ¹	Association of thyroid function with abnormal lipid metabolism in young patients with first-episode and drug nalle major depressive disorder. 14, Caudate gray matter volumes and risk of relapse in Type A alcohol-dependent patients: A 7-year MRI follow-up study. 14, Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A	0
71 70 69	Association of thyroid function with abnormal lipid metabolism in young patients with first-episode and drug naWe major depressive disorder. 14, Caudate gray matter volumes and risk of relapse in Type A alcohol-dependent patients: A 7-year MRI follow-up study. 14, Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. 2023, 180, 241-251	O O 2
71 70 69	Association of thyroid function with abnormal lipid metabolism in young patients with first-episode and drug nale major depressive disorder. 14, Caudate gray matter volumes and risk of relapse in Type A alcohol-dependent patients: A 7-year MRI follow-up study. 14, Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. 2023, 180, 241-251 Serum inflammatory cytokines levels and the correlation analyses in Parkinson® disease. 11, Prevalence and risk factors for abnormal tandem gait in patients with essential tremor syndrome: A	O O 2
71 70 69 68	Association of thyroid function with abnormal lipid metabolism in young patients with first-episode and drug naWe major depressive disorder. 14, Caudate gray matter volumes and risk of relapse in Type A alcohol-dependent patients: A 7-year MRI follow-up study. 14, Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study. 2023, 180, 241-251 Serum inflammatory cytokines levels and the correlation analyses in Parkinson® disease. 11, Prevalence and risk factors for abnormal tandem gait in patients with essential tremor syndrome: A cross-sectional study in Southwest China. 14, Differences in intracellular protein levels in monocytes and CD4+ lymphocytes between bipolar depressed patients and healthy controls: A pilot study with tyramine-based signal-amplified flow	O O O O

63	Double-Blind Placebo-Controlled Study of Memantine in Trichotillomania and Skin-Picking Disorder.	O
62	Application of Stress and Anxiety to Viral Epidemics-6 to Measure the Anxiety Response of Cold Chain Practitioners During the COVID-19 Post-Pandemic Era in China. 2023 , 20, 75-83	O
61	Exopioid Receptor Plasma Levels Are Associated With Sex and Diagnosis of Major Depressive Disorder But Not Response to Ketamine. 2023 , 43, 89-96	O
60	Importance of telemedicine in mild cognitive impairment and Alzheimer disease patients population during admission to emergency departments with COVID-19. 2023 , 102, e32934	O
59	A Comparison of Psychological Well-Being, Coping Strategies, and Emotional Problems Between Taiwanese and Australian Nursing Students. 2023 , 31, e264	O
58	Shared and unique effects of ApoEA and pathogenic gene mutation on cognition and imaging in preclinical familial Alzheimer disease. 2023 , 15,	O
57	Altered neuroimaging patterns of cerebellum and cognition underlying the gait and balance dysfunction in cerebral small vessel disease. 15,	О
56	Psychiatric symptomatology in skin-restricted lupus patients without axis I psychiatric disorders: A post-hoc analysis. 2023 , 18, e0282079	O
55	Factors associated with hopelessness, depression and anxiety in the Honduran-Central America population during the COVID-19 pandemic. 14,	0
54	Emotional subtypes in patients with depression: A cluster analysis.	O
53	Factors of Anxiety-Affective Symptoms Persistence in Depressions of Various Origins. 2023, 21, 34-42	0
52	Serum angioneurin levels following electroconvulsive therapy for mood disorders.	O
51	Impact of educational and psychological interventions compared with standard care in college/university students with autism spectrum disorder: a systematic review protocol. Publish Ahead of Print,	0
50	Prevalence, risk factors and clinical correlates of glucose disturbances in a large sample of Han Chinese patients with first-episode drug-nalle major depressive disorder.	O
49	Functional connectivity between pre-supplementary motor area and inferior parietal lobule associated with impaired motor response inhibition in first-degree relatives of patients with obsessive-compulsive disorder.	O
48	Treatment of Refractory Myofascial Pain of the Neck and Shoulder Girdle with Botulinum Toxin A. 2023 , 79-88	O
47	TRPV1 is a risk factor for sleep disturbance in patients with gastro-oesophageal reflux disease: a case control study. 1-12	O
	Effect of health education-based yoga & naturopathy lifestyle interventions on personality of	

45	Tryptophan catabolites, inflammation, and insulin resistance as determinants of chronic fatigue syndrome and affective symptoms in Long COVID.	О
44	Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial. 026988112311548	O
43	Association between Inflammation and Thrombotic Pathway Link with Pathogenesis of Depression and Anxiety in SLE Patients. 2023 , 13, 567	О
42	Clinical characteristics associated with relapse 2 years after electroconvulsive therapy for major depression.	O
41	A Cross-over Trial of Chlordiazepoxide-with-Amitriptyline and Amitriptyline alone. 1969 , 23, 459-461	0
40	Lorazepam in Sexual Disorders. 1975 , 29, 175-176	1
39	Improving the effectiveness of pharmacotherapy in comorbid patients with chronic cerebral ischemia on an outpatient basis. 2023 , 123, 51	О
38	Exploring the Potential of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 as Promising Psychobiotics Using SHIME. 2023 , 15, 1521	O
37	Neurofunctional Correlates of Activities of Daily Living in Patients with Posterior Cortical Atrophy. 2023 , 1-11	0
36	Effects of transcranial direct current stimulation (tDCS) in K iss nightclub fire[patients with post-traumatic stress disorder (PTSD): A phase II clinical trial. 2023 , 11, 205031212311609	O
35	Dectin-1 signaling on colonic IT cells promotes psychosocial stress responses. 2023 , 24, 625-636	О
34	Potentiated processing of reward related decision making in depression is attenuated by suicidal ideation. 2023 , 332, 111635	o
33	Elevated serum platelet count inhibits the effects of brain functional changes on cognitive function in patients with mild cognitive impairment: A resting-state functional magnetic resonance imaging study. 15,	О
32	Fronto-striato-thalamic circuit connectivity and neuromelanin in schizophrenia: an fMRI and neuromelanin-MRI study.	O
31	Abnormal focal segments in left uncinate fasciculus in adults with obsessiveBompulsive disorder. 14,	О
30	The impact of treatment resistance on outcome and course of electroconvulsive therapy in major depressive disorder.	O
29	Effect of fluvoxamine on preventing neuropsychiatric symptoms of post COVID syndrome in mild to moderate patients, a randomized placebo-controlled double-blind clinical trial. 2023 , 23,	0
28	Perseverative thinking is associated with features of spoken language. 2023 , 104307	O

27	Promoting Recovery from Disasters, Pandemics, and Trauma: A Systematic Review of Brief Psychological Interventions to Reduce Distress in Adults, Children, and Adolescents. 2023 , 20, 5339	0
26	ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH CARDIOVASCULAR COMPLAINTS AND ANXIETY DURING THE RUSSIAN-UKRAINIAN WAR: CASE SERIES. 2023 ,	O
25	Differential relationship of observer-rated and self-rated depression and anxiety scales with heart rate variability features. 14,	O
24	A transdiagnostic systematic review and meta-analysis of ketamine∃anxiolytic effects. 026988112311616	O
23	The effect of regular exercise on depression, anxiety, treatment motivation and mindfulness in addiction: a randomized controlled trial. 1-8	O
22	Guided self-help for anxiety among Huntington disease gene expansion carriers (GUIDE-HD) compared to treatment as usual: a randomised controlled feasibility trial.	O
21	Comparisons of 25 cerebrospinal fluid cytokines in a casefontrol study of 106 patients with recent-onset depression and 106 individually matched healthy subjects. 2023 , 20,	О
20	Efficacy of dynamic interpersonal therapy for major depressive disorder in China: results of a multicentered, three-arm, randomized, controlled trial. 1-13	O
19	Relationship Matters in Dementia Caregiving: A Comparative Study in West Bengal, India. 2277436X2311529	О
18	COPD Assessment Test as a Screening Tool for Anxiety and Depression in Stable COPD Patients: A Feasibility Study. 2023 , 20, 144-152	О
17	Association between Cognitive Impairment and Freezing of Gait in Patients with Parkinson Disease. 2023 , 12, 2799	Ο
16	Anxiety Neurosis in General Practice. 1974 , 28, 65-66	Ο
15	A 2-year longitudinal evaluation of the impact of the COVID-19 pandemic on individuals with pre-existing anxiety disorders. 1-8	O
14	A Controlled Trial of Anxiolytic Therapy in Pre-Operative Patients. 1982 , 36, 261-265	O
13	Effect of electroacupuncture treatment combined with rehabilitation care on serum sirt3 level and motor function in elderly patients with stroke hemiparesis. 2023 , 102, e33403	O
12	The Controlled Evaluation of a New Tranquillizing Drug Medazepam in the Treatment of Anxiety. 1971 , 25, 172-174	1
11	Husband and Healthcare Provider Support Toward the Prenatal Anxiety in Indonesia. 2023, 416-424	О
10	Parkinson disease patients combined with constipation tend to have higher serum expression of microRNA 29c, prominent neuropsychiatric disorders, possible RBD conversion, and a substandard quality of life.	О

9	T helper-1 activation via interleukin-16 is a key phenomenon in the acute phase of severe, first-episode major depressive disorder and suicidal behaviors.	O
8	The neuropsychology of healthy aging: the positive context of the University of the Third Age during the COVID-19 pandemic. 2023 , 13,	O
7	The current state-of-the-art in pharmacotherapy for pediatric generalized anxiety disorder. 1-13	0
6	Childhood trauma and its influence on the clinical features of bipolar disorder. 2023 , 141, 106203	o
5	Association between subclinical hypothyroidism and psychotic features in Chinese young adults with first-episode and untreated major depressive disorder. 2023 ,	О
4	Impact of pharmaceutical care integrated at a psychosocial intervention to reduce caregiver's burden in Alzheimer's disease or related dementias: Negative results at 18 months and difficulties to conduct PHARMAID RCT. 2023 , 101146	O
3	Anxiety due to Long COVID is partially driven by activation of the tryptophan catabolite (TRYCAT) pathway.	0
2	White matter hyperintensities burden in the frontal regions is positively correlated to the freezing of gait in Parkinson⊠ disease. 15,	o
1	Suprachiasmatic nucleus functional connectivity related to insomnia symptoms in adolescents with major depressive disorder. 14,	0